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Abstract 
Merja Kataja-Tuomola. Antioxidants, weight change and risk of type 2 diabetes. 
National Institute for Health and Welfare (THL). Research no. 59. 135 pages. 
Helsinki, Finland 2011. 
ISBN 978-952-245-461-4 (printed); ISBN 978-952-245-462-1 (pdf) 
 
The incidence of type 2 diabetes has increased rapidly worldwide. Obesity is one of 
the most important modifiable risk factors of type 2 diabetes: weight gain increases 
and weight loss decreases the risk. However, the effects of weight fluctuation are 
unclear since the findings of published studies are inconsistent. 
 
Reactive oxygen species are presumably part of the complicated mechanism for the 
development of insulin resistance and beta-cell destruction in the pancreas. The 
association of antioxidants with the risk of incident type 2 diabetes has been studied 
in several longitudinal prospective human studies, but so far there is no clear 
conclusion about any protective effect of dietary or of supplementary antioxidants 
on diabetes risk. 
 
The present study examined 1) weight change and fluctuation as risk factors for 
incident type 2 diabetes; 2) the association of baseline serum alpha-tocopherol or 
beta-carotene concentration and dietary intake of antioxidants with the risk of type 2 
diabetes incidence; 3) the effect of supplementation with alpha-tocopherol or beta-
carotene on the risk of incident type 2 diabetes; and on macrovascular complications 
and mortality among type 2 diabetics. 
 
This investigation was part of the Alpha-Tocopherol, Beta-Carotene Cancer 
Prevention (ATBC) Study, a randomized, double-blind, placebo-controlled 
prevention trial, which has undertaken to examine the effect of alpha-tocopherol and 
beta-carotene supplementation on the development of lung cancer, other cancers, 
and cardiovascular diseases in male smokers aged 50-69 years at baseline. Men in 
their late middle age and who were smokers were randomly assigned to receive 
either 50 mg (50 IU) synthetic dl-alpha-tocopheryl acetate, 20mg synthetic beta-
carotene, both, or placebo daily in a 2 x 2 factorial design experiment during 1985-
1993. At study inclusion several background variables were assessed that covered 
medical history, weight, height, serum lipids, and blood pressure. At baseline the 
ATBC Study participants completed a detailed and validated food frequency 
questionnaire, and their serum alpha-tocopherol and beta-carotene concentrations 
were determined. Weight was measured once a year, every twelfth month, during 
the follow-up visits. Cases of incident diabetes were identified through a nationwide 
register of drug reimbursements of the Social Insurance Institution. As diabetic 
subjects at baseline were defined those who reported a history of physician-
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diagnosed diabetes and those incident cases who had elevated fasting serum glucose 
(≥7.0 mmol/l) at baseline. Among those (n = 27 379) with no diabetes at baseline 
305 new cases of type 2 diabetes were recognized during the intervention period and 
705 during the whole follow-up to 12.5 years. 
 
Among 20 952 participants, weight gain and weight fluctuation measured over a 
three year period were independent risk factors for 535 subsequent diabetes cases 
recorded for up to 9 years of follow-up. Multivariate adjusted relative risk (RR) was 
1.77 (95% confidence interval [CI] 1.44-2.17) for weight gain of at least 4 kg 
compared to those with a weight change of less than 4 kg. The RR in the highest 
weight fluctuation quintile compared to the lowest was 1.64 (95% CI 1.24-2.17). 
 
Dietary alpha-tocopherol or other tocopherols and tocotrienols as well as dietary 
carotenoids, flavonols, flavones and vitamin C were not associated with the risk of 
type 2 diabetes in 660 cases of incident diabetes reported during a median follow-up 
time of 10.2 years after multivariate adjustment. Baseline serum alpha-tocopherol 
and beta-carotene concentrations in the placebo group or in the whole study cohort 
were not associated with the risk of incident diabetes during follow-up of 12.5 years. 
Neither alpha-tocopherol nor beta-carotene supplementation affected the risk of 
diabetes during intervention or during a total follow-up at 12.5 years. The relative 
risks for participants who received alpha-tocopherol compared with nonrecipients 
and for participants who received beta-carotene compared with nonrecipients were 
0.92 (95% CI 0.79-1.07) and 0.99 (95% CI 0.85-1.15), respectively. Furthermore, 
alpha-tocopherol or beta-carotene supplementation did not affect the risk of 
macrovascular complications or mortality of diabetic subjects during the 19 years 
follow-up time. 
 
In conclusion, in this study of older middle-aged male smokers, weight gain and 
weight fluctuation were independent risk factors for type 2 diabetes. Intake of 
antioxidants, serum alpha-tocopherol or serum beta-carotene concentrations were not 
associated positively or inversely with the risk of type 2 diabetes. Supplementation 
with alpha-tocopherol or beta-carotene did not prevent type 2 diabetes. Neither did 
they prevent macrovascular complications, or mortality among diabetic subjects. 
 
 
 
Keywords:  epidemiology, alpha-tocopherol, beta-carotene, antioxidant, weight 
change, weight fluctuation, diabetic complications, mortality, randomized controlled 
trial, cohort study, type 2 diabetes 
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Tiivistelmä 
Merja Kataja-Tuomola. Antioxidants, weight change and risk of type 2 diabetes.  
[Antioksidantit, painon muutos ja tyypin 2 diabeteksen riski]. Terveyden ja 
hyvinvoinnin laitos (THL). Tutkimus nro 59. 135 sivua. Helsinki, Finland 2011. 
ISBN 978-952-245-461-4 (painettu); ISBN 978-952-245-462-1 (pdf) 
 
Tyypin 2 diabeteksen ilmaantuvuus on kasvanut nopeasti maailmanlaajuisesti. 
Lihavuus on eräs tärkeimmistä tyypin 2 diabeteksen riskitekijöistä, joihin voidaan 
vaikuttaa: painon nousu lisää ja painon lasku vähentää riskiä. Painon vaihtelun 
vaikutus diabetesriskiin on kuitenkin epäselvä. 
 
Reaktiiviset happiradikaalit ovat luultavasti osa insuliiniresistenssin kehittymisen ja 
haiman beetasolujen tuhoutumisen monimutkaista mekanismia. Antioksidanttien ja 
tyypin 2 diabeteksen kehittymisen yhteyttä on tutkittu useissa pitkittäisissä 
prospektiivisissa tutkimuksissa ihmisillä. Toistaiseksi selvää käsitystä ruokavalion 
tai ravintolisänä annettujen antioksidanttien vaikutuksesta tyypin 2 diabeteksen ris-
kiin ei kuitenkaan ole. 
 
Väitöskirjatyön tavoitteena oli tutkia: 1) painon muutoksen ja painon vaihtelun 
merkitystä tyypin 2 diabeteksen riskitekijöinä, 2) lähtötilanteen seerumin alfatoko-
ferolin ja beetakaroteenin pitoisuuksien ja ravinnosta saatavien antioksidanttien 
yhteyttä tyypin 2 diabeteksen riskiin, 3) ravintolisänä annettujen alfatokoferolin ja 
beetakaroteenin vaikutusta tyypin 2 diabeteksen riskiin sekä näiden valmisteiden 
vaikutusta makrovaskulaarisiin komplikaatioihin ja kuolleisuuteen tyypin 2 diabee-
tikoilla. 
 
Tutkimus tehtiin osana SETTI-tutkimusta (the Alpha-Tocopherol, Beta-Carotene 
Cancer Prevention Study [ATBC]), joka on satunnaistettu, lumekontrolloitu kaksois-
sokkokoe, jonka tavoitteena oli selvittää, voidaanko keuhkosyöpää ja muita syöpiä 
ehkäistä beetakaroteeni- ja E-vitamiinivalmisteilla. Toissijaisena tavoitteena oli 
tutkia, mikä oli näiden valmisteiden vaikutus kuolleisuuteen sekä sydän- ja 
verisuonitautien ilmaantuvuuteen. Tutkittavilta kerätyt monipuoliset taustatiedot 
(sairaushistoria, paino, pituus, verenpaine) sekä laboratoriomääritykset (lähtötilan-
teen seerumin alfatokoferoli- ja beetakaroteenipitoisuudet), tekevät mahdollisiksi 
myös tutkimukset muiden kroonisten kansantautien, kuten tyypin 2 diabeteksen 
riskitekijöistä. Tutkimuksen kohderyhmänä olivat 50-69-vuotiaat tupakoivat miehet. 
Tutkimuksen osallistujat, 29 133 miestä, satunnaistettiin neljään yhtä suureen 
ryhmään, joista yksi ryhmä sai beetakaroteenia 20 mg, toinen alfatokoferolia 50 mg 
(50 IU), kolmas molempia ja neljäs lumevalmistetta päivittäin vuosina 1985-1993. 
Lähtötilanteessa tutkittavat täyttivät yksityiskohtaisen ja validoidun ruokavaliokyse-
lyn. Paino mitattiin vuosittain seurantakäyntien yhteydessä. Diabetestapaukset kerät-
 
 
THL 2011 — Research 59 10 Antioxidants, weight change and risk of type 2 diabetes 
 
tiin Kansaneläkelaitoksen ylläpitämästä kansallisesta lääkekorvattavuusrekisteristä. 
Diabeetikoiksi lähtötilanteessa määriteltiin ne tutkittavat, jotka kertoivat lääkärin 
diagnosoineen heillä diabeteksen, sekä ne seurannan aikana ilmaantuneet uudet 
diabetestapaukset, joiden lähtötilanteen paastoseerumin sokeriarvo oli koholla (≥7,0 
mmol/l). Lähtötilanteessa tyypin 2 diabetes oli 1700 tutkittavalla. Intervention aika-
na uusia diabetestapauksia ilmaantui 305 ja koko 12,5 vuoden seurannan aikana 705. 
 
Painon nousu ja painon vaihtelu kolmen vuoden aikana olivat toisistaan riippu-
mattomia diabeteksen riskitekijöitä. Ne, joiden paino nousi vähintään 4 kg, suh-
teellinen riski oli 1,77 (95 % luottamusväli 1,44-2,17) verrattuna niihin, joiden paino 
muuttui vähemmän kuin 4 kg. Kun painon vaihtelun ylintä viidennestä verrattiin 
alimpaan, riski oli 1,64 (95 % luottamusväli 1,24-2,17). 
 
Ruokavalion alfatokoferoli tai muut tokoferolit ja tokotrienolit, karotenoidit, flavo-
nolit ja flavonit kuten myöskään C-vitamiini eivät olleet yhteydessä tyypin 2 diabe-
teksen riskiin. Yhteyttä ei todettu myöskään lähtötilanteen seerumin alfatokoferoli- 
tai beetakaroteenipitoisuuden ja diabeteksen ilmaantuvuuden välillä. Ravintolisänä 
annetulla alfatokoferolilla tai beetakaroteenilla ei todettu olevan vaikutusta tyypin 2 
diabeteksen riskiin intervention tai koko 12,5 vuoden seurannan aikana. Suhteellinen 
riski niillä, jotka saivat alfatokoferolivalmistetta oli 0,92 (95 % luottamusväli 0,79-
1,07) verrattuna niihin, jotka eivät saaneet ja beetakaroteenia saaneilla 0,99 (95 % 
luottamusväli 0,85-1,15) verrattuna niihin, jotka eivät saaneet beetakaroteenia. 
Ravintolisänä annetulla alfatokoferolilla tai beetakaroteenilla ei myöskään ollut 
vaikutusta makrovaskulaaristen komplikaatioiden ilmaantumiseen tyypin 2 diabee-
tikoilla tai heidän kuolleisuuteensa 19 vuoden seuranta-aikana. 
 
Väitöskirjatyön tulokset osoittavat, että painon nousu ja painon vaihtelu keski-
ikäisillä ja vanhemmilla tupakoivilla miehillä olivat toisistaan riippumattomia tyypin 
2 diabeteksen riskitekijöitä. Antioksidanttien saanti ravinnosta tai seerumin alfato-
koferolin tai beetakaroteenin pitoisuudet eivät olleet yhteydessä tyypin 2 diabe-
teksen riskiin. Ravintolisänä annettu alfatokoferoli tai beetakaroteeni eivät estäneet 
uusia tyypin 2 diabetestapauksia eivätkä ne myöskään estäneet diabeteksen makro-
vaskulaarikomplikaatioita tai vähentäneet kuolleisuutta tyypin 2 diabeetikoilla. 
 
 
 
Avainsanat: epidemiologia, alfatokoferoli, beetakaroteeni, antioksidantti, painon 
muutos, painon vaihtelu, diabeteksen komplikaatiot, kuolleisuus, satunnaistettu 
kontrolloitu tutkimus, kohorttitutkimus, tyypin 2 diabetes 
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1 Introduction 
It is estimated that by the year 2030 the prevalence of diabetes for all age-groups 
worldwide will be 4.4% (Wild et al. 2004). This percentage equates to 366 million 
people. The incidence of type 2 diabetes is increasing all over the world, but 
especially high numbers of estimated cases of diabetes will be found in India, China, 
U.S., Indonesia and Pakistan. In Finland, there are about 500 000 individuals with 
both types of diabetes: approximately 75% of them have type 2 diabetes (Diabetes 
2009). During the 2004-2005 period 7.4% of men and 4.3% of women aged 45 to 74 
had previously diagnosed diabetes (Peltonen et al. 2006). More than half of the 
patients with type 2 diabetes younger than 50 years of age were unaware of their 
disease in an urban population in Finland (The DECODE Study Group 2003). 
 
Most often type 2 diabetes begins in adulthood (Narayan et al. 2003), and it is often 
accompanied by obesity, high blood pressure and disturbance of blood lipids 
(Laakso and Lehto 1998). The risk of type 2 diabetes increases with increasing 
values of body mass index (BMI) and with the duration of overweight and obesity 
(Wannamethee and Shaper 1999). There are inconsistencies in the findings 
concerning the association of weight fluctuation or cycling and risk for type 2 
diabetes (Holbrook et al. 1989, Lissner et al. 1990, Morris and Rimm 1992, Hanson 
et al. 1995, French et al. 1997, Brancati et al. 1999, Field et al. 2004). Sedentary life 
style (Hu et al. 2001), unhealthy dietary habits (van Dam et al. 2002), smoking 
(Rimm et al. 1995, Mikhailidis et al. 1998), high levels of alcohol consumption 
(Wannamethee et al. 2002), age (Warram et al. 1997), ethnic group (Harris et al. 
1998) and low birth weight (Hales et al. 1991, Eriksson et al. 2006) are other risk 
factors for type 2 diabetes. 
 
The concordance of type 2 diabetes in monozygotic twins is approximately 60% 
compared with 20% in dizygotic twins (Newman et al. 1987, Kaprio et al. 1992). 
The consortia of several genome-wide association studies for type 2 diabetes have 
identified 19 common gene variants that increase the suspectibility to this disease 
(Lyssenko and Groop 2009). 
 
Continuous diabetic hyperglycemia may predispose individuals to macrovascular 
(cardiovascular disease and peripheral vascular disease) (Pyörälä et al. 1987, 
Beckman et al. 2002) and microvascular (nephropathy, retinopathy, neuropathy) 
(Vinik and Vinik 2003) complications. Impaired glucose tolerance is itself 
associated with an increased risk of mortality (Balkau et al. 2004). Oxidative stress 
is one of several proposed mechanisms by which vascular endothelial function 
becomes impaired in diabetes (Guzik et al. 2002) and it has been proposed to be an 
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explanatory factor for the increased atherosclerosis seen in diabetes sufferers 
(Ceriello and Motz 2004). 
 
The aim of this work was to study weight change and fluctuation as risk factors for 
incident type 2 diabetes and antioxidants in preventing incident type 2 diabetes and 
the complications of diabetes in a cohort of Finnish male smokers. 
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2 Review of literature 
2.1 Type 2 diabetes 
2.1.1 Definition 
Diabetes is a condition with long-term increased blood glucose concentration. Type 
2 diabetes is characterized by insulin resistance, but impaired insulin secretion also 
exists to a varying extent (Weyer et al. 1999, Lebovitz 2001a and 2001b). The 
diagnosis of type 2 diabetes is based on the measured blood glucose level. There is a 
direct relation between the risk of complications of diabetes and glycemia over time 
(Stratton et al. 2000) 
 
The cut-off points for plasma glucose levels which are indicative of diabetes 
diagnosis are based on certain thresholds above which the incidence of diabetic 
vascular complications begin to increase (American Diabetes Association [ADA] 
1997, Balkau 2000, Balkau et al. 2004), but these have changed over the years. 
 
At the time when the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study 
(ATBC) started in the 1980’s, the diabetes diagnosis criteria were set at when the 
fasting plasma glucose concentration was ≥7.8 mmol/l, or when the two-hour plasma 
glucose concentration in an oral glucose tolerance test with 75 g glucose was 11.1 
mmol/l or more (World Health Organization [WHO] 1985). A fasting plasma 
glucose concentration below 7.8 mmol/l and a 2 hour glucose tolerance test value 
between 7.8 mmol/l and 11.0 mmol/l indicated impaired glucose tolerance (WHO 
1985). 
 
In 1999 the World Health Organization (WHO) updated the concentration criteria as 
follows: in a person with no symptoms, the fasting blood plasma glucose 
concentration of at least 7.0 mmol/l, on two occasions, or plasma glucose ≥ 11.1 
mmol/l in a 2-hour oral glucose test, was set to be the diagnostic threshold values for 
diabetes. Fasting plasma glucose concentration of less than 7.0 mmol/l, but 2-hour 
glucose tolerance test values of between 7.8 mmol/l and 11.1 mmol/l indicate 
impaired glucose tolerance. Impaired fasting glucose refers to a state for which 
fasting plasma glucose is slightly increased (6.1-6.9 mmol/l) and the 2-hour glucose 
tolerance test value is less than 7.8 mmol/l (WHO 1999). 
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2.1.2 Pathogenesis 
A person is at risk of having diabetes if he or she has impaired glucose tolerance, 
impaired fasting glucose or in the case of females if she has had diabetes during 
pregnancy (Metzger et al. 1993). The development of type 2 diabetes results from 
the interaction between an individuals genetic background and environment (Gerich 
1998). In type 2 diabetes impaired two-phasic pancreatic insulin secretion from beta- 
cells and decreased insulin action lead to elevated glucose levels. It has been 
estimated that approximately 50-60% of beta-cell insulin secretion capacity is lost 
by the time diabetes is clinically diagnosed (Butler et al. 2003). Hyperglycemia has 
been proposed to lead to an accumulation of a large number of reactive oxygen 
species in the beta-cells, with subsequent damage to the cellular components 
(Stumvoll et al. 2005). 
 
Insulin resistance is a factor in which a given concentration of insulin is associated 
with a subnormal glucose response (Moller and Flier 1991). A few known genes are 
presumed to induce insulin resistance (Florez 2008). According to one hypothesis 
any perturbation that results in an accumulation of intracellular fatty acyl coenzyme 
As or other fatty acid metabolites in muscle and liver, either through increased 
delivery or decreased metabolism, might be expected to induce insulin resistance 
(Shulman 2000). Liver fat content has been shown to correlate significantly with 
fasting serum insulin concentrations when analysis was adjusted for insulin 
clearance (Spearman's nonparametric rank correlation coefficient, r = 0.43, p<0.0001) 
and with directly measured hepatic insulin sensitivity (r = - 0.40, p = 0.0002) (Kotro-
nen et al. 2007). 
 
Moreover, inherited or acquired defects in mitochondrial function that cause an 
alteration in the ability of muscle and liver to metabolize fatty acids, would also lead 
to an intracellular accumulation of fatty acid metabolites and subsequent defects in 
insulin signalling and action. Non-esterified fatty acids stimulate gluconeogenesis in 
the liver (Boden and Shulman 2002). Key enzymes of hepatic glucose production, 
such as phosphoenolpyruvatecarboxykinase and glucose-6-phosphatase, when 
overexpressed, have been shown to induce insulin resistance in vivo, and also 
disturbances of both glucose and lipid homeostasis (Postic et al. 2004). 
 
Recently, it was stated that 19 genetic variants that are associated with an increase in 
the risk of type 2 diabetes are known (Groop and Lyssenko 2009). Most of them 
seem to influence the capacity of the beta-cells to increase insulin secretion. A 
hypothesis exists that hyperglycemia is the consequence of intrinsic beta-cell 
function deficiency rather than of a defect in the mechanism of compensation for 
insulin resistance (Mari et al. 2010). 
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2.1.3 Complications 
Globally, type 2 diabetes is of considerable relevance because of its adherence to 
macro- and microvascular complications (Goldberg 1981, Laakso and Barrett-
Connor 1989, Laakso et al. 1993). The risk for myocardial infarction in a diabetic 
person is as high as in a person with an earlier myocardial infarction (Schramm et al. 
2008) and the risk of stroke for individuals in the 35-54 age group is 2.0 to 4.0 fold 
that of the general population (Folsom et al. 1999, Kissela et al. 2005). 
 
Patients with diabetes more commonly develop the symptomatic forms of peripheral 
arterial disease and intermittent claudication than nondiabetic persons (Uusitupa et 
al. 1990). Diabetic nephropathy is the predominant cause of renal failure, and it 
accounts for nearly 44% of new cases (National Institute of Diabetes and Digestive 
and Kidney Diseases et al. 2007). Diabetic retinopathy is a leading cause of new-
onset blindness in industrialized countries and an increasingly frequent cause of 
blindness in middle-income countries (Resnikoff et al. 2004). The WHO has 
estimated that diabetic retinopathy is responsible for 4.8% of the 37 million cases of 
blindness throughout the world (Resnikoff et al. 2004). The estimated prevalence of 
diabetic retinopathy and vision-threatening diabetic retinopathy was 28.5% and 4.4% 
among US adults with diabetes, respectively (Zhang et al. 2010). In Finland most of 
these complications are treated in hospital outpatient wards, and therefore the 
frequency of these complications cannot be determined on the basis of hospital 
discharge registers (Niemi and Winell 2006). Diabetic neuropathy, which is the most 
prevailing form of neuropathy worldwide, is the linchpin in diabetic foot ulcer 
(Boulton 2004, Boyko et al. 2006). 
 
In a multicentre study the prevalence of neuropathy was 32.1% in type 2 diabetic 
patients in the United Kingdom hospital clinic population (Young et al. 1993). The 
annual mortality rate in a British study on 1694 diabetic patients was more than four 
times that of the mortality rate of the nondiabetic population, and cardiovascular 
disease accounted for almost one-half (49.1%) of all deaths in the diabetic 
population (Morgan et al. 2000). 
2.2 Weight and type 2 diabetes 
2.2.1 Mechanisms of the association 
Studies reported in the 1980s and 1990s indicated that central obesity as estimated 
by waist hip ratio was predictive of the development of type 2 diabetes (Ohlson et al. 
1988, Carey et al. 1997). Increased waist girth corresponds to increased amounts of 
visceral adipose tissue (Lemieux et al. 1996) and is, in turn, related to the 
development of type 2 diabetes (Alberti et al. 2005, Meisinger et al. 2006). 
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According to one hypothesis, visceral adipose tissue may have promoting influence 
on the development of insulin resistance by releasing free fatty acids, which drain 
directly into the liver and cause hepatic insulin resistance, and it is also suspected to 
contribute to the development of muscle insulin resistance (Boden and Shulman 
2002). Weight loss studies have shown that the improvement in insulin sensitivity 
correlates with changes in visceral adipose tissue mass but not with total or 
subcutaneous adipose tissue mass (Goodpaster et al. 1999). 
2.2.2 Epidemiological studies 
2.2.2.1 Body mass index 
Body mass index (BMI, kg/m2) has been shown to be associated positively with type 
2 diabetes in three large meta-analyses (Hartemink et al. 2006, Vazquez et al. 2007, 
Abdullah et al. 2010) and in one smaller meta-analysis (Guh et al. 2009) (Table 1). 
Vazquez et al. performed a meta-analysis on 32 studies selected from 432 
publications. The publications were categorised in terms of different populations and 
being either normoglycemic or having impaired glucose tolerance at baseline with 
up to 25 years follow-up. All studies analyzed the progression from non-diabetes to 
diabetes. To assess the association between BMI and the incident diabetes rate, the 
pooled estimate across all studies for the relative risk was calculated. The pooled 
estimate of relative risk for incident diabetes per standard deviation increase for 
body mass index was 1.87 (95% CI 1.67-2.10) (Vazquez et al. 2007). 
 
In another meta-analysis the selection of studies yielded 31 articles on 
epidemiologic studies of type 2 diabetes as a function of body mass index. It showed 
that the pooled relative risk for type 2 diabetes was 1.18 (95% CI 1.16-1.20) per unit 
of increasing body mass index, although there was a clear heterogeneity of studies 
(Hartemink et al. 2006) (Table 1). 
 
In a meta-analysis of 7 studies with North American and European populations, 
elevated BMI was significantly associated with type 2 diabetes in men and women 
(Guh et al. 2009) (Table 1). The association between being overweight as defined by 
BMI (BMI ≥ 25 kg/m2) and the incidence of type 2 diabetes was stronger in females: 
RR was 3.92 (95% CI 3.10-4.97) when overweight women were compared to those 
with normal weight. In overweight men the relative risk for incident type 2 diabetes 
was lower 2.40 (95% CI 2.12-2.72) compared to men with normal weight. Obesity 
(BMI ≥30 kg/m2) was most strongly associated with the incidence of type 2 diabetes 
in women (RR 12.4; 95% CI 9.0-17.1). 
 
One objective in the most recent meta-analysis was to examine the magnitude of the 
risks for developing type 2 diabetes for overweight and obese populations and 
compare them with those individuals of normal weight. That meta-analysis study 
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combined 16 prospective cohort studies and 2 nested case control studies with North 
American, European and Asia-Pacific origin populations. Overweight was 
associated with a 3 fold higher risk for diabetes compared to those with normal 
weight (RR 2.99; 95% CI 2.42-3.72). Obese individuals were associated with a 7 
fold higher risk of diabetes compared to those with normal weight (RR 7.19; 95% CI 
5.74-9.00) (Abdullah et al. 2010) (Table 1). 
 
The results of a recently published follow-up study of the relation of incident type 2 
diabetes to weight patterns during middle age in a subset of the Framingham Heart 
Study were in line with previous studies. In 1476 adults, 217 cases of type 2 diabetes 
were diagnosed. Overall weight status observed between 40 to 50 years of age was 
strongly associated with the development of type 2 diabetes. Multivariate adjusted 
hazard ratio (HR) was 2.90 (95% CI 2.0-4.10) for overweight participants compared 
to those with normal weight, and multivariate adjusted HR for obese participants 
was 7.70 (95% CI 4.90-12.10) (Waring et al. 2010). 
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Table 1. Summary of the meta-analyses of prospective cohort studies or nested case-control studies for the association 
between BMI and the risk of type 2 diabetes.  
RR, relative risk; SD, standard deviation
Reference 
 
Studies Sample size of the 
cohorts 
 
Review period/ follow-
up years 
Risk for type 2 diabetes  95% Confidence 
interval 
Hartemink et al. 2006 31 cohort studies 
women, men 
EU, U.S. 
766–46 634 
 
1980–2004 / 4–25 RR / BMI unit 
increase  
 
 1.18 1.16 – 1.20
 
 
 
Vazquez et al. 2007 
 
31 cohort studies and 1 
nested case control 
study 
women, men 
EU, U.S., Canada, 
Korea, Jamaica, 
Taiwan, Mexico, Japan 
 
72–31 702 
 
 
1966–2004 / 2−25 
 
 
RR / SD increase in 
BMI 
 
 1.87 
 
1.67 – 2.10 
 
 
Guh et al. 2009 
 
 7 studies 
women, men 
U.S., Germany, UK  
 
Men  
3055–22 172 
 
 Women 
2957–84 941 
  
 
Review period not 
shown/ 
3.7–23.8 for men, 
6.9–16 for women 
 
Pooled RR for men:  
overweight vs. normal 
obese vs. normal 
 
for women: 
overweight vs. normal 
obese vs. normal 
 
 
2.40 
6.74 
 
 
 3.92 
12.41 
 
 
 
2.12 – 2.72 
5.55 – 8.19 
 
 
3.10 – 4.97 
9.03 –17.06 
 
Abdullah et al. 2010  
 
16 cohort studies and 2 
nested case-control  
studies 
women, men 
U.S., Asia-Pacific, 
Europe 
 
2902–154 989 
 
1966–2008 / 2−27 
 
 
Pooled  RR  
overweight vs. normal 
obese vs. normal 
 
 
 2.99 
 7.19 
 
 
2.42 – 3.72 
5.74 − 9.00 
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2.2.2.2 Weight gain 
 
Of the 13 prospective follow-up studies shown in Table 2, nine have reported increased 
risk of type 2 diabetes with weight gain, and most of them have also demonstrated a higher 
risk with higher body weight gains (Holbrook et al. 1989, Colditz et al. 1995, Hanson et al. 
1995, Ford et al. 1997, Resnick et al. 2000, Koh-Banerjee et al. 2004, Oguma et al. 2005, 
Wannamethee et al. 2005, Jacobs-van der Bruggen et al. 2010). Estimation of weight, time 
range for weight change and follow-up period have largely varied between different studies. 
Most of the studies assessed the change in body weight, two studies used change in body 
mass index (Oguma et al. 2005, Waring et al. 2010). With a few exceptions the studies 
originate from the United States and they include results from large prospective American 
cohorts. 
 
In a large prospective follow-up study, the Nurses’ Health Study (NHS) with up to 114 281 
middle-aged women, those who had gained at least 20 kg of weight in adulthood were 
found to have a 12 fold risk for clinical diabetes than those with loss or gain of weight of 
under 5 kg (Colditz et al. 1995) (Table 2). However, in the National Health and Nutrition 
Examination Survey Epidemiologic Follow-up Study (NHEFS) the risk for diabetes was 
much lower (RR 3.84; 95% CI 2.04-7.22) for those who gained ≥20 kg of weight (Ford et 
al. 1997). In a subsample of 1929 adults in the same study aged 25 to 74 years who at 
baseline were already overweight, one kg of weight gained annually over 10 years was 
associated with a 49% increase in risk of developing diabetes in the subsequent 10 years 
(Resnick et al. 2000). The association between weight gain and risk of incident type 2 
diabetes is well-established in long-term prospective follow-up studies (Holbrook et al. 
1989, Colditz et al. 1995, Oguma et al. 2005, Wannamethee et al. 2005). Nonetheless, there 
is a discrepancy between the above mentioned results and the result of a recent substudy of 
the Framingham Heart Study: weight gain compared to stable weight during middle age 
was not associated with incident diabetes in 1476 participants during follow-up to 25 years 
(multivariate adjusted HR 1.20; 95% CI 0.80-1.70) (Waring et al. 2010). Far less is known 
about short-term weight change and risk of incident type 2 diabetes, the results of few 
prospective follow-up studies are inconsistent (Ishikawa-Takata et al. 2002, Mishra et al. 
2007, Jacobs-van der Bruggen et al. 2010). Among Dutch adults 5-year weight gain during 
subsequent follow-up of five years was associated with an increased risk of type 2 diabetes 
when adjusted for initial BMI. However, no significant association was found if the 
association was adjusted for attained BMI (Jacobs-van der Bruggen et al. 2010). 
2.2.2.3 Weight loss 
 
Weight loss has been shown to reduce the risk of developing type 2 diabetes in the Finnish 
Diabetes Prevention Study with 522 participants (Tuomilehto et al. 2001). Similar findings 
have been obtained in U.S. in the Multiple Risk Factor Intervention Trial (MRFIT) with   
11 827 participants and in the Diabetes Prevention Program with 1079 participants (Davey 
 
 
THL 2011 — Research 59 24 Antioxidants, weight change and risk of type 2 diabetes 
 
Smith et al. 2005, Hamman et al. 2006). These three studies were intervention trials with a 
mean of 3.2 follow-up years for Diabetes Prevention Study and for Diabetes Prevention 
Program and up to 7 years follow-up for the MRFIT study. A weight loss of between 3-5 
kg was associated with a reduced risk developing diabetes when compared with the weight 
stable group. The hazard ratio (HR) was 0.40 (95% CI 0.30-0.70 p<0.001) in the Diabetes 
Prevention Study and 0.42 (95% CI 0.35-0.51 p<0.0001) in the Diabetes Prevention 
Program. In the MRFIT study the decrease in BMI of 1kg/m2 in the intervention group 
reduced the risk for incident type 2 diabetes by 25% (HR 0.75; 95% CI 0.70-0.81) and in 
the usual care group by 16% (HR 0.84; 95% CI 0.78-0.90) in non-smokers. In smokers 
with this BMI decrease the risk for incident type 2 diabetes reduced by 17% in the 
intervention group (HR 0.83 95% CI 0.79-0.88) and by 19% in the usual care group (HR 
0.81; 95% CI 0.77-0.86). 
 
Large long-term prospective follow-up studies have shown weight loss to be inversely 
associated with the risk of incident diabetes (Colditz et al. 1995, Will et al. 2002, 
Wannamethee et al. 2005) (Table 2). In the Nurses’ Health Study, type 2 diabetes risk was 
approximately halved by a weight decrease of between 5-10 kg and among those with at 
least 20 kg weight decrease the diabetes risk was diminished by nearly 90% (Colditz et al. 
1995). Among adult U.S. men and women self-reported intentional weight loss was 
associated with a lower diabetes risk, which was gradually decreased by increased weight 
loss (Will et al. 2002). In the British Regional Heart Study on 6194 participants, weight 
loss reduced the risk of developing diabetes when compared with those whose weight was 
stable; the relative risk was 0.62 (95% CI 0.42-0.90) for those who lost more than 4% of 
their weight during 5 years (Wannamethee et al. 2005) (Table 2). Significant decreased risk 
of type 2 diabetes during follow-up of four years was also demonstrated among the Health 
Professional Study participants with a weight loss of at least 6 kg over 10 years (Koh-
Banerjee et al. 2004). In the NHEFS cohort, one kg weight loss annually over 10 years was 
associated with a 33% lower risk of diabetes among those who were initially overweight 
(Resnick et al. 2000). Nevertheless, in a previous analysis of the whole NHEFS cohort with 
8545 adults participants with weight loss were found to have no reduction in the risk of 
developing diabetes when compared with those whose weight was stable (Ford et al. 1997). 
Similarly, several other prospective studies reported non-significant associations between 
weight loss and type 2 diabetes risk (Ishikawa-Takata et al. 2002, Oguma et al. 2005, 
Mishra et al. 2007, Jacobs-van der Bruggen et al. 2010, Waring et al. 2010). In contrast, a 
weight loss of 4.5 kg compared to a stable weight increased the risk of type 2 diabetes in 
2000 U.S. participants aged 50 years or over (RR 1.70, p<0.05) (Holbrook et al. 1989). 
Accordingly, there are clear discrepancies in the results of the prospective follow-up 
studies of weight loss and risk of incident type 2 diabetes. 
 
 
THL 2011 — Research 59 25 Antioxidants, weight change and risk of type 2 diabetes 
 
2.2.2.4 Weight fluctuation 
 
The association of obesity and weight increase with risk of type 2 diabetes is well 
established, but the association between weight fluctuation and risk of type 2 diabetes is 
unclear. Among middle aged U.S. women fluctuation of self-reported weight determined as 
an index of standard error of the estimate (i.e. the slope of the regression line describing 
weight as a function of age) was associated with increased risk of type 2 diabetes in a 
retrospective study (Morris and Rimm 1992). A summary of the prospective studies are 
shown in Table 3. In the Iowa Women’s Health Study with up to 914 cases of incident 
diabetes, large weight cycling was positively associated with the risk of diabetes (RR 1.70; 
95% CI 1.25-2.29) when compared with combined stable weight plus small weight gain 
categories (French et al. 1997). Small weight cycling was not associated with a risk of 
diabetes in the same study (RR 1.38; 95% CI 0.94-2.03). High BMI variability between 20 
to 49 years of age in former medical male students in the U.S. was associated with an 
increased risk of diabetes (Brancati et al. 1999). The risk was doubled in the highest BMI 
variability quartile compared to the others (Brancati et al. 1999). 
 
Conversely, neither those women with severe weight cycles (severe cyclers), nor mild 
weight cycles (mild cyclers) had an increased risk for incident diabetes in the Nurses’ 
Health Study during a six year follow-up (Field et al. 2004) (Table 3). Women were 
classified as severe weight cyclers, if they had intentionally lost weight ≥9.1 kg, at least 
three times over the previous 4 years. Women who had intentionally lost ≥ 4.5 kg three or 
more times, but did not meet the criteria for severe weight cyclers, were classified as mild 
weight cyclers. In a study on Pima Indians (383 women and 201 men), there was no 
association found between weight fluctuation and incident diabetes (Hanson et al. 1995). In 
a recently published follow-up study, a subset of the Framingham Heart Study, cycling of 
BMI 1 kg/m2 or more during middle age increased the risk for incident diabetes compared 
to non-cycling weight (hazard ratio 1.60; 95% CI 1.20–2.10) (Waring et al. 2010). 
However, after adjustment for overall weight status, weight cycling was no longer 
associated with incident diabetes (hazard ratio 1.10; 95% CI 0.80-1.50). 
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Table 2. Prospective follow-up studies of the association between weight gain or weight loss and the risk of type 2 
diabetes. 
Reference 
 
Study 
population/ 
follow-up time 
Cases Weight 
measurement, 
time range for 
weight change
Reference
weight, kg 
Weight 
gain, kg 
 Weight
loss, kg  
RR (95% CI) RR (95% CI)
Holbrook 
et al. 1989 
 
U.S., 1114 women  
886 men  
aged ≥50 years/ 
15 years 
142 
women 
142 men 
Weight history 
interview, weight 
change between 
ages 40-60 years 
No loss, 
no gain 
 
4.5 1.90a 4.5 1.70a 
Colditz 
et al. 1995 
 
 
U.S., 114 281 women 
aged 30-55 years/ 
14 years 
2204 Self-reported 
at 18 years and at 
baseline 
Loss/gain 
0-4.9 
5.0-7.9 
8.0-10.9 
11.0-19.9 
>  20 
1.9b (1.5-2.3) 
2.7  (2.1-3.3) 
5.5  (4.7-6.3) 
12.3  (10.9-13.8) 
5.0-10.9 
11.0-19.9 
>20 
0.54b (0.4-0.8) 
0.23  (0.1-0.4) 
0.13  (0.1-0.3) 
Hanson  
et al. 1995 
 
U.S., 906 women  
552 men 
 aged >20 years/  
7.4 years (women),  
7.2 years (men) 
306 
women 
155 men 
Weight measured 
at least 2 years apart 
0 kg/year 2.7 kg/year  
2.6 kg/year  
IRR 0.98c (0.87-1.11) 
        1.24  (1.04-1.49) 
  
Ford et al. 
1997 
 
 
U.S., 8545 women, men,  
aged >25 years/ 
8-10 years 
297 
women 
190 men 
Weight measured 
in 1971-1975 and 
1982-1984 
Loss/gain 
0-4.9  
5-<8 
8-<11 
11-<20 
>20 
HR 2.11d (1.40-3.18) 
       1.19  (0.75-1.89) 
       2.66  (1.84-3.85) 
       3.84  (2.04-7.22) 
5-<11 
> 11 
HR 1.13d (0.72-1.80) 
       0.80  (0.46-1.40)  
Resnick  
et al. 2000 
 
U.S., 1929 women, men 
aged 25-74 years/ 
10 years 
 
251 Weight measured 
approximately 
10 years apart  
0 kg/year 0.1kg/year 
0.5 
1.0 
1.5 
2.0 
OR 1.04e (1.03-1.06) 
       1.22  (1.13-1.31) 
       1.49  (1.29-1.73) 
       1.82  (1.46-2.27) 
       2.22  (1.66-2.98) 
0.1kg/year 
0.5 
1.0 
1.5 
2.0 
OR 0.96e (0.95-0.97) 
       0.82  (0.76-0.88) 
       0.67  (0.58-0.78) 
       0.55  (0.44-0.68) 
       0.45  (0.34-0.60) 
Ishikawa- 
Takata et al. 
2002 
Japan, 4385 men 
aged 18-59 years/  
4 years 
242 Weight measured 
annually 
 
Loss/gain 
0-2 
>2 1.14f  (0.85-1.54) >2 1.16f  (0.80-1.69) 
Will  
et al. 2002 
 
 
 
U.S.,  111 285 women 
101 285 men 
aged > 30 years/ 
13 years 
5658 
women 
 
 
 
Self-reported 
(intentional 
weight loss) 
at baseline  
No change   0.1-9.0 
9.1-18.1 
18.2-27.1 
27.2-36.2 
>36.3
IDR 0.76g (0.70-0.84) 
        0.72  (0.65-0.78) 
        0.66  (0.57-0.77) 
        0.47  (0.34-0.66) 
       0.36  (0.21-0.60)
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Will et al 
(continued) 
 
4669 
men 
0.1-9.0 
9.1-18.1 
18.2-27.1 
27.2-36.2 
>36.3 
        0.85g (0.76-0.95) 
        0.77  (0.68-0.86) 
        0.74  (0.59-0.93) 
        0.31  (0.16-0.60) 
        0.36  (0.13-0.98) 
Koh-Banerjee 
et al. 2004 
 
U.S., 22 171 men 
aged 40-75 years/ 
4 years 
305 Self-reported 
biannually, weight 
change over 10 
years 
Loss/gain 
0-2 
3-5 
6-8 
>9 
1.4h (1.0-1.9) 
1.6  (1.1-2.4) 
2.1  (1.5-3.0) 
3-5 
>6 
1.0h (0.7-1.5) 
0.5  (0.3-0.9) 
Oguma 
et al. 2005 
 
U.S., 20 187 men 
mean age  
45.9 years/ 
up to 36 years  
 
1223 Weight measured  
at mean age of 
18.5 years, 
self-reported 
at mean age of 
45.9 years 
BMI change 
per decade 
+ 0.5 
BMI 
change 
per decade 
>0.5-1.0 
>1.0-1.5 
>1.5-2.0 
>2.0-3.0 
>3.0 
 
 
 
1.13i (0.92-1.40) 
1.69  (1.38-2.06) 
2.08  (1.69-2.56) 
3.45  (2.81-4.23) 
5.34  (4.13-6.89)  
BMI 
change 
per decade 
< -0.5 
 
 
 
1.30i (0.87-1.92) 
 
Wannamethee 
et al. 2005 
 
UK., 6194 men 
aged 40-59 years/ 
15 years 
327 Weight measured 
and self-reported 5 
years later 
Loss/gain 
< 4%  
 
4-10% 
>10% 
1.26j (0.97-1.64) 
1.76  (1.16-2.67) 
> 4% 0.62j (0.42-0.90) 
Mishra et al. 
2007 
Australia, 7239 women 
aged 45-50 years/ 
3 years 
207 Self-reported, 
weight change over 
3 years 
Loss/gain 
per year 
<1.5%  
1.5 to 
< 2.5% 
2.5-5.0% 
>5% 
OR 1.24k(0.82-1.87) 
 
       0.93 (0.60-1.42) 
       1.54 (0.92-2.56) 
1.5 to 
<2.5% 
2.5-5.0% 
>5.0%  
OR 0.63k(0.32-1.21) 
 
       1.34 (0.82-2.14) 
       0.56 (0.22-1.41) 
Jacobs-van 
der Bruggen 
et al. 2010 
The Netherlands, 7837 
women, men  
aged 20-59 years/ 
5 years 
124 Weight measured, 
weight change over 
5 years 
Loss/gain 
+ 2.0  
2.0-4.0 
4.0-6.0 
>6.0 
 
2.0-4.0 
4.0-6.0 
>6.0 
OR 0.9l (0.5-1.6) 
       1.3 (0.8-2.3) 
       2.4 (1.4-4.0) 
 
OR 0.7m(0.4-1.2) 
       0.8 (0.5-1.4) 
       1.0 (0.6-1.7)    
>2.0  
 
 
 
>2.0 
 OR 0.7l(0.4-1.3) 
 
 
 
  OR 1.1m(0.6-2.1) 
Waring 
et al. 2010 
 
U.S., 1474 women, men 
aged 28-40 years / 
up to 25 years 
217 Weight measured 
biannually, 
weight change 
between ages of 40-
50 years 
BMI change 
+ 0.6 (IQR)  
BMI 
change 
0.6 to 2.4 
(IQR) 
 
HR 1.2n (0.8-1.7) 
BMI 
change 
-0.6 to -2.1 
(IQR) 
 
  HR 1.1n (0.7-1.8) 
 
TH
L 2011 – R
esearch 59
27
A
ntioxidants, w
eight change 
   and risk of type 2 diabetes
 
 
THL 2011 — Research 59 28 Antioxidants, weight change and risk of type 2 diabetes 
 
Table 2 (continued) 
RR, relative risk; CI, confidence interval; IRR, Incidence rate ratio; HR, hazard ratio; OR, odds ratio; IDR, incidence density ratio; BMI, body mass index; 
IQR, interquartile range. 
Multivariate analyses are adjusted for: 
a age, sex, current body mass index and current smoking status, and weight and dieting variables listed. 
bage and body mass index at age 18 years. 
cage and BMI (women), smoking (men).  
dage, age2, sex, race, education, education2, smoking status, cholesterol, cholesterol2, systolic blood pressure, systolic blood pressure2, antihypertensive 
medication, baseline body mass index, and alcohol consumption.  
eage, age2, BMI, sex, race, skinfold ratio and systolic blood pressure.   
fage, BMI at 1994, smoking, alcohol intake, family history, and baseline value of systolic blood pressure, fasting blood glucose, or total cholesterol. 
gage, prebaseline BMI, race, educational level, dietary intakes of fat and carbohydrates, alcohol use, smoking frequency, exercise level, history of heart 
disease, stroke, hypertension, cancer or cirrhosis, symptoms including pain in chest, shortness of breath, fatigue, loss of appetite, blood in stool, or blood in 
urine, and general health status. 
hsmoking status,  physical activity, family history, dietary fiber, and body mass index in 1986. 
iage, physical activity, smoking, hypertension, and family history of diabetes. 
jage,social class, smoking, physical activity, alcohol intake, antihypertensive treatment, undiagnosed coronary heart disease, forced expiratory volume in 1 
second  (FEV1), systolic blood pressure, total cholesterol, and initial BMI. 
kage,BMI, physical activity, smoking status, education, menopause status, area of residence.  
lage, agexage, gender, initial BMI, initial hypertension, and initial total/high density lipoprotein cholesterol ratio.  
mage, agexage, gender, attained BMI, atteined hypertension, and 5-year change in total/high density lipoprotein cholesterol ratio.  
 nweight status at age 25 years, gender, ever use of hormones (women), alcohol consumption, smoking, education, overall weight status and weight cycling.
TH
L 2011 – R
esearch 59
28
A
ntioxidants, w
eight change 
   and risk of type 2 diabetes
 
 
THL 2011 — Research 59 29 Antioxidants, weight change and risk of type 2 diabetes 
 
Table 3. Prospective follow-up studies of the association between weight fluctuation and the risk of type 2 diabetes. 
Reference 
 
Country, study 
population/  
follow-up time 
Cases Weight
measurement 
Determination
of weight fluctuation 
Weight fluctuation 
categories RR (95% CI) 
Hanson et al. 
1995 
U.S., 383 women 
201 men, aged > 20 
years/median 6.3 
years 
162 Weight measured
approximately 2 
years apart 
The root-mean-square error (RMSE) of 
the slope of the regression line of  weight 
with time over approximately 6 years  
75th percentile of 
RMSE (4.9 kg) vs. 
25th percentile (2.0 
kg)
IRR 1.03a
(0.85-1.25) 
French 
et al. 1997 
 
U.S., 33 834 women 
55-69 years/ 
6 years 
914 Recalled weights 
at ages 18, 30, 40  
and 50 years 
Weight change between any two adjacent 
ages (at 30 and 40 years) 
- large cycle: weight gain >10% of weight 
and weight loss >10% of weight during 
different intervals, 
- small cycle: weight gain >5% of weight 
and weight loss >5% of weight during 
different intervals. 
Large cycle vs.
stable weight + 
small gaina 
 
Small cycle vs. 
stable weight + 
small gaina  
1.70b (1.25-2.29)
 
 
 
1.38b (0.94-2.03) 
Brancati 
et al. 1999 
 
U.S., 916 men 
aged 50 years/ 
mean 15.6 years 
35 Weight measured
at 20 to 29 years, 
self-reported  
thereafter every  
3 to 5 years up to 
49 years of age
Sum of squared distances between the 
reported BMI and the BMI predicted 
from the random-effects model at the 
same age, divided by the number of 
reported BMI values during 20 to 49 
years.
Highest BMI 
variability quartile vs. 
other quartiles 
2.10c (1.00-4.60)
Field  
et al. 2004 
 
U.S., 46 634 women 
aged 25-43 years/ 
6 years 
418 Self-reported 
intentional  
weight loss  
over past 4 years 
at baseline 
Intentional weight loss over the previous 
four years 
- severe cycler: ≥9.1 kg three or four times  
- mild cycler: ≥4.5 kg three or more 
times, but not severe cycle  
- non-cycler: person who did not meet the 
criteria described above. 
Severe cycler vs. non-
cycler 
 
Mild cycler vs. non-
cycler 
1.39d (0.90-2.13) 
 
 
1.11d (0.80-1.37) 
 
Waring 
et al. 2010 
 
U.S., 1476 women, 
men, 28-40 years/ 
mean 24 years 
217 Weight measured 
biannually 
  
Weight cycling was determined by 
principal component analysis of BMI 
during middle age (from 40 to 50 years)  
Cycling of  BMI 
1kg/m2  or more  
 vs. no cycling  
HR 1.1e (0.8-1.5)
 
RR, relative risk; CI, confidence interval; RMSE, root-mean-square error; IRR, incidence rate ratio; HR, hazard ratio   
Multivariate analyses are adjusted for: 
aage, sex, BMI, smoking, rate of weight gain, the time between the initial and referent examinations. 
 bbaseline age, waist/hip ratio, BMI, BMI2 smoking status, pack years of cigarettes, education, physical activity, alcohol, marital status, hormone  replacement. 
 cage at enrollment, BMI at age 25,  physical activity level at enrollment, maternal history of diabetes, time-dependent smoking,  
dage, BMI, smoking, family history of diabetes, hours per week of vigorous activity, hours per week of sitting, alcohol intake,  magnesium intake and total calories. 
  eweight status at age 25 years, gender, ever use of hormones (women), alcohol consumption,  smoking, education, overall weight status, weight changes during middle age.   
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2.3 Antioxidants and type 2 diabetes 
2.3.1 Biology and sources of antioxidants 
Nonenzymatic dietary antioxidants include inter alia vitamins E and C and 
carotenoids (Johansen et al. 2005). Vitamin E is a lipid-soluble, plant-origin vitamin 
that consists of eight structurally related compounds, which react directly with 
peroxyl and superoxide radicals and singlet oxygen moieties, and in so doing protect 
membranes from lipid peroxidation (Maritim et al. 2003, Hensley et al. 2004). 
 
Alpha-tocopherol is the most active form of vitamin E in humans (Johansen et al. 
2005), and these terms are used synonymously in this thesis. One United States 
Pharmacopeia (USP) unit of vitamin E has the activity of 1mg of all rac-alpha-
tocopheryl acetate (formerly dl-alpha-tocopheryl acetate) or 0.74 mg of natural 
(RRR-) alpha-tocopheryl acetate (Institute of Medicine 2000). In human nutrition, 
the richest sources of vitamin E are vegetable oils, unprocessed cereal grains and 
nuts (National Institute for Health and Welfare. Nutrition Unit 2010). 
 
All carotenoids possess a polyisopropenoid structure (Britton 1995). They are 
natural pigments synthesized by plants and micro organisms, but not by animals, and 
classified into carotenoid hydrocarbons (known as carotenes) and oxygenated 
carotenoids (known as xanthophylls) according to their chemical composition (Paiva 
and Russell 1999). Among 600 carotenoids approximately 50 have vitamin A 
activity (Bendich and Olson 1989). A wide range of carotenoids have been 
identified in human plasma and tissues including: cyclic (beta-carotene, alpha-
carotene), acyclic carotenes (lycopene, phytoene) together with a number of 
xanthophylls (zeaxanthin, lutein and beta-cryptoxanthin) (Khachik et al. 1997). 
Good sources of carotenoids are carrots and colourful vegetables (National Institute 
for Health and Welfare. Nutrition Unit 2010). 
 
Vitamin C (ascorbic acid) is a non-enzymatic, water-soluble six-carbon lactone, that 
scavenges (reduces a reactive free radical by the formation of a less reactive 
compound) superoxide, peroxyl, hydroxyl, and sulphur radicals and nitrogen-oxygen 
radicals (Clark 2002, Padayatty et al. 2003) and in combination with vitamin E 
ascorbic acid inhibits hydroxyperoxide formation (Maritim et al. 2003). Citrus fruits 
and vegetables are the best sources of vitamin C (Clark 2002). 
 
Over 8000 phenolic and polyphenolic compounds are produced by plants (Duthie 
and Crozier 2000). Flavonoids represent important polyphenols in the human diet 
and can be divided into several classes according to the degree of oxidation of the 
oxygen heterocycle (flavonols, flavones, flavanols, flavanones and anthocyanidins) 
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(Tapiero et al. 2002, Prior  2003). In human nutrition dietary sources of flavonoids 
and phenolic acids include: tea and red wine as catechins, citrus fruits as flavanones, 
onions, olives, apples, cultivated and wild berries in the form of flavonols, such as 
quercetin, cherries, strawberries, grapes, colored fruits for anthocyanides and coffee 
for caffeic acid (Hertog et al. 1992 and 1993, Croft 1998, Häkkinen et al. 1999). 
However, large differences exist in the content of these compounds that depend 
upon the cultivar (Herrmann 1988), and also upon growing conditions. There are 
indications for positive effects on glucose homeostasis exerted by polyphenols and 
polyphenol-rich plant extracts in in vitro and animal studies, and epidemiological 
evidence supports beneficial effects of polyphenol- rich diets (Hanhineva et al. 
2010). Dietary polyphenolic compounds may influence glucose metabolism by 
several different mechanisms, such as the inhibition of carbohydrate digestion and 
glucose absorption in the intestine, stimulation of insulin secretion from the 
pancreatic beta-cells, modulation of glucose release from the liver, activation of 
insulin receptors, alteration of glucose uptake by the insulin-sensitive tissues, 
modulation of hepatic glucose output (Hanhineva et al. 2010). 
2.3.2 Free radicals and type 2 diabetes and its complications 
Free radicals are atoms or molecules that have one or more unpaired electrons in 
their atomic structure and are thus generally highly reactive. The term is also used of 
other reactive species that lead to or result from free radical reactions (Devasagayam 
et al. 2004). Oxygen can give rise to highly reactive oxygen species (ROS), but also 
nonoxygen reactive species do exist, such as nitrogen and chlorine species (Rosen et 
al. 2001). 
 
Overproduction of ROS results in oxidative stress, a process that can be an 
important mediator of cell structure damage, including lipids and membranes, 
proteins and DNA (Valko et al. 2007). Oxidative stress has been defined as a serious 
imbalance between the production of reactive species and antioxidant defences 
(Halliwell 1995, Turrens 2003) and it may play a role in the development of insulin 
resistance (Fridlyand and Philipson 2006). Mitochondria are known to be the main 
source of ROS (Turrens 2003). In diabetes, hyperglycemia is one cause of enhanced 
free radical production (Brownlee 2001). Fatty acid oxidation can increase ROS 
production (Fridlyand and Philipson 2006), but free radicals are also produced as 
by-products of normal aerobic metabolism (Clark 2002), and concentrations of free 
radicals in the body may also be increased by environmental factors such as 
cigarette smoke (Fang et al. 2002, Devasagayam et al. 2004). 
  
Beta-cells are particularly susceptible to oxidative stress (Maechler et al. 1999). In 
type 2 diabetes, excessive ROS could promote the inhibition of insulin synthesis 
(Evans et al. 2002, Robertson et al. 2003, Robertson and Harmon 2007). It has been 
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confirmed from in vivo studies that high glucose concentrations induce 
mitochondrial ROS, which suppresses the first phase insulin secretion (Sakai et al. 
2003). Increased plasma concentration of free fatty acid (FFA) that induces 
intramyocellular lipid accumulation in humans has been proposed to play a critical 
role in pancreatic beta-cell death (McGarry 2002, Azevedo-Martins et al. 2006). The 
FFA and high glucose induce inflammation through oxidative stress whereas 
antioxidants have been shown to reverse this phenomen (Esposito et al. 2002, 
Newsholme et al. 2007). 
 
Diet-derived vitamins C and E detoxify free radicals directly. However, under some 
conditions these vitamins foster toxicity by producing pro-oxidants (Maritim et al. 
2003). Antioxidants have been able to prevent the destruction of beta-cells by 
inhibiting the peroxidation chain reaction (Slonim et al. 1983, Murthy et al. 1992). 
Beta-carotene is a precursor of vitamin A and seems to act as a lipid antioxidant by 
singlet oxygen quenching in vitro (Paiva and Russell 1999). Flavonoids can act as 
antioxidants through a number of pathways: by free radical scavenging (Croft 1998), 
by their metal chelating properties, by their effects on cell signalling pathways and 
by their effects on gene expression (Soobrattee et al. 2005). 
 
Free radicals are also hypothesized to be involved in the development of the 
complications of diabetes. Hyperglycemia leads to an increased production of ROS 
by the non-enzymatic glycoxidation of proteins (Jakus and Rietbrock 2004). The 
advanced glycation end products increase vascular permeability and procoagulant 
activity and are suggested to contribute significantly to the multiorgan complications 
of patients with diabetes (Bucala et al. 1994). 
2.3.3 Epidemiological studies of fruits, vegetables and antioxidants 
and risk of type 2 diabetes 
2.3.3.1 Fruits and vegetables 
 
The results of the prospective follow-up studies on the effects of fruit and vegetable 
intake on the risk of diabetes or disturbance in glucose metabolism are contradictory. 
In two prospective cohort studies the National Health and Nutrition Examination 
Survey (NHANES) I Epidemiologic Follow-up Study, and the Finnish Mobile 
Clinic Health Examination Survey higher intake of fruits, vegetables and berries was 
inversely associated with the risk of diabetes (Ford and Mokdad 2001, Montonen et 
al. 2005). Among 5207 women in the NHANES I Epidemiologic Follow-up Study 
in the USA with a follow-up of up to 20 years the relative risk for those who 
consumed five or more servings of fruit and vegetables per day was 0.61 (95% CI 
0.42-0.88) compared to those who consumed none (Ford and Mokdad 2001). A 
limitation of the study was the use of a single 24-h dietary recall. The total energy 
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intake was not included in the adjustments either. In a Finnish study which 
investigated a total of 4304 participants aged 40-69 years and followed-up for 23 
years, 383 incident cases of diabetes were diagnosed (Montonen et al. 2005). The 
relative risks of developing type 2 diabetes between the extreme quartiles of the 
intakes were 0.69 (95% CI 0.50-0.93; p = 0.02 trend) for green vegetables and 0.69 
(95% CI 0.51-0.92; p = 0.03 trend) for fruit and berries. In a cohort study of 338 
elderly Finnish and Dutch males followed for 30 years, an inverse association 
between higher consumption of vegetables and legumes and impaired glucose 
tolerance (2-h postload glucose concentration) was found (Feskens et al. 1995). 
However, in the Nurses’ Health Study, which was a large follow-up study on 4529 
cases of incident diabetes with 18 years of follow-up, no association between fruit 
and vegetable intake and the risk of diabetes was detected in age-adjusted or 
multivariate models (Bazzano et al. 2008). Neither was a protective association 
found in two other follow-up studies (Iowa Women’s Health Study and Women’s 
Health Study) between the intake of fruit and vegetables and risk of incident type 2 
diabetes (Meyer et al. 2000, Liu et al. 2004). 
2.3.3.2 Prospective studies on antioxidants 
 
In a meta-analysis of antioxidant intake and the risk of diabetes on up to 139 793 
participants and 8813 incident cases of type 2 diabetes with a mean follow-up of 13 
years, the pooled relative risk of type 2 diabetes was 0.87 (95% CI 0.79-0.98; p = 
0.02) for the highest compared with the lowest estimated antioxidant levels (Hamer 
and Chida 2007). A significant heterogeneity between the studies was displayed, 
though (p = 0.01). In subgroup analysis, a significant protective effect was 
demonstrated for vitamin E (RR 0.56; 95% CI 0.35-0.88; p = 0.01), and for total 
carotenoids (RR 0.76; 95% CI 0.58-0.99; p = 0.04). This meta-analysis included 
nine prospective cohorts with healthy participants at baseline. Antioxidant status 
was assessed by a range of methods, including plasma and serum levels, and 
estimated dietary intake. There was heterogeneity for the associations of vitamin E, 
which was attributed to the different types of vitamin E measures (p = 0.04). 
 
When vitamin E and carotenoid intake and the risk of incident diabetes were studied 
in the Finnish Mobile Clinic Health Examination Survey, an inverse association was 
found between the intake of vitamin E and beta-cryptoxanthin and the risk of 
incident diabetes (p = 0.02 trend over quartiles of vitamin E,  and p<0.001 trend over 
beta-cryptoxanthin quartiles) (Montonen et al. 2004, Table 4). However, the 
majority of studies that have examined antioxidant intake and the risk of diabetes 
have shown no significant association (Table 4). The largest studies with up to 
38 018 participants were drawn from cohorts of U.S. participants (Song et al. 2005, 
Nettleton et al. 2006, Wang et al. 2006a). In two Finnish studies (Knekt et al. 2002, 
Montonen et al. 2004) the antioxidant intake was estimated by dietary history 
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interview, whereas in the other studies (Mayer-Davis et al. 2002, Song et al. 2005, 
Nettleton et al. 2006, Wang et al. 2006a) the antioxidant intake was self-reported in 
a food frequency questionnaire. None of the studies from U.S. showed an 
association between antioxidant intake (vitamin C, vitamin E, total flavonol, 
flavones, flavonoids or lycopene) and the risk of incident diabetes. Similarly, in the 
Finnish Mobile Clinic Health Examination Survey an association was not found 
between flavonoid intake and risk of incident diabetes for up to 28 years follow-up, 
as the hazard ratio between the highest and lowest quartile was 0.98 (95% CI 0.77-
1.24) (Knekt et al. 2002). Table 4 shows the prospective cohort studies (studies less 
than 100 cases excluded) of association between intake of antioxidants and risk of 
type 2 diabetes. 
 
The concentration of antioxidant in plasma or serum may reflect its function more 
closely, because blood antioxidant concentration is a measure of dietary intake, 
absorption and also metabolism. In some follow-up studies, an inverse association 
has been shown between the incidence of type 2 diabetes and serum or plasma 
concentrations of vitamin E (Salonen et al. 1995, Mayer-Davis et al. 2002) and beta-
carotene (Hozawa et al. 2006, Arnlöv et al. 2009, Table 5). In a large study, the 
European Prospective Investigation of Cancer Norfolk Study, with 21 831 participants 
and 731 cases of incident diabetes, plasma vitamin C concentration was inversely 
associated with the risk of incident diabetes during 12 years of follow-up (OR 0.38; 
95% CI 0.28-0.52) (Harding et al. 2008).  However, other studies have found no 
association. For example, no protective association was observed between baseline 
plasma carotenoids and the risk of type 2 diabetes during 10 years of follow-up in 
the Women’s Health Study with 470 cases and controls (Wang et al. 2006b). In the 
Finnish Mobile Clinic Health Examination Survey no association was found 
between serum alpha-tocopherol or beta-carotene concentration and the risk of 
diabetes during 20 years of follow-up (Reunanen et al. 1998). The follow-up studies 
of baseline serum or plasma antioxidant concentrations and risk of incident diabetes 
are shown in table 5. 
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Table 4. Prospective cohort studies of the association between intake of antioxidants and risk of type 2 diabetes. 
 
Reference Study population/ follow-up time Cases Assessment tool Exposure Results 
 
Knekt et al. 2002 
 
9878 Finnish women, 
and men aged 
49.2±13.1 years/ 
22-28 years  
526 Dietary history 
interview 
 
Total flavonoids, 
five individual 
flavonoids 
 
No association  
Mayer-Davis 
et al. 2002 
895 U.S.  
women, and men 
aged 40-69 years/ 
5 years 
148 Food frequency 
questionnaire  
Alpha-tocopherol No association 
Montonen et al. 2004 304 Finnish 
women, and men 
aged 40-69 years/ 
23 years 
383
 
Dietary history 
interview 
Vitamin E, 
carotenoids, 
vitamin C 
 
RRa 0.69 (95% CI 0.51-0.94) for highest 
vs. lowest quartile of vitamin E 
RR 0.58 (95% CI 0.44-0.78) for  
β-cryptoxanthin, other carotenoids and 
vitamin C 
no association
Song et al. 2005 38 018 U.S. 
women aged ≥45 
years/ 
8.8 years 
1614 Food frequency 
questionnaire 
 
Total flavonoids, 
individual flavonols 
and flavones 
No association
Nettleton et al. 2006 35 816 U.S. 
women aged 55-69 
years/ 
8 years 
3395 Food frequency 
questionnaire 
 
Total flavonoids, 
seven flavonoid 
subclasses 
No association
Wang et al. 2006a 35 783 U.S. 
women aged ≥45 
years/ 
10.2 years 
1544 Food frequency 
questionnaire 
Lycopene No association
RR, relative risk; CI, confidence interval. 
aadjusted for age, sex, geographic area, occupation, smoking, body mass index, and family history of diabetes, and energy intake. 
TH
L 2011 – R
esearch 59
35
A
ntioxidants, w
eight change 
   and risk of type 2 diabetes
 
 
THL 2011 — Research 59 36 Antioxidants, weight change and risk of type 2 diabetes 
 
Table 5. Follow-up studies of baseline serum or plasma antioxidant concentrations and risk of incident type 2 diabetes. 
Reference Study population/  
follow-up time 
Cases Exposure Results 
Salonen et al. 1995 944 Finnish men, 
aged 42−60 years/ 4 years 
45 Lipid standardized plasma 
alpha-tocopherol  
RR = 3.90b (95% CI 1.76-8.61) for those 
with plasma vitamin E below median 
Reunanen et al. 1998 106 cases 
201 controlsa 
Finnish women, men, aged 15−99 
years/ 14−20 years 
106 
 
Serum alpha-tocopherol  
and beta-carotene 
No association 
 
Mayer-Davis et al. 
2002 
895 U.S. women, men,  
aged 40−69 years/ 5 years 
148 Plasma alpha-tocopherol 
adjusted for plasma 
cholesterol and triglycerides 
RR = 0.12c (95% CI 0.02-0.68) for 
highest vs. lowest quintile in supplement 
non-users 
Hozawa et al. 2006 4493 U.S. 
women, men, aged 18−30 years/ 
10−15 years 
148 Serum alpha-carotene, 
beta-carotene, lutein plus 
zeaxanthin, beta-
cryptoxanthin and lycopene  
RH = 0.53d (95% CI 0.33-0.86)/ 
SD increase in beta-carotene 
concentration in non-smokers, 
no association for others 
Wang et al. 2006b 470 cases 
470 controlsa, U.S. women, aged 
45 years or older/ 10 years 
470 
 
Plasma lycopene, 
alpha-carotene, beta-
carotene, beta-
cryptoxanthin, lutein / 
zeaxanthin 
No association  
Harding et al. 2008 21831 British women, men, aged 
40−75 years/ 12 years 
735 Plasma vitamin C OR = 0.38e (95% CI 0.28-0.52) for 
highest vs. lowest quintile 
Arnlöv et al. 2009 846 Swedish  men aged 50 years/ 
27 years 
 
245 Lipid standardized serum 
alpha-tocopherol, serum 
 beta-carotene 
No association for alpha-tocopherol, 
for beta-carotene OR = 0.68f (95% CI 
0.53-0.89)/ SD increase in concentration 
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RR, relative risk; CI, confidence interval, RH, relative hazard; SD, standard deviation; OR, odds ratio. 
anested case-control study 
badjusted for age, socioeconomic status, body mass index, cigarettes smoked daily, the ratio of serum saturated fatty acids to the sum of monoenes and 
polyenes. 
cadjusted for glucose tolerance status at baseline, age, ethnicity, clinic, sex, general health, family history of diabetes, calorie intake, body mass index, waist 
circumference, smoking status,  participation in vigorous physical activity, total fat intake, fiber intake, alcohol intake, and intake of magnesium and 
 vitamin C from food and supplements. 
dadjusted for race, sex, study center, age, education, systolic blood pressure, ethanol intake, plasma levels of total cholesterol, high density lipoprotein  
 cholesterol, triglycerides, total energy intake, body mass index, total energy expenditure, and use of vitamin supplements. 
eadjusted for age, sex, family history of diabetes, alcohol consumption, physical activity, smoking, educational level, occupational social class, vitamin 
supplements, body mass index and waist circumference. 
fadjusted for body mass index, level of physical activity, smoking status and metabolic model (the baseline covariates for the baseline at age 50 years were 
impaired fasting glucose, insulin sensitivity [HOMA, homeostasis model assessment], and acute insulin response at intravenous glucose tolerance test 
[IVGTT]; for the baseline at age 70 years they were impaired fasting glucose, insulin sensitivity [clamp], and early insulin response in the oral glucose 
tolerance test [OGTT].   
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2.3.4 Antioxidant supplementation trials on type 2 diabetes and its 
complications 
2.3.4.1 Risk of type 2 diabetes 
Only a few randomized controlled trials have studied the effects of antioxidant 
supplementation on the incidence of type 2 diabetes (Table 6). In the Physicians’ 
Health Study during 12 years of follow-up, 798 cases of incident diabetes were 
diagnosed in a study population of 21 468 participants. Supplementation with 50 mg 
of beta-carotene on alternate days had no effect on the risk of incident diabetes (Liu 
et al. 1999). Likewise, in the Women’s Health Study on 1696 cases of incident 
diabetes in a study population of 38 716 participants, supplementation with 600 IU 
vitamin E every other day over 10 years of follow-up had no effect on the risk of 
incident diabetes (Liu et al. 2006). Moreover, no effect of supplemental antioxidants 
on diabetes risk was found in the Heart Outcomes Prevention Evaluation (HOPE) 
trial with 261 cases of incident diabetes with a mean follow-up time 4.5 years (Lonn 
et al. 2002). Two recent studies, the Women’s Antioxidant Cardiovascular Study 
with 895 cases of incident diabetes during a 9.2 year follow-up, and the Selenium 
and Vitamin E Cancer Prevention Trial (SELECT) with 700 cases of incident 
diabetes with a median of 5.46 years of follow-up, found no association between 
supplemental antioxidants and the risk of incident diabetes (Song et al. 2009, 
Lippman et al. 2009). Similarly, in a French study (the Supplementation en 
Vitamines et Mineraux Antioxydants, SU.VI.MAX), combination of antioxidants 
had no effect on fasting plasma glucose in 3146 participants (Czernichow et al. 
2006). 
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Table 6. Placebo-controlled trials of antioxidant supplementation and risk of type 2 diabetes. 
a substudy of the Heart Outcomes Prevention Evaluation (HOPE) trial with 9541 participants 
bsubstudy of the Selenium and Vitamin E Cancer Prevention Trial (SELECT) 
cadjusted for age, aspirin assignment, smoking status, alcohol intake, physical activity, body mass index, history of high cholesterol or hypertension, and use 
of multivitamins. 
dadjusted for age and randomized assignment of aspirin and beta-carotene. 
Reference Study population  Supplementation Follow-up Cases Relative risk 
(95% Confidence interval)  
Liu et al. 1999 21 468 men, U.S. 
aged 40-84 years 
Beta-carotene 50 mg on alternate 
days 
Mean 
12 years 
798 0.99c(0.86-1.14) 
 
Lonn et al. 2002a 5887 women, men 
19 countries from Europe, 
North and South America, 
aged ≥ 55 years   
Vitamin E 400 IU  
(RRR-alpha-tocopheryl acetate) 
every day 
 
Mean  
4.5 years 
261 No effect 
p = 0.55 
Liu et al. 2006 38 716 women, U.S.  
aged ≥45 years 
Alpha-tocopherol 
600 IU on alternate days 
Median 
10 years 
1696 0.95d(0.87-1.05) 
 
Lippman et al. 2009b 
 
 
 
 
8737 men, U.S., Canada and 
Puerto Rico,  
aged ≥50 years 
(African-American), 
≥55 years (all other men) 
Selenium 200 µg  
(L-selenomethionine) every day, 
vitamin E 
400 IU (all-rac-alpha-tocopheryl 
acetate) every day, or both 
Median 
5.46 years 
 
700 
 
Vitamin E 1.04 (0.91-1.18) 
Selenium   1.07 (0.94-1.22) 
Vitamin E+ 
selenium    0.97 (0.76-1.16) 
  
Song et al. 2009 6574 women 
U.S.  
aged ≥40 years 
  
 
Vitamin C 500 mg every day,  
vitamin E 600 IU 
(RRR-alpha-tocopherol 
 acetate) every other day, 
beta-carotene 50 mg every other 
day 
Median 
9.2 years 
895 Vitamin C 0.89 (0.78-1.02) 
Vitamin E 1.13 (0.99-1.29) 
Beta-carotene 0.97 (0.85-1.11) 
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2.3.4.2 Complications of type 2 diabetes 
 
Only a few controlled trials about the effects of antioxidant vitamin intakes and the 
development of complications of type 2 diabetes exist, and their results have not 
shown discernable effects (Table 7). In the HOPE trial, participants in several 
countries were randomly allocated to receive either a daily treatment with 400 IU 
vitamin E or placebo and were followed for a mean of 4.5 years. In all, 3654 people 
had diabetes at baseline, and vitamin E had no detectable effect on the cardiovascular 
outcomes (Lonn et al. 2002). In the Medical Research Council/ British Heart 
Foundation (MRC/BHF) Heart Protection Study on 3982 participants aged 40-80 
years with diabetes at baseline, there was no significant effect of antioxidant 
supplementation on the complications of diabetes (The Heart Protection Study 
Collaborative Group 2002). In the Women’s Health Study, Women’s Antioxidant 
Cardiovascular Study and Physicians Health Study II antioxidants had no effect on 
the incidence of cardiovascular complications of diabetes (Lee et al. 2005, Cook et 
al. 2007, Sesso et al. 2008). 
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Table 7. Placebo-controlled trials of antioxidant supplementation and the risk of complications of type 2 diabetes. 
Reference Country Study type Study population Duration of 
treatment, 
years, mean 
Daily dose Results 
Lonn et al. 2002a  19 countries from 
Europe, North and 
South America 
Randomized, 
double-blind  
3654 women, men, 
aged ≥55 years 
4.5 Vitamin E 400 IU  
(RRR-alpha-tocopheryl 
acetate) 
No effect 
   
Heart Protection 
Study Collaborative 
Group 2002b 
United Kingdom Randomized,  
double-blind  
3982 women, men, 
aged 40-80 years 
5 Beta-carotene 20 mg, 
alpha-tocopherol 600 mg and 
vitamin C 250 mg 
No effect 
   
Lee et al. 2005c U.S. Randomized, 
double-blind 
1027 women, 
aged ≥45 years 
10.1 Alpha-tocopherol 600 IU 
every other day 
No effect 
   
Cook et al. 2007d U.S. Randomized, 
double-blind,  
factorial 
1564 women, 
aged ≥40 years 
9.4 Vitamin C 500 mg every day, 
vitamin E 600 IU 
(RRR-alpha-tocopherol 
 acetate) every other day, 
beta-carotene 50 mg every 
other day 
No effect   
   
Sesso et al. 2008e U.S. Randomized, 
double-blind,  
factorial 
905 men, 
aged ≥50 years 
8 Vitamin C 500 mg every day, 
alpha-tocopherol 
400 IU every other day, 
multivitamin daily 
 No effect 
Substudy of: athe Heart Outcomes Prevention Evaluation (HOPE) trial with 9541 participants 
bthe Heart Protection Study with 20 536 participants 
cthe Women’s Health Study with 39 876 participants 
dthe Women’s Antioxidant Cardiovascular Study with 8171 participants 
ethe Physicians’ Health Study II with 14 641 participants 
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3 Aims of the study 
Previous studies have shown that obesity and weight gain associate with incident 
type 2 diabetes, but the findings of a few studies with regard to weight fluctuation 
and risk of diabetes are inconsistent. Antioxidants have been hypothesized to protect 
individuals from the development of type 2 diabetes and its complications, but the 
support for the hypothesis from studies is conflicting. 
 
Accordingly, this study was undertaken to provide more data on the association 
between weight change, its extent of fluctuation and the risk of diabetes, and to 
assess the relevance of - both dietary and supplementary antioxidants - on the risk of 
type 2 diabetes and its complications. 
 
The specific aims of this study were as follows: 
 
1. To study the association between weight change and fluctuation and risk of type 2 
diabetes (Study I). 
 
2. To study the association between dietary antioxidants and serum alpha-tocopherol 
and beta-carotene concentrations and risk of type 2 diabetes (Studies II and III). 
 
3. To study the effect of alpha-tocopherol and beta-carotene supplementation on the 
incidence of type 2 diabetes (Study III). 
 
4. To study the effect of alpha-tocopherol and beta-carotene supplementation on the 
incidence of macrovascular complications and mortality in subjects with type 2 
diabetes (Study IV). 
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4 Subjects and methods 
4.1 The ATBC Study  
The Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study was a 
randomized, double-blind, placebo-controlled, primary prevention trial (The ATBC 
Cancer Prevention Study Group 1994). The primary aim was to test the effect of 
alpha-tocopherol and beta-carotene supplementation on the incidence of lung cancer. 
The second aim was to evaluate the effects of alpha-tocopherol and beta-carotene on 
other cancers, all-cause mortality, and incidence of other diseases including 
atherosclerotic disorders. The study was carried out in 14 areas of southwestern 
Finland each area with its own study center. The ATBC Study was a joint project 
between the National Public Health Institute of Finland and the National Cancer 
Institute, USA. The Institutional Review Boards of the National Public Health 
Institute, and of the National Cancer Institute approved the ATBC Study. A brief 
overview of the recruitment, baseline evaluations, interventions and follow-up of the 
ATBC Study participants is presented. These details have been fully described 
elsewhere (The ATBC Cancer Prevention Study Group, 1994). 
4.1.1 Eligibility, inclusion and exclusion criteria 
Participants for the ATBC Study were recruited from the total male population aged 
50-69 years living in the study area (n = 290 406) during the 1985-88 period. A 
postal questionnaire that inquired about smoking habits and willingness to 
participate in the ATBC Study was sent to all these males. To be eligible, subjects 
had to smoke five or more cigarettes/day, be willing to participate in the study, and 
give their written informed consent. In all, 42 957 men were invited to the baseline 
examination. Exclusion criteria were previous malignancy (other than non-
melanoma skin cancer or cancer in situ), severe angina on exertion, chronic renal 
insufficiency, cirrhosis of the liver, chronic alcoholism, anticoagulant therapy, use of 
supplements containing vitamin E (over 20 mg/day), beta-carotene (over 6 mg/day) 
or vitamin A (over 20 000 IU/day), or other medical problems that might limit long-
term participation (The ATBC Cancer Prevention Study Group 1994). 
4.1.2 Baseline examination and randomization 
Men were mailed an invitation letter with a questionnaire on their general 
background characteristics, medical and smoking histories, level of education, and 
occupational histories to be filled in at home. Each participant subsequently visited 
his local study center twice before randomization. During the first baseline visit a 
nurse checked the questionnaire and completed it when needed. Height and weight 
of each individual was measured, and his BMI was calculated as the weight in 
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kilograms divided by square of his height in meters (kg/m2). Blood pressure was 
measured by a mercury sphygmomanometer under standardized conditions, and the 
lower of two measurements taken at least one minute apart was recorded. Overnight 
fasting blood samples were drawn and the serum stored at -70 oC. The participants 
received a referral for chest x-ray and a given food frequency questionnaire to be 
filled in at home. 
Two weeks after the first visit men attended their second baseline visit at which time 
a study nurse reviewed the food frequency questionnaire. The final study eligibility 
of each man was then assessed based on the x-ray finding, and the recruited study 
participants were randomized into the intervention groups in blocks of eight. A total 
of 29 133 participants were randomized into the trial (The ATBC Cancer Prevention 
Study Group 1994). All subjects provided their written, informed consent before 
randomization. 
4.1.3 Dietary assessment 
Diet was assessed by a food frequency questionnaire (FFQ) specifically designated 
for the ATBC Study (Pietinen et al. 1988). The questionnaire included 276 food 
items and mixed dishes with a picture booklet, which contained inter alia 122 
photographs of foods, each of which had with 3-5 different portion sizes (Pietinen et 
al. 1988). Each subject was asked to report his usual consumption and the usual 
portion size of foods during the previous 12 months. A study nurse reviewed and 
completed the questionnaire together with the subject during the study visit. Then, 
registered dieticians in the study coordinating centers checked all the questionnaires 
for final approval. The questionnaire was satisfactorily completed by 27 111 
participants (93%). Food consumption data were computed into daily nutrient intake 
values based on the food composition database at the National Public Health 
Institute. Vitamin E, vitamin C and carotenoid contents of the foods were based on 
Finnish analyses (Piironen 1986, Heinonen 1990). In contrast, flavonol and flavone 
content of foods were based mainly on composition analyses obtained from the 
Netherlands (Hertog et al. 1992 and 1993) with the exception of the flavonol content 
of berries, which were based on Finnish analyses (Häkkinen et al. 1999). 
 
Validity of the dietary questionnaire was tested in a pilot study on 189 men by using 
food records kept for 12 two-day periods as a reference method (Pietinen et al. 
1988). The Spearman correlations between the FFQ and food records obtained from 
these data ranged from: 0.59 to 0.68 for tocopherols, from 0.53 to 0.67 for 
tocotrienols, from 0.44 to 0.58 for carotenoids, from 0.46 to 0.66 for flavonoids, and 
0.55 for vitamin C. 
4.1.4 Interventions and compliance 
The participants were randomized into groups to receive the following supplemental 
regimes: alpha-tocopherol (synthetic dl-alpha-tocopherol acetate, 50% powder) 50 
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mg/day (50 IU/day), or beta-carotene (synthetic beta-carotene, 10% water-soluble 
beadlets) 20 mg/day, or both or placebo, in a 2 x 2 factorial design. The study 
capsules were identical gelatine capsules. The active intervention time ended on 
April 30, 1993 (range 5 to 8 years, median 6.1 years) (The ATBC Cancer Prevention 
Study Group 1994). 
 
The compliance was calculated by dividing the number of capsules taken by the 
number of days in the trial, and it was found to be 93% without significant 
differences between the supplementation groups. About 4% were poor compliers 
(i.e., took less than 50% of their capsules). Almost all poor compliers dropped out of 
the study during their first trial year. The overall dropout rate varied only slightly 
across the four randomized groups (from 30.1% to 30.3%)  (The ATBC Cancer 
Prevention Study Group 1994). 
4.1.5 Trial follow-up  
The participants visited their local study centers once every four months. Each time 
the men were asked about their health, medication, use of over-the-counter vitamin 
supplements, possible side-effects of the trial capsules, and smoking habits (The 
ATBC Cancer Prevention Study Group 1994). During the study 6 131 (21%) of the 
participants stopped smoking in approximately equal numbers across the 
supplementation groups (The Alpha-Tocopherol, Beta Carotene Cancer Prevention 
Study Group 1994). The used capsule packs were returned during the follow-up 
visits and a new pack was dispensed. Weight was measured once a year, every 
twelfth month after commencement of the study up to April 30, 1993. A fasting 
blood sample was taken from all participants still in the study at the end of the third 
year (The ATBC Cancer Prevention Study Group 1994).  
4.1.6 Laboratory analyses 
The baseline and third year serum alpha-tocopherol, beta-carotene and retinol 
concentrations were determined by high-performance liquid chromatography assay 
(Milne and Botnen 1986). The between run coefficients of variation (the ratio of the 
standard deviation to its mean) were 2.2% for alpha-tocopherol, 3.6% for beta-
carotene, and 2.4% for retinol. Serum alpha-tocopherol level increased by 50% 
among the supplement users: baseline median alpha-tocopherol concentration was 
11.50 mg/l vs. 17.31 mg/l at 3 years with alpha-tocopherol supplementation. Serum 
beta-carotene level increased 17-fold: baseline median beta-carotene was 172 µg/l vs. 
3001 µg/l at 3 years with beta-carotene supplementation. In the placebo group, 
serum concentrations were similar at baseline and at three years: median 11.41 mg/l, 
and 12.40 mg/l, respectively, for serum alpha-tocopherol, and 172 µg/l and 183 µg/l, 
respectively, for serum beta-carotene (Rapola 1998). Serum total cholesterol and 
high-density lipoprotein cholesterol (HDL) were determined enzymatically by using 
the cholesterol oxidase-4-aminophenazone (CHOD-PAP) method (Kostner 1976, 
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Kattermann et al. 1984). HDL-cholesterol was measured after precipitation of very 
low-density and low-density lipoproteins with dextran sulphate-magnesium chloride. 
Glucose in baseline serum samples of identified cases was determined by the 
enzymatic hexokinase method using an Optima analyzer (ThermoFischer, Vantaa, 
Finland). 
4.2 Subjects 
Of the 29 133 men randomized into the ATBC Study, 1754 reported a history of 
physician-diagnosed diabetes at baseline or had elevated fasting serum glucose (≥7.0 
mmol/l) at baseline. For this reason, all these men were excluded leaving a total of 
27 379 without diabetes at baseline for the study on the effect of alpha-tocopherol 
and beta-carotene supplementation on the incidence of type 2 diabetes. Of these, 
6867 men belonged to the placebo group, for which the association between baseline 
serum alpha-tocopherol and beta-carotene and the risk of diabetes was studied. The 
association between baseline serum alpha-tocopherol and beta-carotene concentrations 
and the risk of incident type 2 diabetes was also studied in the whole cohort of 
27 379 men. 
 
In study on weight change 6427 men were excluded from the study because of one 
or more of the first four annual weight measurement were missing and/or because 
they had cancer or diabetes diagnosed within three years of the baseline. Thus, 
20 952 men were included in the study of weight change and fluctuation as risk 
factors for type 2 diabetes. 
 
Of the 27 379 men without diabetes at baseline, 1874 men had incompletely filled in 
the food frequency questionnaire. Thus, 25 505 participants were included for 
studying of the relationship between intake of antioxidants and the risk of type 2 
diabetes. The men excluded due to incomplete FFQ did not differ significantly in 
their baseline characteristics from those who had filled in the FFQ satisfactorily 
except for physical activity during leisure time. Those who had filled in the FFQ 
satisfactorily participated in moderate or heavy exercise more often than those who 
filled in the FFQ incompletely (58.8% vs. 54.6%, p = 0.001). 
 
Of the 1754 men with a history of diabetes or serum glucose ≥7.0 mmol/l at baseline, 
54 were likely cases of type 1 diabetes (insulin as only medication for diabetes) and 
462 had a history of physician-diagnosed myocardial infarction, angina pectoris, 
stroke or claudication. Thus, 1238 participants with diabetes at baseline were 
included in the study of the effect of alpha-tocopherol and beta-carotene 
supplementation on macrovascular complications. Figure 1 shows a summary of 
exclusions, number of subjects and end points in studies I to IV. 
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Figure 1. The numbers of study subjects and end points for studies I to IV. 
 
    aduring intervention period   (Study I)                      (Study II)                            (Study III)                                                                                                (Study IV) 
       No diabetes at baseline, 
              n = 27 379        
Study of weight change 
and fluctuation, during 
three years, 
 n = 20 952,  
follow-up to 9 years 
(median  7.6 years) 
Participants randomized in the ATBC Study 
                        n = 29 133
 
Weight measurement 
missing and/or cancer 
or diabetes diagnosed 
within three years from 
the baseline, 
 n = 6427 
Diabetes 
n = 535 
Diabetes 
n = 660 
Incompletely filled 
food frequency 
questionnaire, 
n = 1874 
Diabetes 
n = 305a 
   n = 705 
History of physician-
diagnosed diabetes or incident 
diabetes cases with elevated 
fasting serum glucose 
 (≥7.0 mmol/l) at baseline. 
 n = 1754
Likely cases of type 1 
diabetes, n = 54 
History of myocardial 
infarction, angina 
pectoris, stroke or 
claudication at 
baseline, n = 462
Study of the effect of 
α-tocopherol and β-carotene 
supplementation on complications 
during intervention and follow-up to 
19 years (median 10.6 years ), 
n = 1238  
Study of dietary 
antioxidants, 
 n = 25 505 
follow-up to 12.5 years 
(median 10.2 years) 
Peripheral 
arterial 
disease 
n = 39a 
n = 156 
Major 
coronary  
events 
n = 120a  
n = 302 
Strokes  
n = 72a 
n = 204 
Deaths 
n = 318a 
n = 1142 
Study of the effect of 
α-tocopherol and 
β-carotene 
supplementation,  
during intervention 
and follow-up 
to 12.5 years 
(median 10.1 years)  
Study of baseline serum 
α-tocopherol and 
β-carotene 
concentrations, 
follow-up to 12.5 years 
(median 10.1 years)  
 
Diabetes 
n = 704 
Study of the 
effect of 
α-tocopherol and 
β-carotene 
supplementation 
on deaths during 
intervention and 
follow-up 
to 19 years 
(median 13.2 
years) 
n = 1700 
In placebo group, 
n = 6867, study of  baseline 
serum α-tocopherol and 
β-carotene concentrations, 
follow-up to 12.5 years 
(median 10.2 years)  
Diabetes 
n = 188 
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4.3 End points 
4.3.1 Incident diabetes 
All patients in Finland who require a prescription for drug treatment of diabetes are 
entitled to reimbursement of their medication expenses. This requires a detailed 
medical certificate issued by the General Practitioner. The Social Insurance 
Institution checks that the case fulfils the criteria set for diabetes and maintains a 
register of these cases. At time of the ATBC Study randomization, in the 1980’s, a 
diabetes diagnosis was confirmed when the fasting plasma glucose concentration 
was 7.8 mmol/l or more, or when the two-hour plasma glucose in an oral glucose 
tolerance test with 75 g glucose was 11.1 mmol/l or more (WHO 1985). The ATBC 
Study participants were linked to the register through their respective unique identity 
numbers, each of which is assigned to every resident in Finland. The incident cases 
of diabetes through to the end of December 1997 were identified from the register (n 
= 1187). Cases whose baseline serum glucose was below 7.0 mmol/l (n = 705) were 
accepted as endpoints for studies I - III, but because of the exclusions shown in 
Figure 1, the number of incident cases of type 2 diabetes varies in studies I, II and 
III (Figure 1). 
4.3.2 Complications of diabetes 
The macrovascular outcomes and deaths were identified through linkage with the 
National Hospital Discharge Register and the Register of Causes of Death using the 
codes of the International Classification of Diseases (ICD). These outcomes were 
identified through to the end of December 2004 and   included major coronary event 
(non-fatal acute myocardial infarction and fatal coronary heart disease, n = 302), 
total stroke (cerebral infarction, intracerebral haemorrhage and subarachnoid 
haemorrhage, n = 204) and peripheral arterial disease (atherosclerosis of lower 
extremities and claudication, n = 156). Major coronary event was sought with ICD-8 
and ICD-9 code 410 until 1996 and then ICD-10 codes I21-I23 since 1997 in the 
Hospital Discharge Register, and with ICD-8 and ICD-9 codes 410-414 and ICD-10 
codes I20-I25 from the Register of Death. In a validity study, 94% of the major 
coronary event diagnoses in the registers were reviewed as a true major coronary 
event according to strict criteria (Rapola et al. 1997). 
 
Stroke was defined according to ICD-8 or ICD-9 codes 430, 431, 433, 434 and 436 
(43101 or 43191, 4330X, 4331X, 4339X excluded) or on ICD-10 codes I60, I61, I63 
and I64. About 90% of the stroke cases were cerebral infarction. A validation study 
of the register diagnoses showed that, according to standard diagnostic criteria, 90% 
of cerebral infarctions, 79% of subarachnoid hemorrhages and 82% of intracerebral 
hemorrhages were valid (Leppälä et al. 1999). 
Peripheral arterial disease was defined based on ICD-8 codes 44020 and 44390, 
ICD-9 code 4402A or ICD-10 code I70.2. 
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4.4 Statistical analyses 
The follow-up time extended from the day of the randomization (in the study of the 
weight change and fluctuation from the date of the fourth annual weight 
measurement) until the occurrence of the endpoint, death or the end of the follow-up. 
 
The associations between the exposure variables and the incidence of type 2 diabetes 
and the effect of intervention were both estimated by using Cox proportional hazards 
regression as relative risks and also 95% confidence intervals. The proportional 
hazards assumption was tested using the Schoenfeld residuals (Grambsch and 
Therneau 1994). Stratified analyses were performed in order to assess the possible 
effect modifications, and the significance of interactions was tested using the 
likelihood ratio test. Tests for linearity across quintiles were performed using the 
Wald test by treating the median value of each quintile as a continuous variable. 
Differences between covariates between subsets was tested using analysis of 
variance (ANOVA). 
 
In the association analyses the basic model was adjusted for age as continuous 
variable and supplementation group as categorical variable. The multivariate model 
was adjusted further for the number of cigarettes smoked daily, years of smoking, 
systolic and diastolic blood pressure, serum total and HDL cholesterol, BMI and 
alcohol (ethanol) consumption as continuous variables. In contrast, leisure time 
physical activity during the past year was treated as categorical (sedentary [e.g. 
reading, watching television] and moderate [e.g. walking, hunting, gardening] vs. 
heavy [e.g. running, skiing, swimming]) data in the multivariate models. These 
leisure time physical activity categories were formed according to participants’ own 
reported estimates. However, these activities were not reported in terms of 
hours/week. 
 
In the study no. II of the dietary intakes of antioxidants and the risk of diabetes, the 
multivariate model also included energy intake and in further analyses adjustments 
were made for the other antioxidants in the same antioxidant group (tocopherols and 
tocotrienols, carotenoids, flavonols and flavones) as continuous; for the 
consumption of fruits, vegetables and berries; and coffee consumption as continuous. 
Protein and saturated fatty acids intake were also regarded as continuous in the 
multivariate model. The dietary intakes of antioxidants, protein and saturated fatty  
acids were energy adjusted according to the Willett residual method (Willett and 
Stampfer 1986, Willett 1990). 
 
In the study no. I of weight change and fluctuation, the average trend in weight 
change was assessed by analysing the slope of the regression line fitted to four 
weight measurements taken 1 year apart. The slope was categorized into three 
classes: a loss of more than 4 kg for weight loss, between - 4 and + 4 kg for stable 
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weight, and more than 4 kg for weight gain over three years. The 4 kg weight 
change over 3 years corresponds to an average weight change of 1.33 kg/year. 
 
The association of risk for diabetes with weight fluctuation was examined by 
calculating the root-mean-square error (RMSE, kg) using annual weight deviations 
from the corresponding estimated regression line (Lissner et al. 1990, Iribarren et al. 
1995, French et al. 1997), and RMSE was divided into quintiles. Weight fluctuation 
and weight change (loss, stable or gain) were also considered as a combined variable, 
in which case the weight fluctuation was categorized into two classes: from quintile 
1 to quintile 4 (Q1-Q4) for minor fluctuations and quintile 5 (Q5) for large 
fluctuations. 
 
The intervention analyses were made on the intention to treat dataset. Crude rates 
per 1000 person years were calculated for the outcomes of each of the four 
intervention groups (alpha-tocopherol, beta-carotene, alpha-tocopherol plus beta-
carotene, placebo) and according to the 2x2 factorial design after testing for no 
interaction between alpha-tocopherol and beta-carotene. Thus the comparisons were 
made between participants who received alpha-tocopherol supplements versus those 
who did not, and participants who received beta-carotene supplements versus those 
who did not. The intervention-specific cumulative incidence of diabetes was 
calculated by the Kaplan-Meier method using the log-rank test to calculate the 
statistical significance of differences between intervention groups. The effect of each 
supplementation during the follow-up period was expressed by calculating the 
relative risks at confidence intervals of 95% within consecutive time intervals each 
of which contained 30 cases of diabetes and then plotting these estimates using 
'super smoother' (Friedman 1984). 
 
In the study no. IV on alpha-tocopherol and beta-carotene supplementation and the 
risk of macrovascular complications of diabetes, the macrovascular outcomes and 
mortality were analyzed for both the intervention time (i.e. through to April 1993) 
and the 19-year follow-up period (i.e. through to December 2004). The multivariate 
model was adjusted for age, number of cigarettes smoked daily, years of smoking, 
systolic and diastolic blood pressure, serum total and HDL cholesterol, BMI and 
alcohol consumption as continuous variables and leisure time physical activity as 
categorical variables. 
 
All analyses were carried out with the R statistical program (R development Core 
team 2009). All p-values were two-sided, and p<0.05 was considered statistically 
significant. 
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5 Results  
5.1 Baseline characteristics of the main study cohort and their 
association for the risk of type 2 diabetes 
The baseline characteristics were evaluated among the 27 379 participants without 
diabetes at baseline, (Table 8). The participants who developed diabetes (n = 705) 
were younger, their serum total cholesterol and HDL cholesterol were lower, daily 
alcohol use was less than that of the whole cohort, but they had higher BMI and 
higher systolic and diastolic blood pressures than the whole cohort. The baseline 
characteristics were equally distributed amongst the supplement groups (Study III). 
 
The multivariate relative risks and 95% confidence intervals for incident type 2 
diabetes by baseline characteristics in participants without diabetes at baseline are 
presented in table 9. Being overweight increased the risk for incident diabetes three 
fold that of men with normal weight, whereas being obese increased the risk nine-
fold (p<0.001 for trend). Heavy smoking (26 or more cigarettes a day) was also a 
risk factor for diabetes. High serum HDL cholesterol was protective for the risk of 
incident diabetes. Age was not associated with risk of incident diabetes (p = 0.16); 
neither was number of smoking years, nor systolic or diastolic blood pressure, nor 
daily alcohol consumption  or leisure time physical activity. 
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Table 8. Baseline characteristics of the cohort and cases of type 2 diabetes in 
the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study. 
Characteristica  Cohort 
 
Cases of 
diabetes   
p-values 
 
Number of subjects 
 
27 379 
 
705 
 
Age, years 57.1   56.3  = 0.01 
Body mass index, kg/m2 25.8   29.7  <0.01 
Number of cigarettes/day 20      20   <0.01 
Smoking years 36      36   = 0.14 
Systolic blood pressure, mmHg 140    142   <0.01 
Diastolic blood pressure, mmHg 88      90   <0.01 
Serum cholesterol, mmol/l 6.16  6.12   = 0.27 
Serum high density lipoprotein 
cholesterol, mmol/l 
1.16  1.00  <0.01 
Alcohol consumption, g/dayb 11.0  9.3   = 0.02 
Leisure time physical 
activity, % 
  <0.01 
      sedentary 41.5 47  
      moderate 52.5 49.8  
      heavy 6.1 3.3  
amedians except leisure time physical activity 
bn = 25 505 for cohort, n = 660 for cases                               
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Table 9. Multivariate adjusted relative risks for incident type 2 diabetes for baseline 
characteristics of those ATBC Study participants without diabetes at baseline.  
aAdjusted for continuous variables age, body mass index, number of cigarettes/day, smoking years, 
systolic and diastolic blood pressure, total and high density lipoprotein cholesterol, alcohol 
consumption, and for categorical variables intervention group and leisure-time physical activity. 
bAlcohol consumption data missing  n = 1874 
Baseline 
characteristics 
 
 n Relative 
riska 
95% Confidence 
interval 
p for 
trend 
Age, years 
 
-54 
55 - 59 
60 - 64 
65 - 
9806 
8789 
5992 
2792 
1.00 
1.06 
1.24 
1.12 
 
0.87 – 1.28 
0.98 – 1.57 
0.79 – 1.59 
= 0.16 
Body mass 
index, kg/m2 
normal 
overweight 
obese 
- 24 
25 - 29 
30- 
10 948 
12 589 
3823 
1.00 
3.02 
9.29 
 
2.31 – 3.93 
7.06 – 12.22 
<0.001 
Number of 
cigarettes/day 
 
 
-14 
15 - 25 
26- 
5603 
16823 
4953 
1.00 
1.17 
1.46 
 
0.94 - 1.45 
1.14 - 1.88 
<0.001 
 
Smoking years 
 
- 36 
37- 
13790 
13533 
1.00 
1.10 
 
0.91 - 1.33 
= 0.30 
Systolic blood 
pressure, mmHg 
 
- 127 
128 -139 
140- 153 
154- 
6158 
6941 
7404 
6873 
1.00 
1.03 
0.95 
1.01 
 
0.80 - 1.31 
0.73 - 1.23 
0.75 - 1.37 
= 0.92 
Diastolic blood 
pressure, mmHg 
 
- 79 
80 - 87 
88 – 93 
94- 
5481 
7704 
6376 
7814 
1.00 
0.92 
0.96 
1.16 
 
0.71 - 1.20 
0.73 - 1.26 
0.86 - 1.55 
= 0.15 
Serum 
cholesterol, 
mmol/l  
- 5.43 
5.44 - 6.14 
6.15 - 6.93 
6.94- 
6710 
6826 
6891 
6921 
1.00 
1.01 
0.97 
0.88 
 
0.81 - 1.24 
0.78 - 1.20 
0.71 - 1.09 
= 0.22 
Serum HDL 
cholesterol, 
mmol/l  
- 0.94 
0.95 -1.11 
1.12 - 1.32 
1.33- 
6477 
6832 
6884 
7152 
1.00 
0.63 
0.52 
0.47 
 
0.52 - 0.76 
0.42 - 0.64 
0.36 - 0.61 
<0.001 
Alcohol 
consumptionb, 
g/day  
0 
1 -5 
6 – 36 
37- 
2799 
15695 
4946 
2065 
1.40 
1.00 
1.00 
0.92 
1.11 - 1.76 
 
0.81 - 1.23 
0.67 - 1.25 
 
= 0.96 
Leisure time 
physical 
activity, % 
 
light 
moderate 
heavy 
11347 
14357 
1662 
1.00 
1.00 
0.64 
 
0.85 - 1.16 
0.42 - 1.00 
= 0.24 
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5.2 Weight change and fluctuation and the risk of incident type 2 
diabetes 
Men who gained at least 4 kg of weight over three years, were slightly younger 
compared to those men whose weight was stable or who had lost at least 4 kg weight 
(Table 10). They also had lower serum total cholesterol levels than those whose 
weight was stable or who had lost at least 4 kg of weight. 
 
Men whose weight fluctuated the most during the subsequent three years (fifth 
quintile), were younger compared to men in all other quintiles, and they also had 
lower serum total cholesterol and HDL-cholesterol concentrations than men in other 
four quintiles (Table 10). They were less physically active during leisure time, and 
they had higher BMI at baseline than men of the four lowest quintiles. 
 
Weight gain positively associated with the risk of type 2 diabetes, multivariate 
relative risk was 1.77 (95% CI 1.44-2.17), for weight gain of at least 4 kg per three 
years compared with those whose weight remained stable (± 4 kg/3 years) (Table 
11). Weight loss was not associated with the risk of type 2 diabetes. The relative 
risks remained similar when the models were adjusted for weight fluctuation. Age 
modified the association between weight change and the risk for type 2 diabetes (p = 
0.007 for weight gain and p = 0.004 for weight loss) (Table 12). Weight gain was 
associated with incident type 2 diabetes in participants aged 60 years or older, (RR 
3.42; 95% CI 1.70 – 6.88), but not in participants younger than 60 years of age. 
Moreover, weight loss was associated with incident type 2 diabetes in participants 
aged 60 years or older (RR 2.07; 95% CI 1.08 – 3.99). The number of cigarettes/day, 
years of smoking, BMI, alcohol consumption or leisure time physical activity did 
not modify the association between weight change and the risk for type 2 diabetes. 
 
Weight fluctuation, which was calculated as the root-mean-square error (RMSE, kg) 
using the annual weight deviations from the corresponding estimated regression line 
was positively associated with the risk for type 2 diabetes, multivariate adjusted 
relative risk was 1.64 (95% CI 1.24-2.17) in the highest quintile (>1.67 kg) 
compared to the lowest quintile (≤0.54 kg) (Table 11). The risk remained similar 
when adjusted for weight change, relative risk was 1.55 (95% CI 1.17-2.06) for the 
highest vs. lowest weight fluctuation quintile. Large weight fluctuation increased the 
risk of diabetes both in men who gained weight (>4 kg), had stable weight (±4 kg), 
and lost weight (>4 kg) compared to those with stable weight and moderate weight 
fluctuation (Study I). 
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Table 10. Baseline characteristics of the participants in categories of weight change and weight fluctuation. 
Q, quintile 
amedians or proportions 
bWeight change is based on the slope of the regression line fitted to the four weight measurements taken one year apart. 
cWeight fluctuation is the mean deviation of the four weight measurements around the slope (RMSE, root-mean-square error). 
Characteristica Weight changeb (kg)  Quintile of weight fluctuationc (kg) 
 Loss (>4) Stable (± 4) Gain (>4)  Q1 Q2 Q3 Q4 Q5 
     -0.54 0.55-0.84 0.85-1.17 1.18-1.67 1.68- 
   
Number of subjects 2108 15347 3497  4248 4244 4224 4163 4073 
   
Age, years 57.6 56.9 56.2  57.1 56.9 57.2 56.8 56.4 
   
Body mass index, kg/m2 27.1 25.6 26.2  25.3 25.5 25.6 26.0 27.1 
   
Number of cigarettes/day 20 20 20  20 20 20 20 20 
   
Smoking years 37 36 35  36 36 36 36 35 
   
Systolic blood pressure, mmHg 142 140 140  140 140 140 140 140 
   
Diastolic blood pressure, mmHg 90 88 88  86 88 86 88 88 
   
Serum cholesterol, mmol/l 6.30 6.20 6.08  6.21 6.20 6.20 6.18 6.16 
   
Serum HDL cholesterol, mmol/l 1.11 1.16 1.16  1.17 1.17 1.16 1.15 1.11 
   
Alcohol consumption, g/day 11 11 11  10 11 11 11 11 
   
Leisure time physical activity, 
moderate or heavy, % 55 62 57 
 
62 63 62 59 56 
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Table 11. Number of cases, person years, incidence/1000 person years and relative risk of type 2 diabetes with 95% confidence  
interval for categories of weight change and weight fluctuation during follow-up of up to 9 years. 
Weight variable Number of cases Person years  Incidence/1000 
person years 
Relative 
riska 
95% Confidence interval 
 
Weight change, 
kg/ 3 years 
 
Loss, >4 
 
71 
 
14 324 
 
5.0 
 
1.17 
 
0.90 – 1.53 
 
 Stable, ±4 310 110 099 2.8 1.00  
 Gain, >4 
  
154 24 688 6.2 1.77 1.44 – 2.17 
Weight fluctuation, 
kgb 
- 0.54 
 
77 30 344 2.5 1.00  
 0.55 - 0.84 82 30 381 2.7 1.04 0.75 – 1.42 
 0.85 - 1.17 90 30 269 3.0 1.13 0.82 – 1.54 
 
 1.18 - 1.67 91 29 679 3.1 1.04 0.76 – 1.42 
 1.68 - 195 28 437 6.9 1.64 1.24 – 2.17 
aAdjusted for continuous variables age, body mass index, number of cigarettes/day, smoking years, systolic and diastolic  blood pressure, total and high 
density lipoprotein cholesterol and alcohol consumption and for categorical variables intervention group and leisure time physical activity.  
bWeight fluctuation is the mean deviation of the four weight measurements around the slope (RMSE, root-mean-square error). 
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Table 12. Effect of modification by age on the association between weight 
change and the risk of type 2 diabetes. 
Weight 
change 
 
Age < 60 years      Age ≥ 60 years      
 Relative 
riska 
95% 
Confidence 
interval 
Relative 
riska 
95% 
Confidence 
interval 
 p-values 
for 
interaction 
 
  
Lossb 0.74 0.55-1.01 2.07 1.08-3.99  p = 0.004   
 
Stablec 
 
1.00 
  
1.00 
     
 
Gaind 
 
1.25 
 
0.90-1.73 
 
3.42 
 
1.70-6.88 
 
 
 
p = 0.007  
  
aAdjusted for continuous variables age, body mass index, number of cigarettes/day, smoking 
 years, systolic and diastolic blood pressure, total and high density lipoprotein cholesterol and 
 alcohol consumption and for categorical variables intervention group and leisure time physical 
 activity. 
b >4 kg/3 years 
c at most ± 4 kg/3 years 
d  >4 kg/3 years 
 
 
Leisure time physical activities modified the risk for type 2 diabetes with weight 
fluctuation (p = 0.02). Large weight fluctuations increased the risk for type 2 
diabetes in men with light leisure time physical activities (RR 1.95; 95% CI 1.28-
2.98) whereas no increase was observed among men with moderate to heavy 
physical activities during leisure time (Table 13). Furthermore, years of smoking 
modified the risk for type 2 diabetes (p = 0.04). The risk for diabetes in the highest 
quintile of weight fluctuation was elevated (RR 1.91; 95% CI 1.27 – 2.88) among 
men who had smoked less than 36 years. Among participants consuming a mean of 
11g or more alcohol daily, weight fluctuation increased the risk more than two times 
(RR 2.17; 95% CI 1.36-3.45), whereas among those who used less than 11g daily 
the increase was 58%, (RR 1.58; 95% CI 1.10-2.28), the interaction was significant 
p = 0.0001 (Table 13). Age, number of cigarettes/day or BMI did not modify the risk 
for type 2 diabetes with weight fluctuation. 
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Table 13. Effect of modification by leisure time physical activity, years of smoking and alcohol consumption on the association 
between weight fluctuation and the risk of  type 2 diabetes, relative risks and 95% confidence intervals in five quintiles.  
 
Effect modifier 
  
Weight fluctuation (RMSE quintiles, kga) 
 
 
   
P for interactions 
 
Quintile 
 
≤0.54 
 
 
0.55 - 0.84 
 
 
0.85 - 1.17 
 
 
1.18 - 1.67 
 
 
>1.67 
 
Leisure time physical activityb:      
 
Light  
 
1.00 
 
1.18 (0.72 - 1.93) 
 
1.39 (0.87 - 2.24) 
 
1.00 (0.61 - 1.64) 
 
1.95 (1.28 - 2.98)  p = 0.02   
Moderate or heavy  1.00 0.92 (0.60 - 1.40) 0.93 (0.61 - 1.41) 1.01 (0.68 - 1.51) 1.38 (0.95 - 2.00) 
 
Years of smokingb: 
     
 
<36 
 
1.00 
 
1.17( 0.73 - 1.88) 
 
1.39 (0.88 - 2.19) 
 
1.36 (0.87 - 2.13) 
 
1.91 (1.27 - 2.88)  p = 0.04 
 ≥36 1.00 0.94 (0.61 - 1.46) 0.94 (0.61 - 1.45) 0.78 (0.50 - 1.22) 1.43 (0.98 - 2.09) 
 
Alcohol consumption/dayb: 
     
 
< 11 g 
 
1.00 
 
0.80 (0.51 - 1.26) 
 
0.97 (0.63 - 1.50) 
 
1.01 (0.66 - 1.53) 
 
1.58 (1.10 - 2.28) p = 0.0001 
≥ 11 g 1.00 1.58 (0.95 - 2.63) 1.39 (0.83 - 2.32) 1.23 (0.74 - 2.07) 2.17 (1.36 - 3.45) 
a Weight fluctuation is the mean deviation of the four weight measurements around the slope (RMSE, root-mean-square error). 
bAdjusted for continuous variables age, body mass index, number of cigarettes/day, smoking years, systolic and diastolic blood pressure, total and high 
density lipoprotein cholesterol and alcohol consumption and for categorical variables intervention group and leisure time physical activity. 
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5.3 Dietary and serum antioxidants and the risk of type 2 diabetes 
Dietary intake of antioxidants was not associated with incident type 2 diabetes 
(Table 14). Dietary alpha-tocopherol was positively associated with the risk of 
diabetes when adjusted for age and intervention group though this was not consistent; 
relative risk in the highest vs. lowest quintile was 1.17 (95% CI 0.91-1.51, p = 0.02 
for trend). However, the association disappeared after multivariate adjustment (RR 
0.92; 95% CI 0.71-1.19, highest quintile vs. the lowest, p = 0.97 for trend). Similarly 
beta-tocopherol and beta-tocotrienol were positively associated with the risk of 
diabetes when age and supplementation were adjusted, but the associations were no 
longer apparent after multivariate adjusted analyses. Other tocopherols or 
tocotrienols had no association with the risk of diabetes (Table 14). 
 
Dietary vitamin C or beta-carotene were not associated with the risk of type 2 
diabetes. Multivariate adjusted relative risk was 1.04 (95% CI 0.81-1.33) for vitamin 
C and 1.03 (95% CI 0.79-1.35) for beta-carotene between the highest vs. lowest 
quintile (Study II). No associations with the risk of diabetes were found with any 
other dietary carotenoids or any flavonoids (Study II). After further adjusting for 
other antioxidants in the same antioxidant group, and also for consumption of fruits, 
for vegetables and berries, for in addition to adjusting for the consumption of coffee, 
protein and saturated fat the results remained similar. Moreover, the results were not 
essentially changed when the first five years of follow-up were excluded (Study II). 
The association between the intakes of antioxidants and the risk of type 2 diabetes 
was not modified by BMI, leisure time physical activity, or supplementation group. 
 
Baseline serum levels of alpha-tocopherol and beta-carotene were not associated 
with the risk of type 2 diabetes in the placebo group. Their relative risk in the 
highest vs. lowest quintile was 1.59 (95% CI 0.89-2.84) for alpha-tocopherol and 
0.66 (95% CI 0.40-1.10) for beta-carotene during follow-up to 12.5 years (Study III). 
Similarly, when studied in the whole cohort (n = 27 379) of the ATBC Study 
baseline serum level of alpha-tocopherol was not associated with the incidence type 
2 diabetes. The relative risk in the fifth quintile compared to the first quintile was 
1.08 (95% CI 0.81-1.45) and when quintiles two, three, four and five were combined 
and compared to quintile one, the relative risk was only 1.04 (95% CI 0.84-1.30) 
(Table 15). 
 
Baseline serum beta-carotene concentration tended to be associated with lower 
diabetes risk in the main cohort (n = 27 379). The relative risk in the fifth quintile 
compared to the first quintile was 0.69 (95% CI 0.52-0.91 (p = 0.01 for trend). 
However, no significant decreased risk was evident when quintiles two, three, four 
and five of serum beta-carotene were combined and compared to the first quintile 
(RR 0.86; 95% CI 0.71-1.04) (Table 15). 
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Table 14. Relative risk (RR) and 95% confidence intervals (CI) for type 2 diabetes 
in quintiles of energy-adjusted intake of tocopherols and tocotrienols, during 
follow-up to 12.5 years. 
amedian 
bAdjusted as continuous for age and intervention group as categorical. 
cAdjusted for continuous variables age, body mass index, number of cigarettes/day, smoking years, systolic 
and diastolic blood pressure, total and high density lipoprotein cholesterol, alcohol consumption and energy 
intake and for categorical variables intervention group and leisure time physical activity. 
 Quintile of intake  
 1
Referent 
2 3 4 5 p-values 
for trend 
α-Tocopherol, mg/daya 6.09 7.34 8.56 10.64 15.47  
Cases 113 113 131 161 142  
RRb  1.00 0.97 1.10 1.34 1.17 = 0.02 
95% CI 0.74 – 1.26 0.85 – 1.43 1.05 – 1.72 0.91 – 1.51  
RRc    1.00 0.97 1.02 1.19 0.92 = 0.97 
95% CI 0.74 – 1.26 0.79 – 1.32 0.92 – 1.52 0.71 – 1.19  
   β-Tocopherol, mg/daya 0.43 0.61 0.78 0.99 1.36  
Cases 115 124 116 150 155  
RRb  1.00 1.06 0.98 1.27 1.31 = 0.01 
95% CI 0.82 – 1.38 0.76 – 1.28 0.99 – 1.62 1.02 – 1.68  
RRc    1.00 1.02 0.89 1.09 1.06 = 0.48 
95% CI 0.79 – 1.32 0.68 – 1.17 0.85 – 1.41 0.82 – 1.36     γ-Tocopherol, mg/daya 1.75 3.54 5.91 9.67 18.66  
Cases 117 126 136 133 148  
RRb  1.00 1.03 1.08 1.05 1.18 = 0.20 
95% CI 0.80 – 1.33 0.84 – 1.40 0.81 – 1.36 0.92 – 1.51  
RRc   1.00 0.99 1.07 0.92 0.94 = 0.44 
95% CI 0.77 – 1.28 0.83 – 1.37 0.71 – 1.19 0.73 – 1.21  
   δ-Tocopherol, mg/daya 0.14 0.31 0.54 1.27 4.29  
Cases 119 124 131 135 151  
RRb 1.00 0.99 1.00 1.03 1.17 = 0.18 
95% CI 0.77 – 1.28  0.78 – 1.29 0.80 – 1.33 0.92 – 1.50  
RRc 1.00 0.92 0.96 0.95 0.95 = 0.81 
95% CI 0.71 – 1.19 0.74 – 1.23 0.74 – 1.23 0.74 – 1.22     α-Tocotrienol, mg/daya 1.01 1.50 1.89 2.34 3.10  
Cases 137 126 131 125 141  
RRb  1.00 0.90 0.94 0.89 1.03 = 0.84 
95% CI 0.71 – 1.16 0.73 – 1.20 0.70 – 1.15 0.81 – 1.31  
RRc    1.00 0.93 0.91 0.83 1.01 = 0.73 
95% CI 0.72 – 1.19 0.71 – 1.17 0.64 – 1.06 0.79 – 1.29  
   β-Tocotrienol, mg/daya 1.55 2.09 2.50 2.93 3.61  
Cases 116 123 118 151 152  
RRb  1.00 1.04 0.99 1.26 1.28 = 0.01 
95% CI 0.80 – 1.34 0.76 – 1.28 0.99 – 1.62 1.00 – 1.63  
RRc 1.00 0.97 0.89 1.10 1.04 = 0.46 
95% CI 0.75 – 1.26 0.68 – 1.17 0.85 – 1.42 0.80 – 1.35     γ-Tocotrienol, mg/daya 0.07 0.12 0.18 0.27 0.45  
Cases 123 125 140 142 130  
RRb  1.00 0.99 1.09 1.07 0.98 = 0.89 
95% CI 0.77 - 1.27 0.85 - 1.39 0.84 - 1.38 0.76 - 1.26  
RRc  1.00 0.99 1.10 1.11 0.90 = 0.73 
95% CI 0.77 - 1.28 0.86 - 1.42 0.87 - 1.43 0.70 - 1.17     
δ-Tocotrienol, mg/daya 0.01 0.02 0.05 0.09 0.22  
Cases 114 132 125 136 153  
RRb 1.00 1.12 1.03 1.07 1.23 = 0.17 
95% CI 0.87 - 1.45 0.79 - 1.33 0.83 - 1.38 0.96 - 1.58  
RRc 1.00 0.98 1.00 1.02 0.99 = 0.96 
95% CI 0.76 - 1.27 0.77 - 1.30 0.79 - 1.32 0.77 - 1.28  
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Table 15. Relative risk (RR) and 95% confidence interval (CI) of type 2 diabetes by quintiles of baseline serum alpha-
tocopherol and beta-carotene in the whole cohort of the ATBC Study (n = 27 379) during follow-up of up to 12.5 years. 
Serum factor   Quintiles   P- value 
for trend 
Quintiles P- value 
for trend 
 1 2 3 4 5  2-5  
Alpha-tocopherol, mg/l         
median 8.30 10.10 11.45 13.00 15.71  12.17  
range 0.14-9.31 9.32-10.78 10.79-12.17 12.18-14.06 14.07-127.70  9.32-127.70  
Number of cases 124 139 128 141 172  580  
Person-years 50 089 52 328 53 064 53 270 52 908  211 571  
Adjusted RRa 1.00 1.07 0.99 1.05 1.08  1.04  
95% CI  0.83-1.37 0.76-1.29 0.80-1.37 0.81-1.45  p = 0.68 0.84-1.30 p = 0.71 
         
Beta-carotene, µg/l         
median 72 124 173 240 385  203  
range 0-99 100-147 148-202 203-292 293-5686  100-5686  
Number of cases 173 163 154 121 93  531  
Person-years 49 640 51 299 52 635 53 500 54 574  212 008  
Adjusted RRa 1.00 0.92 0.92 0.80 0.69  0.86  
95% CI  0.73-1.14 0.74-1.16 0.62-1.02 0.52-0.91 p = 0.01 0.71-1.03    p = 0.10 
aAdjusted for continuous variables age, body mass index, number of cigarettes/day, smoking years, systolic and diastolic blood pressure, total and high 
density lipoprotein cholesterol and alcohol consumption and for categorical variables intervention group and leisure-time physical activity. 
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5.4 Antioxidant supplementation and the risk of type 2 diabetes 
The effects of alpha-tocopherol and beta-carotene supplementation on the incidence 
of type 2 diabetes were studied in cases diagnosed during the intervention period 
and in cases diagnosed during intervention and 4.5 years post-trial combined (up to 
December, 1997). Neither alpha-tocopherol alone, nor beta-carotene alone, nor both 
combined had any effects on the risk of incident type 2 diabetes during the 
intervention period (Table 16) (Study III). When alpha-tocopherol supplemented 
were compared to those with no alpha-tocopherol supplementation, and beta-
carotene supplemented were compared to those with no beta-carotene 
supplementation, no effect on the risk of incident diabetes was observed for either 
supplement and the relative risks were 0.97 (95% CI 0.77-1.22), and 1.01 (95% CI 
0.80-1.26), respectively. 
 
The results remained similar when alpha-tocopherol supplemented were compared 
to non alpha-tocopherol supplemented and beta-carotene supplemented to non beta-
carotene supplemented (RR 0.92; 95% CI 0.79-1.07 and RR 0.99; 95% CI 0.85-1.15, 
respectively) when the follow-up was extended for 4.5 years post-intervention 
(Table 16) (Study III). After excluding those cases that occurred during the first two 
years of follow-up, the adjusted relative risk was 0.91 (95% CI 0.78-1.06) for alpha-
tocopherol supplemented vs. no alpha-tocopherol supplemented, and 0.99 (95% CI 
0.85-1.16) for beta-carotene supplemented vs. no beta-carotene supplemented during 
the extended follow-up to 12.5 years. 
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Table 16. Risk of type 2 diabetes in the supplementation groups during intervention period and whole follow-up to 12.5 years. 
Follow-up Treatment Number of cases/ 
number of  participants 
 at risk 
Incidence/1000 
person years 
Relative risk 95% Confidence 
interval 
Intervention period      
 Alpha-tocopherol 75 / 6862 1.9 0.97 0.70 -1.33 
 Beta-carotene 77 / 6832 1.9 1.00 0.72 -1.38 
 Alpha-tocopherol + 
Beta-carotene 
75 / 6818 1.9 0.98 0.71 -1.35 
 Placebo 78 / 6867 1.9 1.00  
 Alpha-tocopherol vs. 
no alpha-tocopherol 
  0.97 0.77-1.22 
 Beta-carotene vs. 
no beta-carotene 
  1.01 0.80-1.26 
Whole follow-up to 
12.5 years   
     
 Alpha-tocopherol 170 / 6862 2.6 0.91 0.73 -1.12 
 Beta-carotene 180 / 6832 2.8 0.97 0.79 -1.20 
 Alpha-tocopherol + 
Beta-carotene 
167 / 6818 2.6 0.91 0.73 -1.12 
 Placebo 188 / 6867 2.8 1.00  
 Alpha-tocopherol vs. 
no alpha-tocopherol 
  0.92 0.79-1.07 
 Beta-carotene vs. 
no beta-carotene 
  0.99 0.85-1.15 
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5.5 Antioxidant supplementation and the risk of macrovascular 
complications and mortality in diabetic subjects 
Alpha-tocopherol or beta-carotene supplementation, or both in combination, had no 
effect on the macrovascular complications or mortality in diabetic subjects either 
during the intervention period, or during the 19-years follow-up of up to December, 
2004 (Table 17). When diabetic participants who had received alpha-tocopherol 
supplement were compared with those who had received no alpha-tocopherol 
supplement, no effect on the incidence of total macrovascular complications of 
diabetes was found during the intervention period (RR 0.86; 95% CI 0.65-1.14) or 
during the extended 19-year follow-up (RR 1.03; 95% CI 0.87-1.21) (Table 18). 
Similarly, when participants who had received beta-carotene supplement were 
compared with those who had received no beta-carotene supplement, no effect on 
the incidence of total macrovascular complications of diabetes was shown either 
during the intervention period (RR 1.13; 95% CI 0.85-1.51), or during the extended 
19-year follow-up (RR 1.05; 95% CI 0.89-1.23). 
 
The incidences of a major coronary event, total stroke and peripheral arterial disease 
were not significantly different between any of the four intervention groups during 
either the intervention period (p = 0.14, p = 0.34 and p = 0.35, respectively) or the 
extended 19-year follow-up (p = 0.36, p = 0.44 and p = 0.30, respectively) (Study 
IV). The risk of a major coronary event adjusted for major coronary risk factors 
decreased  statistically significantly for those who received alpha-tocopherol 
compared to those who did not receive alpha-tocopherol (RR 0.64; 95% CI 0.43-
0.95) during the intervention period, but during the whole 19-year follow-up the 
association was non-significant (RR 0.83; 95% CI 0.65-1.06) (Table 18). Beta-
carotene supplementation had no effect on the risk of major coronary event. 
 
When alpha-tocopherol supplemented participants were compared to subjects 
unsupplemented with alpha-tocopherol and beta-carotene supplemented participants 
were compared to those without beta-carotene supplement, no effects on the risks 
for total stroke or for peripheral arterial disease were detected (Table 18). However, 
the risk of stroke was two-fold for those participants with beta-carotene 
supplementation during the intervention period, who at baseline had diabetes 
medication (RR 2.02; 95% CI 0.87- 4.69, p = 0.13 for interaction). There was no 
other effect modification factors (BMI, physical activity or hypertension) on 
macrovascular complications. 
 
There was no significant differences between the four intervention groups during 
either the intervention period (p = 0.93) or the whole 19-year follow-up (p = 0.32) 
for mortality among the diabetic subjects (Study IV). No difference in mortality was 
 
 
THL 2011 — Research 59 65 Antioxidants, weight change and risk of type 2 diabetes 
 
found among those participants who received alpha-tocopherol supplementation 
compared to subjects unsupplemented with alpha-tocopherol either during the 
intervention time or up to 19-years follow-up time (RR 1.02; 95% CI 0.81-1.30, and 
1.03; 95% CI 0.91-1.17, respectively) (Table 18). Similarly, no difference in 
mortality was found among those participants who received beta-carotene 
supplementation compared to subjects with no beta-carotene supplement during 
either the intervention time (RR 0.98; 95% CI 0.77-1.25), or up to 19-years follow-
up (RR 1.03; 95% CI 0.91-1.16). No effect of modification by BMI, physical 
activity or hypertension was observed. 
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Table 17. Effects of antioxidant supplementation on the risk of total macrovascular complications and mortality in diabetic 
subjects during the intervention period and follow-up to 19-years (n = 1238 for incident macrovascular outcomes and n = 1700 
for mortality). 
aRR, relative risk; CI, confidence interval 
bAdjusted  for continuous variables age, body mass index, number of cigarettes/day, smoking years, systolic and diastolic blood pressure, total and high 
density lipoprotein cholesterol and alcohol consumption and for categorical variable leisure-time physical activity. 
Follow-up Treatment Number of 
cases/ 
number of 
participants 
at risk 
Incidence/
1000 
person 
years 
Macrovascular 
complications, 
total, RRa 95% CI, 
crude 
Macrovascular 
complications, 
total, RRa 95% CI, 
multivariate 
adjustedb 
Number 
of deaths 
Mortality, RRa  
95% CI, 
crude 
Mortality, RRa 
95% CI, 
multivariate 
adjustedb 
Intervention 
period 
        
 Alpha-
tocopherol 
51 / 294 31.8 1.00 (0.68-1.49) 1.02 (0.66-1.55) 78 1.04 (0.75-1.45) 1.00 (0.71-1.42) 
 Beta-carotene 74 / 331 42.2 1.34 (0.93-1.92) 1.30 (0.88-1.93) 84 1.11 (0.81-1.53) 0.96 (0.68-1.37) 
 Alpha-
tocopherol+ 
beta-carotene 
54 / 314 31.1 0.98 (0.66-1.44) 0.98 (0.64-1.49) 84 1.06 (0.77-1.47) 1.01 (0.72-1.42) 
 Placebo 52 / 299 31.8 1.00 1.00 72 1.00 1.00 
         
19-year 
follow-up 
        
 Alpha-
tocopherol 
159 / 294 52.1 1.12 (0.90-1.41) 1.13 (0.89-1.43) 292 1.17 (0.99-1.39) 1.11 (0.93-1.33) 
 Beta-carotene 184 / 331 53.0 1.14 (0.91-1.41) 1.14 (0.90-1.44) 296 1.16 (0.98-1.37) 1.10 (0.92-1.32) 
 Alpha-
tocopherol+ 
beta-carotene 
161 / 314 48.1 1.03 (0.82-1.29) 1.08 (0.85-1.37) 299 1.13 (0.95-1.34) 1.07 (0.89-1.28) 
 Placebo 158 / 299 47.5 1.00 1.00 255 1.00 1.00 
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Table 18. Effets of alpha-tocopherol and beta-carotene supplementation on the risks for macrovascular outcomes and  
mortality among diabetic participants during the intervention period and the whole 19-year follow-up (n = 1238 for incident 
macrovascular outcomes and n = 1700 for mortality). 
RR, relative risk; CI, confidence interval 
aRate per 1000 person-years 
bAdjusted for continuous variables age, body mass index, number of cigarettes/day, smoking years, systolic and diastolic blood pressure, total and high 
density lipoprotein cholesterol and alcohol consumption and for categorical variable leisure-time physical activity.
  Intervention period  19-year follow-up 
  Alpha-
Tocopherol 
No Alpha-
Tocopherol 
Beta-
Carotene 
No Beta- 
Carotene 
 Alpha-
Tocopherol 
No Alpha-
Tocopherol 
Beta-
Carotene 
No Beta- 
Carotene 
Macrovascular 
outcomes, total 
Number 105 126 128 103 320 342 345 317
Ratea 31.4 37.2 36.7 31.8 50.0 50.3 50.6 49.7
RRb 
95% CI 
0.86 
0.65 - 1.14 
1.00 1.13
0.85 -1.51
1.00 1.03 
0.87 - 1.21 
1.00
 
1.05
0.89 -1.23
1.00
     
Major coronary Number 49 71 69 51 132 170 151 151
event Ratea 14.7 20.9 19.8 15.7 20.6 25.0 22.1 23.7
 RRb 
95% CI 
0.64 
0.43 - 0.95 
1.00 1.31
0.88 -1.94
1.00 0.83 
0.65 - 1.06 
1.00 0.98
0.77-1. 25
1.00
     
Total stroke Number 34 38 43 29 108 96 112 92
 Ratea 10.2 11.2 12.3 9.0 16.9 14.1 16.4 14.4
 RRb 
95% CI 
1.09 
0.64 - 1.86 
1.00 1.21
0.71 -2.08
1.00 1.31 
0.97 - 1.78 
1.00 1.12
0.82 -1.51
1.00
     
Peripheral  Number 22 17 16 23 80 76 82 74
arterial disease Ratea 6.6 5.0 4.6 7.1 12.5 11.2 12.0 11.6
 RRb 
95% CI 
1.31 
0.68 - 2.55 
1.00 0.65
0.34 -1.27
1.00 1.16 
0.82 - 1.62 
1.00
 
1.10
0.78 -1.54
1.00
     
Total mortality Number 162 156 168 150 591 551 595 547
 Ratea 32.9 32.8 33.9 31.8 56.3 53.2 56.0 53.5
 RRb 
95% CI 
1.02 
0.81 - 1.30 
1.00 0.98
0.77 -1.25
1.00 1.03 
0.91 - 1.17 
1.00 1.03
0.91 -1.16
1.00
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6 Discussion 
6.1 Methodological considerations 
6.1.1 The ATBC Study population 
The ATBC Study was primarily designed to evaluate the effects of alpha-tocopherol 
and beta-carotene supplementation on the risk of lung cancer and other cancers in a 
large male population. The trial was based on a 2x2 factorial design, which made the 
study of the separate effects of each supplement possible. Moreover, the trial 
enabled the study of the effects of the supplements on other end points such as 
diabetes data of which were available from national registers. 
 
The ATBC Study protocol included questionnaires on medical histories and 
lifestyles and measurement of anthropometric characteristics at baseline, which 
enabled the investigation of the risk factors of diabetes in a cohort setting. These 
baseline measurements included general risk factors of type 2 diabetes such as BMI, 
physical activity, blood pressure and serum lipids. An exception to these factors was 
a family history of diabetes. The annual measurement of weight opened up the 
possibility to examine the association of a 3-year weight change with the risk for 
type 2 diabetes. 
 
The participants in the ATBC Study were older middle-aged men with a long history 
of smoking. Smoking is a risk factor for diabetes (Rimm et al. 1995, Mikhailidis et 
al. 1998). According to the oxidation hypothesis, it is to be expected that smokers 
might have benefited most from antioxidant supplementation (Chow 1993). About 
21% of the study participants stopped smoking during their active participation in 
the study (The ATBC Cancer Prevention Study Group 1994). There were, however, 
no smoking data on individuals after stopping the supplementation and during the 
post-intervention follow-up. It is possible that those men who stopped smoking were 
more health-conscious and thus, their dietary antioxidant intakes might have been 
higher than those of the other participants and being more health-conscious, they 
might also have kept their weight more stable compared to the other participants. It 
can also be assumed that they may have undergone more health check-ups and thus 
it was more likely that they had their diabetes diagnosed than was the case for the 
less health-conscious men. These factors may have attenuated the association of 
weight change and antioxidants with diabetes risk towards unity. 
 
Men in the ATBC Study were already at risk of diabetes and atherosclerotic vascular 
changes at baseline because of their age. In general, background characteristics were 
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very similar across the supplementation groups. Study subjects represented the male 
population, but no studies suggest that antioxidants influence males differently than 
females. The selection process of both the ATBC study program and studies I to IV 
in this dissertation must be kept in mind when interpreting the results and 
extrapolating them to other groups of people. Because of several study variables and 
tests, many significant findings may appear by chance and thus need careful 
consideration. 
6.1.2 Compliance and drop-out 
The capsule taking compliance was high with a mean of study subjects taking over 
90% of their capsules during their active participation. Only 4% of participants were 
poor compliers (i.e. took less than 50% of the capsules). The rise in serum alpha-
tocopherol and beta-carotene levels measured in the third follow-up year confirmed 
this good compliance (Rapola 1998). The overall dropout rate during the study was 
30.8% for all the intervention groups. Overall drop-out rate varied from 30.1% to 
31.3% between the supplementation groups. The commonest causes for drop-out 
were death and illness 22% and 21%, respectively, followed by no contact (20%) 
and self-perceived side-effects (14%). The drop-out rate was 11% during the first 
year, 6% in the second, and then leveled off to about 4% annually (The ATBC 
Cancer Prevention Study Group 1994). 
6.1.3 Assessment of measurements 
6.1.3.1 Anthropometric measures 
Weight was measured by a trained study nurse, not self-reported by the study 
participants, during first four annual follow-up visits one year apart to within 100 g 
accuracy. Each participant wore only light clothing and no shoes during the 
weighing. Participants had to be compliant for those visits during which the annual 
weight measurement was planned in order to be included in the study about weight 
change. Between the measurements there were no data about the weight change and 
we have no information about whether the weight changes were intentional on the 
part of the subject. Height was measured at baseline and body mass index for each 
participant was calculated.  
 
Waist or hip girth was not measured. Waist and hip circumferences measure 
different aspects of body composition and fat distribution and have independent 
effects on cardiovascular disease risk factors (Seidell et al. 2001). A narrow waist 
and wide hips may both protect against cardiovascular disease (Seidell et al. 2001). 
We categorized weight change as loss, stable or gain. The 4 kg change in weight 
over 3 years corresponded to a mean weight change of 1.33 kg/year. In the Finnish 
Diabetes Prevention Study the 2-year net weight reduction, 3.5 kg, was associated 
with a 58% reduction in diabetes risk (Tuomilehto et al. 2001). The regression slope 
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fitted to the 4 weight measures over three years was used to assess the trend in 
weight change. Since there were only four weight measurements taken at intervals 
of one year, it was not possible to study weight fluctuations that might have 
occurred over shorter or longer periods of time. 
 
Weight fluctuation was assessed by calculating the root-mean-square error (RMSE, 
kg) using annual weight deviations from the corresponding estimated regression line. 
The RMSE estimate may have misclassified those participants who had continuous 
non-linear weight gain without real weight fluctuation. 
6.1.3.2 Dietary and serum antioxidants 
The underlying principle of the food-frequency approach was that average long-term 
diet was conceptually a more important exposure than intakes record on a few 
specific days (Willett 1990). The result of the food frequency questionnaire (FFQ) is 
always a very subjective picture of the respondent’s own dietary habits and may 
over-report of healthy food consumption and under-report unhealthy food 
consumption. In the ATBC Study, the dietary antioxidants were evaluated by using  
a validated FFQ, which is a standardized epidemiological method (Pietinen et al. 
1988). The dietary measurements were recorded at baseline before the diagnosis of 
diabetes; thus the disease did not influence the recall. At the first visit, the men 
received the FFQ with instructions and a picture booklet to assess the portion size, 
which was to be filled in at home. A study nurse used up to half an hour to check the 
FFQ with each participant. Nutrition professionals revised the questionnaires and 
made the final acceptance about of the FFQ. In all, 93% of the FFQs were 
considered satisfactorily completed. The diet was assessed only once at baseline, 
and thus, dietary changes may have occurred during the follow-up. However, there 
is no reason to suppose that the dietary changes were dissimilar in the 
supplementation groups, and thus are unlikely to have had an effect on the risk 
estimates of the supplementation. 
 
The validity of the dietary assessment instrument as Spearman correlations varied 
between nutrients from 0.4-0.7, which is acceptable for an epidemiologic study. In 
validation studies for nutrient intakes, correlation coefficients between 0.5-0.6 are 
typical (Willett 1990). High correlations between nutrient intakes and that dietary 
intake reported in an epidemiological study of nutrition may not reflect tissue 
concentrations accurately may evoke problems (Willett 1990). 
 
A single measurement of blood alpha-tocopherol can represent long-term vitamin E 
intake to a reasonable degree, and reflect both a capacity to integrate intake over a 
few weeks and indicate an element of long-term stability of diet among persons 
(Willett 1990). Nevertheless, plasma lipid content can influence alpha-tocopherol 
concentration and needs to be taken in account in the analyses (Hunter 1998) 
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because serum alpha-tocopherol is transported by lipoproteins. However, adjustment 
for serum cholesterol had no effect on risk estimates of diabetes for serum alpha- 
tocopherol in this study. A single measurement of blood beta-carotene is also a 
potentially good index of dietary intake because of its sensitivity to intake and the 
capacity to integrate over a period of several weeks (Willett 1990). Adjustment for 
serum cholesterol had no effect on risk estimates for serum beta-carotene. 
6.1.4 End points  
6.1.4.1 Incident diabetes 
The information on incident diabetes was obtained from a nationwide register of 
drug reimbursements. From the year 1964, patients in Finland with physician 
diagnosed diabetes are entitled to receive compensation for their diabetes medication 
from the Social Insurance Institution. According to the Social Insurance Institution 
records, the drug registry covers over 90% of persons who have medical treatment 
for type 2 diabetes (Montonen 2005). Therefore, the validity of the diabetes cases 
obtained from the register of drug reimbursement in Finland is relatively good 
(Montonen 2005). 
 
The register does not include persons with diabetes who were concurrently 
undergoing dietary therapy only, which may have led to conservative estimates of 
the effects and associations between antioxidants and diabetes risk. In 1997, a 
median of approximately 34% of men with diabetes aged 25-64 years had diet only 
as a treatment for diabetes as self-reported in a Finnish survey of six urban areas 
(Korhonen 1999). Each of these areas included 2000 participants (Korhonen 1999). 
The persons with diabetes treated by diet only and in good metabolic control 
(HbA1c <6% on controls) often have a milder form of the disease, although they are 
at increased risk of macrovascular complications (Diabetes 2009). However, so far 
there are no human studies that show that antioxidants have an association with the 
risk of type 2 diabetes treated by diet only. There is no reason to assume any causal 
association between alpha-tocopherol or beta-carotene supplementation and the way 
of diagnosing incident diabetes cases. Nonetheless, in the cohort study we can 
assume that for more health-conscious men who undergo more physical 
examinations, incident diabetes is diagnosed more often than for the less health-
conscious men. This difference could have had an effect on the association of 
antioxidants and the risk of incident diabetes. 
 
The register for drug reimbursement for diabetes contains no data on the type of 
diabetes. In Finland, approximately 90% of all cases of diabetes are of type 2 
(Diabetes 2009). A total, 96% of all diabetic subjects who were diagnosed after the 
age of 55 had type 2 diabetes in a Finnish study (Laakso and Pyörälä 1985). It is 
 
 
THL 2011 — Research 59 72 Antioxidants, weight change and risk of type 2 diabetes 
 
reasonable to assume that almost all cases would be of type 2 diabetes because all of 
the new diabetes cases in this study were aged between 50 to 69 years at baseline. 
6.1.4.2 Macrovascular end-points and mortality 
The National Hospital Discharge Register in Finland includes the dates of hospital 
admission and discharge, and up to four coded discharge diagnoses, the first of 
which is the principal cause of the hospital stay. The National Register of Causes of 
Death contains data on the date and causes of death. A survey of death certificates 
and cause of death examinations concluded that cause of death statistics of 
degenerative heart diseases in Finland are reliable (Penttilä and Ahonen 1975). In a 
Finnish autopsy study, agreement of coronary heart disease antemortem (clinical) 
diagnoses with autopsy diagnoses was good (Stenbäck 1986). 
 
In a validity study, 94% of the major coronary event diagnoses in the registers were 
reviewed according to strict criteria as a true major coronary event in the ATBC 
Study (Rapola et al. 1997). However, there is no reliable register for milder forms of 
coronary heart disease such as angina pectoris. In the ATBC Study, a validation 
study of the register diagnoses showed that, according to standard criteria, 90% of 
cerebral infarctions, 79% of subarachnoid hemorrhages and 82% of intracerebral 
hemorrhages were valid (Leppälä et al. 1999). By definition claudication is a 
symptom that is indicative of peripheral atherosclerosis. For this reason, the mildest 
cases were not retrievable from the above-mentioned registers. However, there was a 
large number of outcomes identified from national registers, and the long follow-up 
time enabled any potential long-term effects of antioxidants to be investigated. 
 
Microvascular complications of diabetes are frequent, and are often treated in 
primary or outpatient care in Finland. However, since there is no reliable register for 
this type of data it was not possible to study the microvascular complications of 
diabetes. 
6.2 Results 
6.2.1 Weight change and fluctuation and risk of type 2 diabetes  
In this study a weight gain more than 4 kg over three years, corresponding 1.33 kg 
weight increase per year nearly doubled the risk of type 2 diabetes during follow-up 
to nine years. This result of weight gain and increased risk of type 2 diabetes is in 
line with previous prospective studies which demonstrated gain in weight or body 
mass index to predict increased risk of type 2 diabetes (Holbrook et al. 1989, Colditz 
et al. 1995, Hanson et al. 1995, Ford et al. 1997, Resnick et al. 2000, Koh-Banerjee 
et al. 2004, Oguma et al. 2005, Wannamethee et al. 2005). Even so, direct 
comparisons are difficult due to differences in how study methods are executed and 
differences between study populations. Among middle-aged and elderly male health 
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professionals weight gains of at least 9 kg over 10 years resulted in a relative risk of 
2.10 compared to those with weight increase or loss not exceeding 2 kg during a 
subsequent follow-up of four years. Nonetheless, it should be noted that in that same 
study a 3-5 kg increase of weight was associated with an increased risk of type 2 
diabetes, relative risk 1.40 (Koh-Banerjee et al. 2004). An even higher risk (RR 5.50; 
95% CI 4.70-6.30) during follow-up of 14 years was found in participants of the 
Nurses’ Health Study who gained at least 11 kg of weight since aged 18 years 
(Colditz et al 1995). Surprisingly, in the NHEFS Study a weight gain of 8-10 kg in 
about 10 years was associated with a non-significant relative risk (RR 1.19; 95% CI 
0.75-1.89) during subsequent follow-up of 8-10 years compared with those whose 
weight had changed less than 5 kg (Ford et al. 1997). When the weight gain was as 
much as 11 to 19 kg in the same study, the relative risk was 2.66 (95% CI 1.84-3.85) 
and even higher among those who gained weight at least 20 kg.  
 
Age per se was not a risk factor for type 2 diabetes in this study, but age was a 
modifying factor in the association of weight gain and the risk of diabetes. Among 
those who were older than 60 years of age at baseline, weight gain was significantly 
associated with a higher risk for diabetes than among those of stable weight. Among 
those who were younger than 60 years at baseline, no such an association was 
observed. Obesity and older age are causes of insulin resistance and may partly 
explain this association (Moller and Flier 1991). Moreover, metabolically active 
increased abdominal fat (Shulman 2000) in relation to diminishing muscle mass may 
also be a contributing factor. 
 
Importance of weight loss in decreasing type 2 diabetes risk is clearly demonstrated 
in intervention studies aimed at decreasing disease risk (Tuomilehto et al. 2001, 
Davey Smith et al. 2005, Hamman et al. 2006). A weight loss of at least 4 kg per 
three years which equates to a mean annual loss of 1.33 kg also corresponds to a 2-
year weight reduction of 2.66 kg which approximates to the reduction that was 
associated with a 58% reduction in diabetes risk in the Finnish Diabetes Prevention 
Study (Tuomilehto et al. 2001). However, in this prospective study weight loss did 
not predict decreased diabetes risk. This result also differs from the findings of other 
prospective cohort studies, which have associated weight losses with decreased risks 
of type 2 diabetes (Colditz et al. 1995, Resnick et al. 2000, Will et al. 2002, Koh-
Banerjee et al. 2004, Wannamethee et al. 2005). These studies include a finding 
from the U.S. men and women who were overweight at baseline (Resnick et al. 2000) 
and also U.S. men and women who reported intentional weight loss at baseline (Will 
et al. 2002). In two large population based studies one on the Nurses’ Health Study 
cohort (Colditz et al. 1995) and the other on middle-aged and elderly male health 
professionals (Koh-Banerjee et al. 2004), the participants because of their profession 
were apparently more aware of healthy lifestyle, which might partly explain their 
results. 
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That the results of the present study for weight loss and the risk of incident type 2 
diabetes differed from above-mentioned studies may also have other explanation. 
Participants in the ATBC Study were middle-aged to older male smokers with an 
increased risk for atherosclerosis and cardiovascular diseases. Although men with 
previous malignancy, severe angina on exertion, chronic renal insufficiency, 
cirrhosis of the liver, chronic alcoholism, and anticoagulant therapy were excluded 
prior to randomization, several other acute or chronic conditions could have 
occurred during the intervention and follow-up periods which cause abnormal 
physiologic states. Therefore, weight loss may have been due to emerging or chronic 
ill health. It is possible that some underlying devastating disease may have affected 
the emerging diabetes. Moreover, there are several previous studies that also 
reported no significant decrease in type 2 diabetes risk upon weight loss (Ford et al. 
1997, Ishikawa-Takata et al. 2002, Oguma et al. 2005, Mishra et al. 2007, Jacobs-van 
der Bruggen et al. 2010, Waring et al. 2010). In one prospective study weight loss was 
even associated with increased risk of type 2 diabetes (Holbrook et al. 1989). 
 
Although weight loss was not associated with an increased risk in the whole study 
population, age was found to be a modifying factor for the association. Weight loss 
predicted increased diabetes risk among older men (≥60 years), but was associated 
with marginally decreased risk among men under 60 years of age. Insulin stimulates 
the uptake, storage and use of glucose in muscle (Moller and Flier 1991). Aging is 
associated with significant changes in body composition, including the loss of 
skeletal muscle mass and increased visceral fat accumulation (Johannsen and 
Ravussin 2010). Aging is also characterized by a drop in resting metabolic rate that 
is disproportionate to the loss of muscle mass, with an associated shift towards 
preferentially oxidizing carbohydrate at the expense of fat. A combination of these 
factors may act to increase muscular lipid infiltration and decrease insulin sensitivity 
(Johannsen and Ravussin 2010). 
 
Weight fluctuation estimated over three years was associated with an increased risk 
for type 2 diabetes; the relative risk in the highest quintile was 1.6 fold compared 
with the lowest quintile of weight fluctuation measurement. This result is in line 
with two previous prospective follow-up studies (French et al. 1997, Brancati et al. 
1999), whereas in three other studies no independent association was found between 
weight fluctuation and the risk of type 2 diabetes (Hanson et al. 1995, Field et al. 
2004, Waring et al. 2010). In the Johns Hopkins Study the participants were U.S. 
men aged 50 years. Their BMI variability from ages 20 to 49 years more than 
doubled their risk for type 2 diabetes (RR 2.1; 95% CI 1.0-4.6) during the mean 
follow-up of 15.6 years (Brancati et al. 1999). In that study sample, the number of 
participants was 916 with only 35 cases of incident diabetes. In another study among 
middle-aged and elderly U.S. women, large weight fluctuations were estimated over 
decades of adult life, and the relative risk for incident type 2 diabetes was found to 
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be 1.70 (95% CI 1.25-2.29) during a follow-up of six years (French et al. 1997). In a 
study on adult women severe weight cycling associated with intentional weight loss 
over four years predicted an elevated risk of type 2 diabetes, but this association was 
not independent of body mass index (Field et al. 2004). In a recent study of middle 
aged men and women weight cycling during middle age was not associated with 
higher rates of type 2 diabetes after adjustment for weight status and weight change 
(Waring et al. 2010). In the present study weight fluctuation estimated over a three 
year period and based on measured body weight was associated with an increased 
risk of diabetes independent of body mass index and of weight change. This finding 
is new, but needs to be confirmed with other studies with different populations, 
more measurements of body weight, and different follow-up times. The root-mean-
square error (RMSE) measurement used to estimate weight fluctuation during the 
three year period has its restrictions. The main restriction is that there were no data 
on the variation of weight for a period more than three years. 
 
Leisure time physical activity modified the association between weight fluctuation 
and risk of type 2 diabetes. When only light exercise was taken, large weight 
fluctuations increased the risk of diabetes two-fold, whereas no association was 
found when the exercise was moderate or heavy. Regular exercise has been found to 
cause several adaptations in the body improving the muscle and whole body insulin 
sensitivity (Perseghin et al. 1996). 
6.2.2 Antioxidants 
6.2.2.1 Dietary and serum antioxidants and the risk of type 2 diabetes 
In this study dietary intake of antioxidants did not have an association with risk of 
incident type 2 diabetes. Thus, these findings do not support the hypothesis that 
dietary antioxidants prevent diabetes. The results are in line with earlier prospective 
cohort studies for which antioxidant intake was found to have no association with 
the risk of incident type 2 diabetes (Knekt et al. 2002, Mayer-Davis et al. 2002, 
Song et al. 2005, Nettleton et al. 2006, Wang et al. 2006a). To date, only one study 
has shown that antioxidant intake is associated with a reduced risk of type 2 diabetes 
(Montonen et al. 2004). In their study the risk of type 2 diabetes was 30% lower 
among persons in the highest vs. lowest quartile of vitamin E intake. Furthermore, 
among the carotenoids considered in their study, beta-cryptoxanthin intake was 
inversely associated with diabetes risk (Montonen et al. 2004). One limitation in that 
study is that no valid data on baseline physical activity were available. It may also 
be possible, that individual antioxidants are only markers for a more healthy diet. In 
the Finnish Mobile Clinic Health Examination Survey population the dietary pattern 
which was characterized by higher consumption of fruits and vegetables was 
inversely associated to type 2 diabetes risk (Montonen et al. 2005). 
The circulating levels of antioxidants in the body may better reflect the capacity of 
the body to combat against oxidants. However, baseline serum levels of alpha-
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tocopherol and beta-carotene were not associated with the risk of incident type 2 
diabetes in the placebo group or in the whole cohort in this study. These results are 
in line with those of three other studies; the Finnish Mobile Clinic Health 
Examination Survey (Reunanen et al. 1998), the Uppsala Longitudinal Study of 
Adult Men for serum alpha-tocopherol (Arnlöv et al. 2009), and the Women’s 
Health Study for plasma carotenoids (Wang et al. 2006b). The findings of the 
prospective studies are, however, contradictory. In two prospective observational 
studies serum alpha-tocopherol levels were associated with lower risks of diabetes 
(Salonen et al. 1995, Mayer-Davis et al. 2002). However, in the Kuopio Ischemic 
Heart Disease Risk Factors Study which studied 944 men, there were only 45 cases 
of incident diabetes (Salonen et al. 1995). Serum beta-carotene concentration was 
associated with reduced risk of incident diabetes in two studies (Hozawa et al. 2006, 
Arnlöv et al. 2009). In these studies the impacts of serum lipids on alpha-tocopherol 
and beta-carotene values were taken into account by utilizing lipid standardized 
serum values or by using an adjustment for serum cholesterol in the analyses. 
Accordingly, differences in the consideration of serum lipids do not seem to explain 
dissimilar results. 
6.2.2.2 Intervention effects 
6.2.2.2.1 Risk of type 2 diabetes  
Supplementation of alpha-tocopherol or beta-carotene separately or in combination 
had no effect on the risk of incident type 2 diabetes during either the intervention 
period with a median follow-up time of 6.1 years, or during the whole follow-up 
which extended for 4.5 years after the intervention. The results of the present study 
support the few previous controlled clinical trials which found no effect with 
antioxidant supplementation on the risk of type 2 diabetes. The dosages of the 
supplements were as follows: in the Physician’ Health Study the supplementation 
dose was 50 of mg beta-carotene on alternate days (Liu et al. 1999), in the HOPE 
Study 400 IU vitamin E a day (Lonn et al. 2002), in the Women’s Health Study 600 
IU vitamin E on alternate days (Liu et al. 2006), in the Women’s Antioxidant 
Cardiovascular Study 500 mg synthetic vitamin C every day, 600 IU vitamin E or 50 
mg beta-carotene every other day (Song et al. 2009), and in the SELECT Study 200 
µg selenium every day or 400 IU vitamin E every day, or both (Lippman et al. 2009). 
In previous studies relative risk for those receiving vitamin E supplement compared 
to placebo group varied between 0.95 (95% CI 0.87-1.05) (Liu et al 2006) and 1.13 
(95% CI 0.99-1.29) (Song et al. 2009). Relative risk for beta-carotene supplement 
receivers compared to those without supplement was 0.97 (95% CI 0.85-1.11) in one 
study which investigated the effect of beta-carotene supplementation (Song et al. 
2009). Relative risk in another study was 0.99 (95% CI 0.86-1.14) with the same 
dosage of beta-carotene supplement compared to non-receivers of beta-carotene 
supplement (Liu et al. 1999). 
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Although the results of the present study are in line with the above-mentioned 
studies there are also dissimilarities between these studies. In the ATBC Study the 
participants were male smokers, whereas in the Physicians’ Health Study the 
participants were possibly more health-conscious men who had healthy diet habits 
and life styles. At baseline, 7.1% of the men in Physicians’ Health Study smoked 
≥20 cigarettes per day (Liu et al. 1999). In the Women’s Health Study 13% of the 
participants of the vitamin E intervention group were current smokers at baseline 
(Liu et al. 2006). In most of the studies daily supplements of antioxidants, especially 
vitamin E, were considerably higher than in the ATBC Study and some studies used 
different combinations of antioxidants (Lippman et al. 2006, Song et al. 2009). The 
results of these studies support the conclusion that vitamin E or beta-carotene as 
supplements are not preventive for type 2 diabetes. 
6.2.2.2.2 Complications of type 2 diabetes 
This study observed that macrovascular complications of diabetes or mortality from 
diabetes were not influenced by antioxidant supplementation. These results are in 
line with the previous randomized double-blinded and placebo-controlled studies 
which had up to 10.1 years mean follow-up time for which neither vitamin E, vitamin 
C, and beta-carotene had no detectable effects on reducing the macrovascular 
complications of diabetes or total or cardiovascular mortality (Lonn et al. 2002, The 
Heart Protection Study Collaborative Group 2002, Lee et al. 2005, Cook et al. 2007, 
Sesso et al. 2008). The dosage of vitamin E supplementation (alpha-tocopherol 50 
mg/day [50 IU]) was low in the ATBC Study compared to above-mentioned studies. 
In the HOPE Study and in the Physicians’ Health Study II the daily dose of vitamin 
E was 400 IU daily or every other day (Lonn et al. 2002, Sesso et al. 2008), and in 
the Women’s Antioxidant Cardiovascular Study and the Women’s Health Study the 
vitamin E dose was 600 IU daily or every other day, respectively (Lee et al. 2005, 
Cook et al. 2007). 
 
The daily dose of beta-carotene (20 mg/day) in the ATBC Study is in line of the 
supplementation dosage of the MRC/BHF Heart Protection Study (The Heart 
Protection Study Collaborative Group 2002). In the Women’s Antioxidant 
Cardiovascular Study the dosage of beta-carotene was 50 mg, but taken every other 
day (Cook et al. 2007). The populations of these intervention studies were drawn 
from different countries in Europe, North America and South America and they 
included both female (Lonn et al. 2002, The Heart Protection Study Collaborative 
Group 2002, Lee et al. 2005, Cook et al. 2007) and male participants (Lonn et al. 
2002, The Heart Protection Study Collaborative Group 2002, Sesso et al. 2008). All 
these earlier studies and this study with different populations and varying dosages of 
supplemented antioxidants conclude that the supplementations with antioxidants do 
not decrease the risk of macrovascular complications or mortality of persons who 
have type 2 diabetes. 
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7 Conclusions 
The ATBC Study demonstrated that weight change and fluctuation were 
independent risk factors for type 2 diabetes, in middle-aged and older smoking 
Finnish men. Furthermore, this study demonstrated that type 2 diabetes was not 
preventable by dietary antioxidants or by antioxidant supplementation (alpha-
tocopherol or beta-carotene). Antioxidant supplementation (alpha-tocopherol or 
beta-carotene) did not prevent macrovascular complications of diabetes nor total 
mortality of diabetics. 
 
The conclusions responding to the objectives of this study are: 
 
1. Weight gain was a risk factor for type 2 diabetes in middle-aged and older 
smoking men. This result is in line with the results in previous prospective cohort 
studies. Weight gain was a risk factor for type 2 diabetes especially in men aged 60 
years or older, as was weight loss for persons aged 60 years or older. Weight 
fluctuation during a three year period was associated with increased risk for type 2 
diabetes independent of weight gain. This finding is new and needs to be confirmed 
in future studies. 
 
2. Intake of dietary antioxidants - tocopherols, tocotrienols, carotenoids, vitamin C 
or flavonoids - at baseline was not associated with the risk of type 2 diabetes. 
Similarly, high baseline serum alpha-tocopherol or beta-carotene levels were not 
associated with lower risk of incident type 2 diabetes in the placebo group or in the 
whole study cohort . 
 
3. Neither alpha-tocopherol nor beta-carotene supplementation prevented type 2 
diabetes when analyzed either during the intervention period or during the whole 
12.5 year follow-up of this study. 
 
4. Neither alpha-tocopherol nor beta-carotene supplementation decreased the 
incidence of macrovascular complications of diabetes or total mortality of diabetic 
men either during the intervention period or during the whole 19-year follow-up in 
this study. 
 
 
The primary aim of this study was to evaluate whether serum or dietary antioxidants 
or supplemented antioxidants (alpha-tocopherol or beta-carotene) have any effect on 
preventing type 2 diabetes or macrovascular complications of diabetes or mortality 
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of diabetic subjects. In line with the negative results from previous controlled trials 
these results give no reason to suggest supplementation with beta-carotene or alpha-
tocopherol for the prevention or treatment of diabetes. Avoiding weight gain and 
weight fluctuation decreased the risk of type 2 diabetes. Consequently, a healthy 
lifestyle with a diverse diet, which keeps the body weight stable are to be 
recommended to the public as measures to prevent type 2 diabetes. 
 
 
THL 2011 — Research 59 80 Antioxidants, weight change and risk of type 2 diabetes 
 
8 Acknowledgements 
This work was carried out at the National Institute for Health and Welfare, Helsinki, 
as part of the ATBC Study, in 2003-2011. I owe my deepest gratitude to Professor 
Jarmo Virtamo, Principal Investigator of the ATBC Study, who acted as my 
supervisor throughout the work. Jarmo’s prodigious experience in epidemiology and 
conducting large trials helped me learn this kind of research. His positive attitude 
towards my work and patience is something that I will always remember with 
gratitude. My other supervisor, docent Satu Männistö, has a far perspective into 
nutritional epidemiology. She helped me actively and her comments and supportive 
enthusiasm have been of great value. 
 
Docent Ritva Järvinen carefully reviewed the manuscript of this thesis. Her firm, but 
constructive criticism and expert guidance reflected her experience in epidemiology, 
which improved this work considerably. Docent Leena Moilanen, the other official 
reviewer of this thesis, with her vast experience and expertise in endocrinology, 
provided me with many helpful comments. I thank you both for your kind and 
important critique. 
 
This kind of research requires the input of an expert team. The data management and 
statistics professionals of the ATBC Study have been the core of this input at all 
stages of my work. During the early phases Mikko Virtanen M.Sc and Jari Sundell 
M.Sc, with their expertise in statistics, helped me with constructive advice. During 
the later phases of this work, I had the joy to work with Jukka Kontto, M.Sc. His 
helpfulness and great assistance during many statistical phases of my work is greatly 
appreciated. Heikki Kilpeläinen, B.Sc. data manager of the ATBC Study, helped me 
in many hardware problems without delay. I also had an opportunity to co-operate 
with Demetrius Albanes, MD, from the National Cancer Institute, USA. His 
assistance in manuscript preparation is appreciated. I wish to thank professor Pirjo 
Pietinen, one of the persons who actually interviewed me at the beginning. She has 
given me much useful advice as an expert in nutritional epidemiology. 
 
The National Institute for Health and Welfare has provided excellent facilities for 
research. The personnel at the library of the National Institute for Health and 
Welfare have always been very helpful. I especially thank Jukka Lindeman, of his 
always professional and positive attitude when I asked for help. Still one person 
from the Chronic Disease Epidemiology and Prevention Unit has to be 
acknowledged for her special role in helping me finish this thesis. Ms. Marketta 
Taimi as a dear friend of mine has rapidly answered all my questions and fulfilled 
my requests. I have enjoyed many nice moments with the people working in the 
 
 
THL 2011 — Research 59 81 Antioxidants, weight change and risk of type 2 diabetes 
 
Chronic Disease Epidemiology and Prevention Unit. I warmly thank you all of your 
good company. I also express my deep gratitude to the Language Center, University 
of Helsinki, for revising the English language of this thesis. 
 
My dear husband Markku and our children Kati and Wille deserve super special 
thanks. You have supported me hugely during these years. Additionally, I express 
my deepest gratitude to my twin sister Helena, M.Sc, librarian, for her great and 
everlasting, positive support. Wäinö, my godson, thank you for your good temper in 
helping me in many ways. Heartfelt support from my mother Helena Kataja has 
made it possible for me to concentrate on the work. 
 
 
 
 
Helsinki, April 2011 
 
Merja Kataja-Tuomola 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THL 2011 — Research 59 82 Antioxidants, weight change and risk of type 2 diabetes 
 
References 
Abdullah A, Peeters A, de Courten M, Stoelwinder J 
(2010): The magnitude of association between 
overweight and obesity and the risk of diabetes: 
A meta-analysis of prospective cohort studies. 
Diabetes Res Clin Pract 89:309-19. 
 
Alberti KG, Zimmet P, Shaw J (2005): The 
metabolic syndrome--a new worldwide 
definition. Lancet 366:1059-62. 
 
American Diabetes Association (1997): Report of the 
Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus. Diabetes 
Care 7:1183-97. 
 
Arnlöv J, Zethelius B, Riserus U, Basu S, Berne C, 
Vessby B, Alfthan G, Helmersson J (2009): 
Serum and dietary beta-carotene and alpha-
tocopherol and incidence of type 2 diabetes 
mellitus in a community-based study of Swedish 
men: report from the Uppsala Longitudinal 
Study of Adult Men (ULSAM) study. 
Diabetologia 52:97-105. 
 
Azevedo-Martins AK, Monteiro AP, Lima CL, 
Lenzen S, Curi R (2006): Fatty acid-induced 
toxicity and neutral lipid accumulation in 
insulin-producing RINm5F cells. Toxicol In 
Vitro 20:1106-13. 
 
Balkau B (2000): The DECODE study. Diabetes 
epidemiology: collaborative analysis of diagnostic 
criteria in Europe. Diabetes Metab 26:282-6. 
 
Balkau B, Hu G, Qiao Q, Tuomilehto J, Borch-
Johnsen K, Pyörälä K (2004): Prediction of the 
risk of cardiovascular mortality using a score that 
includes glucose as a risk factor. The DECODE 
Study. Diabetologia 47:2118-28.
 
 
Bazzano LA, Li TY, Joshipura KJ, Hu FB (2008): 
Intake of fruit, vegetables, and fruit juices and risk 
of diabetes in women. Diabetes Care 31:1311-7. 
 
Beckman JA, Creager MA, Libby P (2002): Diabetes 
and atherosclerosis: epidemiology,  
pathophysiology, and management. JAMA 
287:2570-81. 
 
Bendich A, Olson JA (1989): Biological actions of 
carotenoids. Faseb J 3:1927-32. 
 
Boden G, Shulman GI (2002): Free fatty acids in 
obesity and type 2 diabetes: defining their role in 
the development of insulin resistance and beta-
cell dysfunction. Eur J Clin Invest 32:14S-23. 
 
Boulton AJ (2004): The diabetic foot: from art to 
science. The 18th Camillo Golgi lecture. 
Diabetologia 47:1343-53. 
 
Boyko EJ, Ahroni JH, Cohen V, Nelson KM, 
Heagerty PJ (2006): Prediction of diabetic foot 
ulcer occurrence using commonly available 
clinical information: the Seattle Diabetic Foot 
Study. Diabetes Care 29:1202-7. 
 
Brancati FL, Wang NY, Mead LA, Liang KY, Klag 
MJ (1999): Body weight patterns from 20 to 49 
years of age and subsequent risk for diabetes 
mellitus: the Johns Hopkins Precursors Study 
Arch Intern Med 159:957-63. 
 
Britton G (1995): Structure and properties of 
carotenoids in relation to function. Faseb J 
9:1551-8. 
 
Brownlee M (2001): Biochemistry and molecular 
cell biology of diabetic complications. Nature 
414:813-20. 
 
 
THL 2011 — Research 59 83 Antioxidants, weight change and risk of type 2 diabetes 
 
Bucala R, Makita Z, Vega G, Grundy S, Koschinsky T, 
Cerami A, Vlassara H (1994): Modification of low 
density lipoprotein by advanced glycation end 
products contributes to the dyslipidemia of 
diabetes and renal insufficiency. PNAS 91:9441-5. 
 
Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza 
RA, Butler PC (2003): Beta-cell deficit and 
increased beta-cell apoptosis in humans with 
type 2 diabetes. Diabetes 52:102-10. 
 
Carey VJ, Walters EE, Colditz GA, Solomon CG, 
Willett WC, Rosner BA, Speizer FE, Manson JE 
(1997): Body fat distribution and risk of non-
insulin-dependent diabetes mellitus in women. 
The Nurses' Health Study. Am J Epidemiol 
145:614-9. 
 
Ceriello A, Motz E (2004): Is oxidative stress the 
pathogenic mechanism underlying insulin 
resistance, diabetes, and cardiovascular disease? 
The common soil hypothesis revisited. 
Arterioscler Thromb Vasc Biol 24:816-23. 
 
Chow CK (1993): Cigarette smoking and oxidative 
damage in the lung. Ann N Y Acad Sci 686:289-
98. 
 
Clark SF (2002): The biochemistry of antioxidants 
revisited. Nutr Clin Pract 17:5-17. 
 
Colditz GA, Willett WC, Rotnitzky A, Manson JE 
(1995): Weight gain as a risk factor for clinical 
diabetes mellitus in women. Ann Intern Med 
122:481-6. 
 
Cook NR, Albert CM, Gaziano JM, Zaharris E, 
MacFadyen J, Danielson E, Buring JE, Manson 
JE (2007): A randomized factorial trial of 
vitamins C and E and beta carotene in the 
secondary prevention of cardiovascular events in 
women: results from the Women's Antioxidant 
Cardiovascular Study. Arch Intern Med 
167:1610-8. 
 
Croft KD (1998): The chemistry and biological 
effects of flavonoids and phenolic acids. Ann N 
Y Acad Sci 854:435-42. 
 
Czernichow S, Couthouis A, Bertrais S, Vergnaud 
AC, Dauchet L, Galan P, Hercberg S (2006): 
Antioxidant supplementation does not affect 
fasting plasma glucose in the Supplementation 
with Antioxidant Vitamins and Minerals 
(SU.VI.MAX) study in France: association with 
dietary intake and plasma concentrations. Am J 
Clin Nutr 84:395-9. 
 
Davey Smith G, Bracha Y, Svendsen KH, Neaton JD, 
Haffner SM, Kuller LH (2005): Incidence of 
type 2 diabetes in the randomized multiple risk 
factor intervention trial. Ann Intern Med 12:313-
22. 
 
Devasagayam TP, Tilak JC, Boloor KK, Sane KS, 
Ghaskadbi SS, Lele RD (2004): Free radicals 
and antioxidants in human health: current status 
and future prospects. J Assoc Physicians India 
52:794-804. 
 
Diabetes (2009): Käypä hoito -suositus: Working 
group appointed by the Finnish Medical Society 
Duodecimin and the Medical Advisory Board of 
the Finnish Diabetes Society. Helsinki: Finnish 
Medical Society Duodecim [updated 15.9.2009]. 
www.kaypahoito.fi (accessed March 2011). 
 
Duthie G, Crozier A (2000): Plant-derived phenolic 
antioxidants. Curr Opin Lipidol 11:43-7. 
 
Eriksson JG, Osmond C, Kajantie E, Forsen TJ, 
Barker DJ (2006): Patterns of growth among 
children who later develop type 2 diabetes or its 
risk factors. Diabetologia 49:2853-8. 
 
 
THL 2011 — Research 59 84 Antioxidants, weight change and risk of type 2 diabetes 
 
Esposito K, Nappo F, Marfella R, Giugliano G, 
Giugliano F, Ciotola M, Quagliaro L, Ceriello A, 
Giugliano D (2002): Inflammatory cytokine 
concentrations are acutely increased by 
hyperglycemia in humans: role of oxidative 
stress. Circulation 106:2067-72. 
 
Evans JL, Goldfine ID, Maddux BA, Grodsky GM 
(2002): Oxidative stress and stress-activated 
signaling pathways: a unifying hypothesis of 
type 2 diabetes. Endocr Rev 23:599-622. 
 
Fang YZ, Yang S, Wu G (2002): Free radicals, 
antioxidants, and nutrition. Nutrition 18:872-9. 
 
Feskens EJ, Virtanen SM, Rasanen L, Tuomilehto J, 
Stengard J, Pekkanen J, Nissinen A, Kromhout D 
(1995): Dietary factors determining diabetes and 
impaired glucose tolerance. A 20-year follow-up 
of the Finnish and Dutch cohorts of the Seven 
Countries Study. Diabetes Care 18:1104-12. 
 
Field AE, Manson JE, Laird N, Williamson DF, 
Willett WC, Colditz GA (2004): Weight cycling 
and the risk of developing type 2 diabetes among 
adult women in the United States. Obes Res 
12:267-74. 
 
Florez JC (2008): Newly identified loci highlight 
beta cell dysfunction as a key cause of type 2 
diabetes: where are the insulin resistance genes? 
Diabetologia 51:1100-10. 
 
Folsom AR, Rasmussen ML, Chambless LE, 
Howard G, Cooper LS, Schmidt MI, Heiss G 
(1999): Prospective associations of fasting 
insulin, body fat distribution, and diabetes with 
risk of ischemic stroke. The Atherosclerosis Risk 
in Communities (ARIC) Study Investigators. 
Diabetes Care 22:1077-83. 
 
Ford ES, Mokdad AH (2001): Fruit and vegetable 
consumption and diabetes mellitus incidence 
among U.S. adults. Prev Med 32:33-9. 
 
Ford ES, Williamson DF, Liu S (1997): Weight 
change and diabetes incidence: findings from a 
national cohort of US adults. Am J Epidemiol 
146:214-22. 
 
French SA, Folsom AR, Jeffery RW, Zheng W, 
Mink PJ, Baxter JE (1997): Weight variability 
and incident disease in older women: the Iowa 
Women's Health Study. Int J Obes Relat Metab 
Disord 21:217-23. 
 
Fridlyand LE, Philipson LH (2006): Reactive species 
and early manifestation of insulin resistance in 
type 2 diabetes. Diabetes Obes Metab 8:136-45. 
 
Friedman JH (1984): SMART user’s guide: Stanford 
University. Laboratory for Computational 
Statistics. Palo Alto. Report No.: 1. 
 
Gerich JE (1998): The genetic basis of type 2 
diabetes mellitus: impaired insulin secretion 
versus impaired insulin sensitivity. Endocr Rev 
19:491-503. 
 
Goldberg RB (1981): Lipid disorders in diabetes. 
Diabetes Care 4:561-72. 
 
Goodpaster BH, Kelley DE, Wing RR, Meier A, 
Thaete FL (1999): Effects of weight loss on 
regional fat distribution and insulin sensitivity in 
obesity. Diabetes 48:839-47. 
 
Grambsch P, Therneau T (1994): Proportional 
hazards tests and diagnostics based on weighted 
residuals. Biometrika 81:515-26. 
 
 
 
THL 2011 — Research 59 85 Antioxidants, weight change and risk of type 2 diabetes 
 
Groop L, Lyssenko V (2009): Genetic basis of beta-
cell dysfunction in man. Diabetes Obes Metab 
11:Suppl 4:149-58. 
 
Guh DP, Zhang W, Bansback N, Amarsi Z, 
Birmingham CL, Anis AH (2009): The incidence 
of co-morbidities related to obesity and 
overweight: a systematic review and meta-
analysis. BMC Public Health 9:88. 
 
Guzik TJ, Mussa S, Gastaldi D, Sadowski J, 
Ratnatunga C, Pillai R, Channon KM (2002): 
Mechanisms of increased vascular superoxide 
production in human diabetes  mellitus: role of 
NAD(P)H oxidase and endothelial nitric oxide 
synthase. Circulation 105:1656-62. 
 
Hales CN, Barker DJ, Clark PM, Cox LJ, Fall C, 
Osmond C, Winter PD (1991): Fetal and infant 
growth and impaired glucose tolerance at age 64. 
BMJ 303:1019-22. 
 
Halliwell B (1995): How to characterize an antioxidant: 
an update. Biochem Soc Symp 61:73-101. 
 
Hamer M, Chida Y (2007): Intake of fruit, 
vegetables, and antioxidants and risk of type 2 
diabetes: systematic review and meta-analysis. J 
Hypertens 25:2361-9. 
 
Hamman RF, Wing RR, Edelstein SL, Lachin JM, 
Bray GA, Delahanty L, Hoskin M, Kriska AM, 
Mayer-Davis EJ, Pi-Sunyer X, Regensteiner J, 
Venditti B, Wylie-Rosett J (2006): Effect of 
weight loss with lifestyle intervention on risk of 
diabetes. Diabetes Care 29:2102-7. 
 
Hanhineva K, Törrönen R, Bondia-Pons I, Pekkinen 
J, Kolehmainen M, Mykkänen H, Poutanen K 
(2010): Impact of dietary polyphenols on 
carbohydrate metabolism. Review. Int J Mol Sci 
11:1365-1402. 
Hanson RL, Narayan KM, McCance DR, Pettitt DJ, 
Jacobsson LT, Bennett PH, Knowler WC (1995): 
Rate of weight gain, weight fluctuation, and 
incidence of NIDDM. Diabetes 44:261-6. 
 
Harding AH, Wareham NJ, Bingham SA, Khaw K, 
Luben R, Welch A, Foroughi NG (2008): Plasma 
vitamin C level, fruit and vegetable consumption, 
and the risk of new-onset type 2 diabetes 
mellitus: The European Prospective Investigation 
of Cancer−Norfolk Prospective Study. Arch 
Intern Med 168:1493-9. 
 
Harris MI, Flegal KM, Cowie CC, Eberhardt MS, 
Goldstein DE, Little RR, Wiedermeyer HM, 
Byrd-Holt DD (1998): Prevalence of diabetes, 
impaired fasting glucose, and impaired glucose 
tolerance in U.S. adults. The Third National 
Health and Nutrition Examination Survey, 1988-
1994. Diabetes Care 21:518-24. 
 
Hartemink N, Boshuizen HC, Nagelkerke NJ, Jacobs 
MA, van Houwelingen HC (2006): Combining 
risk estimates from observational studies with 
different exposure cutpoints: a meta-analysis on 
body mass index and diabetes type 2. Am J 
Epidemiol 163:1042-52. 
 
Heinonen M (1990): Carotenoids and retinoids in 
Finnish foods and the average diet. Department 
of Food Chemistry and Technology, University 
of Helsinki, EKT: 811. Helsinki. 
 
Hensley K, Benaksas EJ, Bolli R, Comp P, Grammas 
P, Hamdheydari L, Mou S, Pye QN, Stoddard 
MF, Wallis G, Williamson KS, West M, 
Wechter WJ, Floyd RA (2004): New 
perspectives on vitamin E: gamma-tocopherol 
and  carboxyelthylhydroxychroman metabolites 
in biology and medicine. Free Radic Biol Med 
36:1-15. 
 
 
 
THL 2011 — Research 59 86 Antioxidants, weight change and risk of type 2 diabetes 
 
Herrmann K (1988): On the occurrence of flavonol 
and flavone glycosides in vegetables. Z Lebensm 
Unters Forsch 186:1-5. 
 
Hertog MGL, Hollman PC, Katan MB (1992): 
Content of potentially anticarcinogenic flavonoids 
of 28 vegetables and 9 fruits commonly consumed 
in the Netherlands. J Agric Food Chem 40:2379-
83. 
 
Hertog MGL, Hollman PC, van de Putte P (1993): 
Content of potentially anticarcinogenic flavonoids 
in tea infusions, wine, and fruit juices. J Agric 
Food Chem 41:1242-6. 
 
Holbrook TL, Barrett-Connor E, Wingard DL (1989): 
The association of lifetime weight and weight 
control patterns with diabetes among men and 
women in an adult community. Int J Obes 
13:723-9. 
 
Hozawa A, Jacobs DR Jr., Steffes MW, Gross MD, 
Steffen LM, Lee DH (2006): Associations of 
serum carotenoid concentrations with the 
development of diabetes and with insulin 
concentration: interaction with smoking: the 
Coronary Artery Risk Development in Young 
Adults (CARDIA) Study. Am J Epidemiol 
163:929-37. 
  
Hu FB, Manson JE, Stampfer MJ, Colditz G, Liu S, 
Solomon CG, Willett WC (2001): Diet, lifestyle, 
and the risk of type 2 diabetes mellitus in women. 
N Engl J Med 345:790-7. 
 
Hunter D: Biochemical indicators of dietary intake. 
In Willett W (editor) (1998): Nutritional 
epidemiology, 2nd ed. Oxford University Press, 
New York, Oxford. 
 
Häkkinen SH, Kärenlampi SO, Heinonen IM, 
Mykkänen HM, Törrönen AR (1999): Content of 
the flavonols quercetin, myricetin and 
kaempherol in 25 edible berries. J Agric Food 
Chem 47:2274-9. 
 
Institute of Medicine (2000): Dietary reference 
intakes for vitamin C, vitamin E, selenium, and 
carotenoids. The National Academies Press, 
Washington D.C. 
 
Iribarren C, Sharp DS, Burchfiel CM, Petrovitch H 
(1995): Association of weight loss and weight 
fluctuation with mortality among Japanese 
American men. N Engl J Med 333:686-92. 
 
Ishikawa-Takata K, Ohta T, Moritaki K, Gotou T, 
Inoue S (2002): Obesity, weight change and risks 
for hypertension, diabetes and hypercholesterolemia 
in Japanese men. Eur J Clin Nutr 56:601-7. 
 
Jacobs-van der Bruggen MA, Spijkerman A, van 
Baal PH, Baan CA, Feskens EJ, Picavet HS, van 
der A DL, Verschuren WM (2010): Weight 
change and incident diabetes: addressing an 
unresolved issue. Am J Epidemiol 172:263-70. 
 
Jakus V, Rietbrock N (2004): Advanced glycation 
end-products and the progress of diabetic 
vascular complications. Physiol Res 53:131-42. 
 
Johannsen DL, Ravussin E (2010): Obesity in the 
elderly: is faulty metabolism to blame? Aging 
health 6:159-67. 
 
Johansen JS, Harris AK, Rychly DJ, Ergul A (2005): 
Oxidative stress and the use of antioxidants in 
diabetes: linking basic science to clinical practice. 
Cardiovasc Diabetol 4:5. 
  
Kaprio J, Tuomilehto J, Koskenvuo M, Romanov K, 
Reunanen A, Eriksson J, Stengard J, Kesäniemi 
YA (1992): Concordance for type 1 (insulin-
dependent) and type 2 (non-insulin-dependent) 
 
 
THL 2011 — Research 59 87 Antioxidants, weight change and risk of type 2 diabetes 
 
diabetes mellitus in a population-based cohort of 
twins in Finland. Diabetologia 35:1060-7. 
 
Kattermann R, Jaworek D, Möller G, Assmann G, 
Björkhem I, Svensson L, Borner K, Boerma G, 
Leijinse B, Desager JP (1984): Multicentre study 
of a new enzymatic method of cholesterol 
determination. J Clin  Chem Clin Biochem 
22:245-51. 
 
Khachik F, Spangler CJ, Smith JC Jr., Canfield LM, 
Steck A, Pfander H (1997): Identification, 
quantification, and relative concentrations of 
carotenoids and their metabolites in human milk 
and serum. Anal Chem 69:1873-81. 
 
Kissela BM, Khoury J, Kleindorfer D, Woo D, 
Schneider A, Alwell K, Miller R, Ewing I, 
Moomaw CJ, Szaflarski JP, Gebel J, Shukla R, 
Broderik JP (2005): Epidemiology of ischemic 
stroke in patients with diabetes: the greater 
Cincinnati/Northern Kentucky Stroke Study. 
Diabetes Care 28:355-9. 
 
Knekt P, Kumpulainen J, Järvinen R, Rissanen H, 
Heliövaara M, Reunanen A, Hakulinen T, 
Aromaa A (2002): Flavonoid intake and risk of 
chronic diseases. Am J Clin Nutr 76:560-8. 
 
Koh-Banerjee P, Wang Y, Hu FB, Spiegelman D, 
Willett WC, Rimm EB (2004):  Changes in body 
weight and body fat distribution as risk factors 
for clinical diabetes in US men. Am J Epidemiol 
159:1150-9. 
 
Korhonen HJ, Jousilahti P, Vartiainen E, Juolevi A, 
Sundvall J, Puska P (1999): FINRISKI 1997: 
Kaupunkiraportti. Kansanterveyslaitos/ National 
Public Health Institute Report No.: B4. Helsinki: 
Hakapaino.  
 
Kostner GM (1976): Letter: Enzymatic 
determination of cholesterol in high-density 
lipoprotein fractions prepared by polyanion 
precipitation. Clin Chem 22:695. 
 
Kotronen A, Vehkavaara S, Seppälä-Lindroos A, 
Bergholm R, Yki-Järvinen H (2007): Effect of 
liver fat on insulin clearance. Am J Physiol 
Endocrinol Metab 293: E1709-15. 
 
Laakso M, Barrett-Connor E (1989): Asymptomatic 
hyperglycemia is associated with lipid and 
lipoprotein changes favoring atherosclerosis. 
Arteriosclerosis 9:665-72. 
  
Laakso M, Lehto S (1998): Epidemiology of risk 
factors for cardiovascular disease in diabetes and 
impaired glucose tolerance. Atherosclerosis 137: 
Suppl:S65-S73. 
 
Laakso M, Lehto S, Penttila I, Pyörälä K (1993): 
Lipids and lipoproteins predicting coronary heart 
disease mortality and morbidity in patients with 
non-insulin-dependent diabetes. Circulation 
88:1421-30. 
 
Laakso M, Pyörälä K (1985): Age of onset and type 
of diabetes. Diabetes Care 8:114-7. 
 
Lebovitz HE (2001a): Diagnosis, classification, and 
pathogenesis of diabetes mellitus. J Clin 
Psychiatry 62:Suppl 27:S5-9. 
 
Lebovitz HE (2001b): Insulin resistance: definition 
and consequences. Exp Clin Endocrinol Diabetes 
109:Suppl 2:S135-48. 
 
Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker 
PM, Manson JE, Hennekens CH, Buring JE 
(2005): Vitamin E in the primary prevention of 
cardiovascular disease and cancer: the Women's 
 
 
THL 2011 — Research 59 88 Antioxidants, weight change and risk of type 2 diabetes 
 
Health Study: a randomized controlled trial. 
JAMA 294:56-65. 
 
Lemieux S, Prud'homme D, Bouchard C, Tremblay 
A, Despres JP (1996): A single threshold value 
of waist girth identifies normal-weight and 
overweight subjects with excess visceral adipose 
tissue. Am J Clin Nutr 64:685-93. 
 
Leppälä JM, Virtamo J, Heinonen OP (1999): 
Validation of stroke diagnosis in the National 
Hospital Discharge Register and the Register of 
Causes of Death in Finland. Eur J Epidemiol 
15:155-60. 
 
Lippman SM, Klein EA, Goodman PJ, Lucia MS, 
Thompson IM, Ford LG, Parnes HL, Minasian 
LM, Gaziano JM, Hartline JA, Parsons JK, 
Bearden JD 3rd, Crawford ED, Goodman GE, 
Claudio J, Winquist E, Cook ED, Karp DD, 
Walther P, Lieber MM, Kristal AR, Darke AK, 
Arnold KB, Ganz PA, Santella RM, Albanes D, 
Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, 
Meyskens FL Jr, Baker LH, Coltman CA Jr 
(2009): Effect of selenium and vitamin E on risk 
of prostate cancer and other cancers: the 
Selenium and Vitamin E Cancer Prevention Trial 
(SELECT). JAMA 301:39-51. 
 
Lissner L, Andres R, Muller DC, Shimokata H 
(1990): Body weight variability in men: 
metabolic rate, health and longevity. Int J Obes 
14:373-83. 
 
Liu S, Ajani U, Chae C, Hennekens C, Buring JE, 
Manson JE (1999): Long-term beta-carotene 
supplementation and risk of type 2 diabetes 
mellitus: a randomized controlled trial. JAMA 
82:1073-5. 
 
Liu S, Lee IM, Song Y, van Denburgh M, Cook NR, 
Manson JE, Buring JE (2006): Vitamin E and 
risk of type 2 diabetes in the women's health 
study randomized controlled trial. Diabetes 
55:2856-62. 
 
Liu S, Serdula M, Janket SJ, Cook NR, Sesso HD, 
Willett WC, Manson JE, Buring JE (2004):A 
prospective study of fruit and vegetable intake 
and the risk of type 2 diabetes in women. 
Diabetes Care 27:2993-6. 
 
Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, 
Zinman B, Bosch J, Dagenais G, Mann JF, 
Gerstein HC et al (2002): Effects of vitamin E on 
cardiovascular and microvascular outcomes in 
high-risk patients with diabetes: results of the 
HOPE study and MICRO-HOPE substudy. 
Diabetes Care 23:1919-27. 
 
Lyssenko V, Groop L (2009): Genome-wide 
association study for type 2 diabetes: clinical 
applications. Curr Opin Lipidol 20:87-91. 
 
Maechler P, Jornot L, Wollheim CB (1999): 
Hydrogen peroxide alters mitochondrial 
activation and insulin secretion in pancreatic beta 
cells. J Biol Chem 274:27905-13. 
 
Mari A, Tura A, Natali A, Laville M, Laakso M, 
Gabriel R, Beck-Nielsen H, Ferrannini E (2010): 
Impaired beta cell glucose sensitivity rather than 
inadequate compensation for insulin resistance is 
the dominant defect in glucose intolerance. 
Diabetologia 53:749-56. 
 
Maritim AC, Sanders RA, Watkins JB 3rd (2003): 
Diabetes, oxidative stress, and antioxidants: a 
review. J Biochem Mol Toxicol 17:24-38. 
 
Mayer-Davis EJ, Costacou T, King I, Zaccaro DJ, 
Bell RA (2002): Plasma and dietary vitamin E in 
relation to incidence of type 2 diabetes: The 
 
 
THL 2011 — Research 59 89 Antioxidants, weight change and risk of type 2 diabetes 
 
Insulin Resistance and Atherosclerosis Study 
(IRAS). Diabetes Care 25:2172-7. 
 
McGarry JD (2002): Banting lecture 2001: 
dysregulation of fatty acid metabolism in the 
etiology of type 2 diabetes. Diabetes 51:7-18. 
 
Meisinger C, Doring A, Thorand B, Heier M, Lowel 
H (2006): Body fat distribution and risk of type 2 
diabetes in the general population: are there 
differences between men and women? The 
MONICA/KORA Augsburg cohort study. Am J 
Clin Nutr 84:483-9. 
 
Metzger BE, Cho NH, Roston SM, Radvany R 
(1993): Prepregnancy weight and antepartum 
insulin secretion predict glucose tolerance five 
years after gestational diabetes mellitus. Diabetes 
Care 16:1598-605. 
 
Meyer KA, Kushi LH, Jacobs DR Jr., Slavin J, 
Sellers TA, Folsom AR (2000): Carbohydrates, 
dietary fiber, and incident type 2 diabetes in 
older women. Am J Clin  Nutr 71:921-30. 
 
Mikhailidis DP, Papadakis JA, Ganotakis ES (1998): 
Smoking, diabetes and hyperlipidaemia. J R Soc 
Health 118:91-3. 
 
Milne DB, Botnen J (1986): Retinol, alpha-
tocopherol, lycopene, and alpha- and beta-
carotene simultaneously determined in plasma by 
isocratic liquid chromatography. Clin Chem 
32:874-6. 
 
Mishra GD, Carrigan G, Brown WJ, Barnett AG, 
Dobson AJ (2007): Short-term weight change 
and the incidence of diabetes in midlife. Diabetes 
Care 30:1418-24. 
 
Moller DE, Flier JS (1991): Insulin resistance-
mechanisms, syndromes, and implications. N 
Engl J Med 325:938-48. 
 
Montonen J (2005): Plant Foods in the Prevention of 
Type 2 Diabetes Mellitus with Emphasis on 
Dietary Fiber and Antioxidant Vitamins. 
Academic dissertation. National Public Health 
Institute and Department of Public Health, 
University of Helsinki. Helsinki: Edita Prima. 
 
Montonen J, Järvinen R, Heliövaara M, Reunanen A, 
Aromaa A, Knekt P (2005). Food consumption 
and the incidence of type II diabetes mellitus. 
Eur J Clin Nutr 59:441-8. 
 
Montonen J, Knekt P, Järvinen R, Reunanen A 
(2004): Dietary antioxidant intake and risk of 
type 2 diabetes. Diabetes Care 27:362-6. 
 
Morgan CL, Currie CJ, Peters JR (2000): 
Relationship between diabetes and mortality: a 
population study using record linkage. Diabetes 
Care 23:1103-7. 
 
Morris RD, Rimm AA (1992): Long-term weight 
fluctuation and non-insulin-dependent diabetes 
mellitus in white women. Ann Epidemiol 2:657-
64. 
 
Murthy VK, Shipp JC, Hanson C, Shipp DM (1992): 
Delayed onset and decreased incidence of 
diabetes in BB rats fed free radical scavengers. 
Diabetes Res Clin Pract 18:11-6. 
 
Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, 
Williamson DF (2003): Lifetime risk for diabetes 
mellitus in the United States. JAMA 290:1884-
90. 
 
National Institute of Diabetes and Digestive and 
Kidney Diseases, National Institutes of Health, 
 
 
THL 2011 — Research 59 90 Antioxidants, weight change and risk of type 2 diabetes 
 
U.S. Department of Health and Human Services 
(2007): United States Renal Data System: 
USRDS 2007 Annual Data Report. Bethesda, 
MD. 
 
National Institute for Health and Welfare. Nutrition 
Unit. Finland (June 1 2010): Finnish Food 
Composition Database. www.fineli.fi (accessed 
March 2011). 
 
Nettleton JA, Harnack LJ, Scrafford CG, Mink PJ, 
Barraj LM, Jacobs DR, Jr (2006): Dietary 
flavonoids and flavonoid-rich foods are not 
associated with risk of type 2 diabetes in 
postmenopausal women. J Nutr 136:3039-45. 
 
Newman B, Selby JV, King MC, Slemenda C, 
Fabsitz R, Friedman GD (1987):  Concordance 
for type 2 (non-insulin-dependent) diabetes 
mellitus in male twins. Diabetologia 30:763-8. 
 
Newsholme P, Haber EP, Hirabara SM, Rebelato EL, 
Procopio J, Morgan D, Oliveira-Emilio HC, 
Carpinelli AR, Curi R (2007): Diabetes 
associated cell stress and dysfunction: role of 
mitochondrial and non-mitochondrial ROS 
production and activity. J Physiol 583:9-24. 
 
Niemi M, Winell K (2006): Diabetes in Finland. 
Prevalence and Variation in Quality of Care. 
Finnish Diabetes Association and STAKES – 
National Research and Development Centre for 
Welfare and Health. Tampere: Kirjapaino 
Hermes Oy.  
 
Oguma Y, Sesso HD, Paffenbarger RS Jr., Lee IM 
(2005): Weight change and risk of developing 
type 2 diabetes. Obes Res 13:945-51. 
 
Ohlson LO, Larsson B, Bjorntorp P, Eriksson H, 
Svardsudd K, Welin L, Tibblin G, Wilhelmsen L 
(1988): Risk factors for type 2 (non-insulin-
dependent) diabetes mellitus. Thirteen and one-
half years of follow-up of the participants in a 
study of Swedish men born in 1913. Diabetologia 
31:798-805. 
 
Padayatty SJ, Katz A, Wang Y, Eck P, Kwon O, Lee 
JH, Chen S, Dutta A, Dutta SK, Levine M 
(2003): Vitamin C as an antioxidant: evaluation 
of its role in disease prevention. J Am Coll Nutr 
22:18-25. 
 
Paiva SA, Russell RM (1999): Beta-carotene and 
other carotenoids as antioxidants. J Am Coll 
Nutr 18:426-33. 
 
Peltonen M, Korpi-Hyövälti E, Oksa H, Puolijoki H, 
Saltevo J, Vanhala M, Saaristo T, Saarikoski L, 
Sundvall J, Tuomilehto J (2006): Lihavuuden, 
diabeteksen ja muiden glukoosiaineenvaihdun-
nan häiriöiden esiintyvyys suomalaisessa aikuis-
väestössä. Suom Lääkäril 61:163-70. 
 
Penttilä A, Ahonen A (1975): Arteriosclerotic and 
other degenerative heart diseases in Finland: II. 
A death certificate study of the examination of 
the cause of death from degenerative heart 
diseases. Scand J Soc Med 3:69-74. 
  
Perseghin G, Price TB, Petersen KF, Roden M, Cline 
GW, Gerow K, Rothman DL, Shulman GI 
(1996): Increased glucose transport-
phosphorylation and muscle glycogen synthesis 
after exercise training in insulin-resistant subjects. 
N Engl J Med 335:1357-62. 
 
Pietinen P, Hartman AM, Haapa E, Räsänen L, 
Haapakoski J, Palmgren J, Albanes D, Virtamo J, 
Huttunen JK (1988): Reproducibility and 
validity of dietary assessment instruments. I. A 
self-administered food use questionnaire with a 
portion size picture booklet. II. A qualitative 
 
 
THL 2011 — Research 59 91 Antioxidants, weight change and risk of type 2 diabetes 
 
food frequency questionnaire. Am J Epidemiol 
128:655-76. 
 
Piironen V (1986): Tocopherols and tocotrienols in 
foods and in the average Finnish diet. Helsinki, 
Finland, Department of Food Chemistry and 
Food Technology, University of Helsinki. EKT 
Ser., 726. 
 
Postic C, Dentin R, Girard J (2004): Role of the liver 
in the control of carbohydrate and lipid 
homeostasis. Diabetes Metab 30:398-408. 
 
Prior RL (2003): Fruits and vegetables in the 
prevention of cellular oxidative damage. Am J 
Clin Nutr 78:Suppl 3: S570-8. 
 
Pyörälä K, Laakso M, Uusitupa M (1987): Diabetes 
and atherosclerosis: an epidemiologic view. 
Diabetes Metab Rev 3:463-524. 
 
R Development Core Team (2009): R: A language 
and environment for statistical computing. 
Vienna. Austria: R Foundation for Statistical 
Computing. 
 
Rapola J (1998): Effects of alpha-tocopherol and 
beta-carotene supplementation on coronary heart 
disease in a controlled trial. Academic 
Dissertation. National Public Health Institute, 
University of Helsinki. Helsinki: Hakapaino Oy. 
 
Rapola JM, Virtamo J, Korhonen P, Haapakoski J, 
Hartman AM, Edwards BK, Heinonen OP 
(1997): Validity of diagnoses of major coronary 
events in national registers of hospital diagnoses 
and deaths in Finland. Eur J Epidemiol 13:133-8. 
 
Resnick HE, Valsania P, Halter JB, Lin X (2000): 
Relation of weight gain and weight loss on 
subsequent diabetes risk in overweight adults. J 
Epidemiol Community Health 54:596-602. 
Resnikoff S, Pascolini D, Etya’ale D, Kocur I, 
Pararajasegaram R, Pokharel GP, Mariotti SP 
(2004): Global data on visual impairment in the 
year 2002. Bulletin of the World Health 
Organization 82:844-851. 
 
Reunanen A, Knekt P, Aaran RK, Aromaa A (1998): 
Serum antioxidants and risk of non-insulin 
dependent diabetes mellitus. Eur J Clin Nutr 
52:89-93. 
 
Rimm EB, Chan J, Stampfer MJ, Colditz GA, Willett 
WC (1995): Prospective study of cigarette 
smoking, alcohol use, and the risk of diabetes in 
men. BMJ 310:555-9. 
 
Robertson RP, Harmon JS (2007): Pancreatic islet 
beta-cell and oxidative stress: the importance of 
glutathione peroxidise. FEBS Lett 581:3743-8. 
 
Robertson RP, Harmon J, Tran PO, Tanaka Y, 
Takahashi H (2003): Glucose toxicity in beta-
cells: type 2 diabetes, good radicals gone bad, 
and the glutathione connection. Diabetes 52:581-
7. 
 
Rosen P, Nawroth PP, King G, Moller W, Tritschler 
HJ, Packer L (2001): The role of oxidative stress 
in the onset and progression of diabetes and its 
complications: a summary of a Congress Series 
sponsored by UNESCO-MCBN, the American 
Diabetes Association and the German Diabetes 
Society. Diabetes Metab Res Rev 17:189-212. 
 
Sakai K, Matsumoto K, Nishikawa T, Suefuji M, 
Nakamaru K, Hirashima Y, Kawashima J, 
Shirotani T, Ichinose K, Brownlee M, Araki E 
(2003): Mitochondrial reactive oxygen species 
reduce insulin secretion by pancreatic beta-cells. 
Biochem Biophys Res Commun 300:216-22. 
 
 
 
THL 2011 — Research 59 92 Antioxidants, weight change and risk of type 2 diabetes 
 
Salonen J, Nyyssonen K, Tuomainen T (1995): 
Increased risk of non-insulin dependent diabetes 
mellitus at low plasma vitamin E concentrations: 
a four year follow up study in men. BMJ 
311:1124-7. 
 
Schramm TK, Gislason GH, Kober L, Rasmussen S, 
Rasmussen JN, Abildstrom SZ, Hansen ML, 
Folke F, Buch B, Madsen M, Vaag A, Torp-
Pedersen C (2008): Diabetes patients requiring 
glucose-lowering therapy and nondiabetics with 
a prior myocardial infarction carry the same 
cardiovascular risk: a population study of 3.3 
million people. Circulation 117:1945-54. 
 
Seidell JC, Perusse L, Despres JP, Bouchard C 
(2001): Waist and hip circumferences have 
independent and opposite effects on 
cardiovascular disease risk factors: the Quebec 
Family Study. Am J Clin Nutr 74:315-21. 
 
Sesso HD, Buring JE, Christen WG, Kurth T, 
Belanger C, MacFadyen J, Bubes V, Manson JE, 
Glynn RJ, Gaziano JM (2008): Vitamins E and C 
in the prevention of cardiovascular disease in 
men: the Physicians' Health Study II randomized 
controlled trial. JAMA 300:2123-33. 
  
Shulman GI (2000): Cellular mechanisms of insulin 
resistance. J Clin Invest 106:171-6. 
 
Slonim AE, Surber ML, Page DL, Sharp RA, Burr 
IM (1983): Modification of chemically induced 
diabetes in rats by vitamin E. Supplementation 
minimizes and depletion enhances development 
of diabetes. J Clin Invest 71:1282-8. 
 
Song Y, Cook NR, Albert CM, Van Denburgh M, 
Manson JE (2009): Effects of vitamins C and E 
and beta-carotene on the risk of type 2 diabetes 
in women at high risk of cardiovascular disease: 
a randomized controlled trial. Am J Clin Nutr 
90:429-37. 
  
Song Y, Manson JE, Buring JE, Sesso HD, Liu S 
(2005): Associations of dietary flavonoids with 
risk of type 2 diabetes, and markers of insulin 
resistance and systemic inflammation in women: 
a prospective study and cross-sectional analysis. 
J Am Coll Nutr 24:376-84. 
 
Soobrattee MA, Neergheen VS, Luximon-Ramma A, 
Aruoma OI, Bahorun T (2005): Phenolics as 
potential antioxidant therapeutic agents: 
mechanism and actions. Mutat Res 579:200-13. 
 
Stenbäck F (1986): Accuracy of antemortem 
diagnoses in the north. An autopsy study. Arct 
Med Res 41:9-15. 
 
Stratton IM, Adler AI, Neil HA, Matthews DR, 
Manley SE, Cull CA, Hadden D, Turner RC, 
Holman RR (2000): Association of glycaemia 
with macrovascular and microvascular 
complications of type 2 diabetes (UKPDS 35): 
prospective observational study. BMJ 321:405-
12. 
 
Stumvoll M, Goldstein BJ, van Haeften TW (2005): 
Type 2 diabetes: principles of pathogenesis and 
therapy. Lancet 365:1333-46. 
 
Tapiero H, Tew KD, Ba GN, Mathe G (2002): 
Polyphenols: do they play a role in the 
prevention of human pathologies? Biomed 
Pharmacother 56:200-7. 
 
The Alpha-Tocopherol, Beta Carotene Cancer 
Prevention Study Group (1994): The effect of 
vitamin E and beta carotene on the incidence of 
lung cancer and other cancers in male smokers. 
N Engl J Med 330:1029-35. 
 
 
 
THL 2011 — Research 59 93 Antioxidants, weight change and risk of type 2 diabetes 
 
The ATBC Cancer Prevention Study Group (1994): 
The alpha-tocopherol, beta-carotene lung cancer 
prevention study: design, methods, participant 
characteristics, and compliance. Ann Epidemiol 
4:1-10. 
 
The DECODE Study Group (2003): Age- and sex-
specific prevalences of diabetes and impaired 
glucose regulation in 13 European cohorts. 
Diabetes Care 1:61-9. 
 
The Heart Protection Study Collaborative Group 
(2002): MRC/BHF Heart Protection Study of 
antioxidant vitamin supplementation in 20 536 
high-risk individuals: a randomised placebo-
controlled trial. Lancet 360:23-33. 
 
Tuomilehto J, Lindström J, Eriksson JG, Valle TT, 
Hämäläinen H, Ilanne-Parikka P, Keinänen-
Kiukaanniemi S, Laakso M, Louheranta A, 
Rastas M, Salminen V, Uusitupa M (2001): 
Prevention of type 2 diabetes mellitus by 
changes in lifestyle among subjects with 
impaired glucose tolerance. N Engl J Med 
344:1343-50. 
  
Turrens JF (2003): Mitochondrial formation of 
reactive oxygen species. J Physiol 552: 335-44. 
 
Uusitupa MI, Niskanen LK, Siitonen O, Voutilainen 
E, Pyörälä K (1990): 5-year incidence of 
atherosclerotic vascular disease in relation to 
general risk factors, insulin level, and 
abnormalities in lipoprotein composition in non-
insulin-dependent diabetic and nondiabetic 
subjects. Circulation 82:27-36. 
  
Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur 
M, Telser J (2007): Free radicals and 
antioxidants in normal physiological functions 
and human disease. Int J Biochem Cell Biol 
39:44-84. 
van Dam RM, Rimm EB, Willett WC, Stampfer MJ, 
Hu FB (2002): Dietary patterns and risk for type 
2 diabetes mellitus in U.S. men. Ann Intern Med 
136:201-9. 
 
Wang L, Liu S, Manson JE, Gaziano JM, Buring JE, 
Sesso HD (2006a): The consumption of lycopene 
and tomato-based food products is not associated 
with the risk of type 2 diabetes in women. J Nutr 
136:620-5. 
 
Wang L, Liu S, Pradhan AD, Manson JE, Buring JE, 
Gaziano JM, Sesso HD (2006b): Plasma lycopene, 
other carotenoids, and the risk of type 2 diabetes in 
women. Am J Epidemiol 164:576-85. 
 
Wannamethee SG, Shaper AG (1999): Weight 
change and duration of overweight and obesity in 
the incidence of type 2 diabetes. Diabetes Care 
22:1266-72. 
 
Wannamethee SG, Shaper AG, Perry IJ, Alberti KG 
(2002): Alcohol consumption and the incidence 
of type II diabetes. J Epidemiol Community 
Health 56:542-8. 
 
Wannamethee SG, Shaper AG, Walker M (2005): 
Overweight and obesity and weight change in 
middle aged men: impact on cardiovascular 
disease and diabetes. J Epidemiol Community 
Health 59:134-9. 
 
Waring ME, Eaton CB, Lasater TM, Lapane KL 
(2010): Incident diabetes in relation to weight 
patterns during middle age. Am J Epidemiol 
171:550-6. 
 
Warram JH, Kopczynski J, Janka HU, Krolewski AS 
(1997): Epidemiology of non-insulin-dependent 
diabetes mellitus and its macrovascular 
complications. A basis for the development of 
 
 
THL 2011 — Research 59 94 Antioxidants, weight change and risk of type 2 diabetes 
 
cost-effective programs. Endocrinol Metab Clin 
North Am 26:165-88. 
  
Vazquez G, Duval S, Jacobs DR Jr., Silventoinen K 
(2007): Comparison of body mass index, waist 
circumference, and waist/hip ratio in predicting 
incident diabetes: a meta-analysis. Epidemiol 
Rev 29:115-28. 
 
Weyer C, Bogardus C, Mott DM, Pratley RE (1999): 
The natural history of insulin secretory 
dysfunction and insulin resistance in the 
pathogenesis of type 2 diabetes mellitus. J Clin 
Invest 104:787-94. 
 
WHO (1999): Definition, diagnosis and 
classifications of diabetes mellitus and its     
complications: Report of a WHO Consultation: 
Part 1. Diagnosis and classification of diabetes 
mellitus. Geneva: World Health Organization, 
Department of Non-communicable Disease 
Surveillance. Available at: http://www.staff.ncl. 
ac.uk/philip.home/who_dmg.pdf (accessed March 
2011).  
 
WHO (1985): Diabetes mellitus: Report of a WHO 
Study Group. Geneva: World Health 
Organization. World Health Organ Tech Rep Ser 
No 727:1-113. 
 
Wild S, Roglic G, Green A, Sicree R, King H (2004): 
Global prevalence of diabetes: estimates for the 
year 2000 and projections for 2030. Diabetes 
Care 27:1047-53. 
 
Will JC, Williamson DF, Ford ES, Calle EE, Thun 
MJ (2002): Intentional weight loss and 13-year 
diabetes incidence in overweight adults year 
diabetes incidence in overweight adults. Am J 
Public Health 92:1245-8. 
 
Willett W (1990): Nutritional Epidemiology. 1st ed. 
New York, NY: Oxford University Press. 
 
Willett W, Stampfer MJ (1986): Total energy intake: 
implications for epidemiologic analyses. Am J 
Epidemiol 124:17-27. 
 
Vinik AI, Vinik E (2003): Prevention of the 
complications of diabetes. Am J Manag Care 9: 
Suppl 3:S63-80. 
 
Young MJ, Boulton AJ, MacLeod AF, Williams DR, 
Sonksen PH (1993): A multicentre study of the 
prevalence of diabetic peripheral neuropathy in 
the United Kingdom hospital clinic population. 
Diabetologia 36:150-4. 
 
Zhang X, Saaddine JB, Chou CF, Cotch MF, Cheng 
YJ, Geiss LS, Gregg EW, Albright AL, Klein BE, 
Klein R (2010): Prevalence of diabetic 
retinopathy in the United States, 2005-2008. 
JAMA 304:649-56. 
 
 
 
 
 
 
 
 
 
 
